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Abstract 
i 
Abstract 
 
Transplantation is often the only therapy for end-stage organ failure. Blood-
borne leukocytes are guided into the grafts by proinflammatory chemokines. To 
achieve full functionality, chemokines interact with heparan sulphate (HS) 
proteoglycans, which are expressed on the majority of all animal cell surfaces, 
predominantly on the endothelium. Due to the modification, especially 
sulphation status of HS, chemokine function can be controlled. This study was 
designed to examine the expression of different HS epitopes during allograft 
rejection, dynamic changes of HS following experimental inflammation and 
investigate the regulation of HS biosynthesis, providing new targets for 
therapeutic intervention. 
 
Human renal and hepatic allografts expressed distinct HS epitopes which were 
indicative for the stage of rejection. In both organs, N-sulphated HS domains 
were elevated during acute phases of rejection whereas 2-O- and 6-O-
sulphation increased significantly during chronic stages. The HS motif 
investigated could be matched to selective HS ligands based on essential target 
modifications. Data from transplant tissues was largely confirmed by in vitro 
studies simulating an inflammatory response employing relevant cell lines and 
N-deacetylase/N-sulphotransferase (NDST1) transfectants. 
 
Investigations of the regulation of HS biosynthesis at the protein level were 
carried out using tandem affinity purification. It revealed an interaction of 
NDST1, the key enzyme in HS biosynthesis, and beta tubulin. This interaction 
could provide an insight into general Golgi localisation and retention of 
glycosylation enzymes. 
 
This study substantiates the strategy of targeting heparan sulphate 
proteoglycans in inflammation and organ rejection, as distinct changes in HS 
epitope expression dependent of the stage of rejection were identified. During 
renal rejection, these specific HS species could be used as a biomarker giving 
evidence about the progression of the disease. Overall, this could lead to a 
Abstract 
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novel anti-inflammatory therapy targeting an array of proinflammatory cytokines 
with less side affects compared to current treatment options. 
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1 Introduction 
1.1 Background to this study 
This thesis addresses the role of Heparan Sulphate in inflammation and organ 
transplant rejection. The immune response is a complex, multistep process 
which can be characterized by a localised response to infection, tissue damage 
or inflammation. During this response, immune cells are required to migrate 
from the blood vessels into subendothelial tissues, a process which has to be 
tightly regulated as not to result in immune pathologies. Molecules directing 
immune cells into the tissue are expressed both on the endothelium as well as 
on leukocytes. Heparan Sulphate, which is expressed abundantly on the 
endothelium, is said to play a crucial role in this process. Heparan sulphate is 
capable of immobilizing a plethora of soluble factors such as cytokines and 
chemokines which then can direct vectorial migration of immune cells into the 
tissue.  
As proinflammatory chemokines expressed during allograft rejection exert their 
function in conjunction with Heparan Sulphate, it appears feasible to target the 
interplay of these two key molecules for therapeutic intervention. 
1.2 Inflammation and leukocyte migration  
Inflammation is a complex immune response to local injury or damage. It is 
tightly regulated and imbalances can cause major harm. It was originally 
described by the following parameters: rubor/redness, calor/heat, 
tumor/swelling and dolor/pain by the Roman encyclopaedist Celsus in the first 
century A.D. (Lucignani, 2007). These signs can be explained by increased 
blood flow to sites of injury (redness and heat), accumulation of fluid and 
migration of leukocytes into the tissue (swelling) and stimulation of nerve 
endings by released factors such as bradykinins (pain).   
Directed migration of leukocytes into the tissue also occurs during organ 
rejection whereby immune cells have to cross the endothelial cell barrier in 
order to infiltrate the transplanted organ. 
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1.2.1 The vascular endothelium 
The vascular endothelium is a layer of cells lining blood vessel walls and 
therefore a critical barrier between blood and tissues. It plays a crucial role in 
inflammation. Under non pathological circumstances the endothelial monolayer 
and the basement membrane are not permeable for immune cells, such as 
leukocytes. During inflammation this barrier gets degraded and leukocytes can 
be recruited into the tissue in a multistep process (Butcher and Picker, 1996, 
Wong et al., 2010). This leukocyte infiltration can only occur when the 
endothelium actively promotes this process. This crucial step in the 
inflammatory cascade is partly regulated by pro-inflammatory chemokines and 
cytokines (Barreiro et al., 2010). 
As blood flow would prevent the formation of a stable gradient, chemokines and 
cytokines are immobilized by cell surface glycosaminoglycans (GAGs) (Tanaka 
et al., 1998, Proudfoot, 2006), of which heparan sulphate is expressed most 
abundantly on the endothelium (Ihrcke et al., 1993). Thus, heparan sulphate 
plays an important role during inflammation. 
1.2.2 Transendothelial migration 
A significant feature of an inflammatory response is the transendothelial 
migration of inflammatory cells. Leukocytes are recruited from the blood vessel 
across the endothelium and the basement membrane into the inflamed tissue. 
This is a multi-step process involving different adhesion molecules.  
The vectorial migration occurs in response to chemokine gradients, where 
chemokines are bound and immobilized by glycosaminoglycans present on the 
endothelium and the extracellular matrix (Middleton et al., 2002, Proudfoot, 
2006). Selectins play an important role in the initial attachment and rolling of 
leukocytes. Selectins are a family of cell adhesion molecules which are 
expressed on the endothelium and the leukocyte (Vestweber and Blanks, 1999, 
Langer and Chavakis, 2009). L-selectin is constitutively expressed on 
leukocytes, whereas P- and E-selectin are upregulated following stimulation 
(Zarbock and Ley, 2008) of the endothelium. As L-selectin is expressed 
constitutively on circulating leukocytes regulation of adhesion takes place by 
controlling the expression of its glycoprotein ligands, such as GlyCAM-1 
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(glycosylated cell adhesion molecule), MAdCAM -1 (mucosal addressing cell 
adhesion molecule), CD34 and Spg200 (Vestweber and Blanks, 1999).These 
molecules can be found both on high endothelial venules as well as activated 
endothelium, thus confirming a role in both homing and inflammation (Rosen, 
1999). After activation L-selectin is rapidly shed. This is thought to be a 
mechanism for limiting further leukocyte activation (Hafezi-Moghadam et al., 
2001). 
During selectin-mediated rolling, the G-protein-coupled chemokine receptors 
present on leukocytes can interact with chemokines, presented by GAGs on the 
endothelium (Dowsland et al., 2003).This leads to the activation of integrins on 
the cell surface (Shimaoka et al., 2002) and further to a more stable adhesion. 
Integrins are heterodimeric proteins consisting of α and ß chains and are 
expressed by all nucleated cells. In humans, 25 different forms of heterodimers 
can be built and the combination of the chains determines the ligand specificity. 
In order to mediate firm adhesion integrins have to be activated. This can occur 
by either clustering on the cell surface or conformational changes of the integrin 
itself (Humphries, 2000).  
One of the most common integrins is LFA-1 (lymphocyte function associated 
antigen-1) or αLß2. It is present on lymphocytes, neutrophils and monocytes 
and binds to ICAM-1 (intercellular adhesion molecule-1) (Schenkel et al., 2004). 
Another member of the integrin family is VLA-4 (very late after activation 
protein-4) or α4ß1. VLA-4 is found on monocytes and lymphocytes and it binds 
to VCAM-1 (vascular cell adhesion molecule-1). Both ICAM-1 and VCAM-1 are 
upregulated on the endothelium during inflammatory processes (Johnson et al., 
2006). After the passage of the immune cells from the blood vessel into the 
tissue, leukocytes follow a sub-endothelial chemokine-gradient and can perform 
multiple immune activities in the target tissue (Figure 1-1).  
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Figure 1-1 Stages of leukocyte extravastion. 
 
Initially leukocytes bind weakly to the endothelium, resulting in leukocytes rolling. The 
chemokine receptor present on the leukocyte is able to interact with GAG bound 
chemokines, leading to integrin mediated firm adhesion. The cells then migrate towards 
a subendothelial chemokine gradient.  
1.3 Chemokines 
Chemokines are small (7-12kDa) chemo-attractant cytokines which can be 
divided into inflammatory (inducible) and homeostatic (constitutive) chemokines 
(Rot, 1996, Rot and von Andrian, 2004). 
Constitutive chemokines play a role in lymphocyte homing under non-
pathological circumstances, whereas inducible chemokines are upregulated 
during inflammation. They can act in a paracrine (on adjacent cells) or in an 
autocrine (self stimulatory) manner.  
A broad range of cells are known to secrete chemokines and they are involved 
in different processes such as homeostasis, cell proliferation, haematopoesis 
and angiogenesis (D'Ambrosio et al., 2003). But most importantly chemokines 
are considered to be crucial in leukocyte extravasation during inflammation 
(Thelen, 2001, Barreiro et al., 2010). 
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Although there is a large degree of sequence diversity between members of the 
chemokines family, they show a similar three-dimensional structure consisting 
of three antiparallel β-strands overlaid by a α-helical region forming the C-
terminus (Pease and Williams, 2006) stabilized by disulphide bonds between 
four conserved cysteines residues. These bonds are built between the first and 
the third and the second and the fourth cysteines.  
Chemokines are synthesised as pro-peptides in an inactive form and it is only 
after cleavage of the signal peptide during the secretion process that the mature 
proteins are released. 
So far, 47 human chemokines and 18 chemokine receptors have been identified 
(Murphy et al., 2000, Ransohoff, 2009). Some chemokines can bind to more 
than one receptor and some receptors can bind different chemokines (Nelson 
and Krensky, 2001b). Members of the chemokine family are categorized into 
four groups, dependent on the position of their first two cysteine residues. The 
two major groups are CC and CXC chemokines. In CC chemokines the two 
cysteine residues can be found next to each other whereas in CXC chemokines 
the cysteines are separated by a single amino acid. The two minor groups with 
one member each are CX3C (three amino acids are between the first two 
cysteines) and C (only one cysteine) chemokines.  
In order to function as chemoattractant cytokines, chemokines must bind to their 
receptors. These are 7-transmembrane G-protein coupled receptors, where the 
N-terminus is extracellular and the C-terminus is intracellular (Gether et al., 
2002). Binding of chemokines to their receptors usually takes place via the N-
terminal domain and the first exposed loop (Monteclaro and Charo, 1996, 
Murdoch and Finn, 2000). Binding of the chemokine leads to the activation of 
the receptor resulting in migratory responses. 
1.3.1 Glycosaminoglycans and chemokine  interactions 
All known chemokines interact with GAGs. Even acidic chemokines, such as 
CCL3 and CCL4, are known to bind GAGs; therefore ruling out the possibility 
that binding is solely charge dependent (Kuschert et al., 1999). Chemokines 
bind to GAGs via their GAG-binding domains which have been identified by 
sequence alignments and site directed mutagenesis studies. These domains 
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generally consist of the basic amino acids arginine and lysine (or more rarely 
histidine), which can be separated by other amino acids, resulting in the two 
consensus GAG-binding motifs XBBXBX and XBBBXXBX, also found in many 
other proteins. Within these motifs B represents the basic amino acid residue 
and X any other (Hileman et al., 1998). CCL5 is an example of the XBBXBX 
family (Proudfoot et al., 2001) whereas CCL7 conforms to the XBBBXXBX motif  
(Ali et al., 2005b). 
Little is known about the corresponding regions of GAGs, albeit N- and O-
sulphation have been reported to be involved (Schenauer et al., 2007). 
1.3.2 Functional role of HS-chemokine interaction 
Binding of chemokines to GAGs occurs both in vitro and in vivo. Studies of 
chemokine binding to HS have highlighted various essential roles for HS- 
dependent chemokine function.  
 
Firstly, binding of chemokines to HS protects them from degradation via 
proteolysis (Sadir et al., 2004) and can facilitate their oligomerisation 
(Hoogewerf et al., 1997). Even though chemokines can form oligomers in vitro, 
to form active oligomers in vivo GAG binding is required. Mutant forms of CCL4 
and CCL5, which were unable to form oligomers, could still stimulate the 
recruitment of cells in vitro, but no longer in vivo (Proudfoot et al., 2003). 
However, oligomerisation seems not to be essential for the function of all 
chemokines. A CCL2 mutant which was unable to form oligomers showed 
normal biological activity, indicating that multimerisation was not necessary for 
its function (Ali et al., 2001). 
 
Secondly, GAGs are required for the presentation of chemokines on the surface 
of the vascular endothelium. Through the binding of chemokines to HS, 
chemokines are immobilized and a stable gradient can be formed. This is 
responsible for the recruitment of leukocytes to sites of inflammation (Middleton 
et al., 2002). A study with non-GAG binding CCL7 in a murine air pouch model 
of inflammation in our group demonstrated that the biologically active CCL7 
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mutant was unable to stimulate the recruitment of leukocytes into the air pouch 
in vivo (Ali et al., 2005b). 
 
Finally, HS is required for the transport of chemokines across the endothelium 
before their presentation on the apical surface. In a model of transendothelial 
migration co-localasiaton of HS domains with CCL2 on the apical surface of 
EA.hy 296 cells after basally administered chemokine was demonstrated.  
Competition assays further confirmed CCL2-HS binding as addition of soluble 
heparin to the culture medium inhibited chemokine-HS binding (Hardy et al., 
2004). Endothelial cells lacking HS were unable to transport chemokines to the 
apical surface of the endothelium and thus unable to stimulate leukocyte 
recruitment (Wang et al., 2005). 
1.3.3 Glycosaminoglycans in inflammation 
As already discussed, HSPGs plays multiple roles during inflammation. They 
are involved in almost every stage of leukocyte transmigration; the initial 
adhesion of leukocytes to the inflamed endothelium, the chemokine-mediated 
transmigration and the establishment of a chronic inflammatory response. A 
detailed listing of HSPGs involved in inflammation can be seen in Table 1-1 
(adapted from (Parish, 2006). 
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Table 1-1 HSPGs in inflammation 
 
HSPG Location Cellular expression Function of HS chains in 
inflammation 
Syndecan 1-
4 
Cell surface, integral 
membrane proteins 
Shed syndecan at 
inflammatory sites 
 Endothelial cells, 
 Macrophages and 
monocytes   
 activated T cells 
 Ligand for L-selectin and 
chemokines 
 Modulator of angiogenic 
growth factor activity 
Glypican 1-6 Cell surface, GPi-
anchored proteins 
 Vascular endothelial cells 
 Macrophages in 
inflammatory sites  
 Activated CD4 T cells 
 Functions similar to 
syndecans 
Perlecan Basement 
membrane and ECM 
 Subendothelial basement 
membrane  
 Barrier to leukocyte 
migration 
 Stabilizes chemokine 
gradients 
 Reservoir for HS binding 
growth factors and 
cytokines 
Type XVIII 
collagen 
Basement 
membrane and ECM 
 Subendothelial basement 
membrane 
 Functions similar to 
perlecan 
 Ligand for L-selectin 
Agrin Basement 
membrane and ECM 
 Subendothelial basement 
membrane 
 Functions similar to 
perlecan  
 
In addition to HS, the GAG hyaluronan (HA) is well known for its influence on 
inflammation. As no chain modifications of GAG chains in HA occur, its function 
seems to be dependent on its size. After injury or during inflammation, HA is 
degraded either enzymatically by HA degrading enzymes or non-enzymatically 
by i.e. free radicals. Low molecular weight HA is able to induce proinflammatory 
cytokines and chemokines (Noble, 2002). 
HA itself is expressed by endothelial cells upon activation with proinflammatory 
cytokines and is involved in leukocyte recruitment to sites of inflammation by its 
interaction with a CD44 isoform present on leukocytes. This interaction seems 
to be tightly controlled, as CD44 molecules on other cell types are not always 
capable of binding HA (Johnson et al., 2000). Another molecule that influences 
the effect of HA in inflammation is TSG-6 (tumour necrosis factor alpha induced 
protein 6), which is only found during inflammatory conditions, by stabilizing the 
HA-CD44 interaction (Lesley et al., 2004). In addition to HA, TSG-6 also binds 
to a range of differentially modified HS species and distinct binding sites for HA 
and HS have been identified. The interaction of TSG-6 with HS on the cell 
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surface or ECM could inhibit HA binding and modulate HA-CD44 interaction 
during inflammation (Mahoney et al., 2005). 
1.4 Glycobiology 
Glycobiology describes the study of structure and function of glycans (sugar 
chains) as well as their conjugates, such as glycoproteins, glycolipids and 
proteoglycans. Glycans can be found widespread on cell surfaces, extracellular 
matrix (ECM) or secreted in fluids. Like proteins, they are omnipresent and 
participate in a vast range of biological functions.  
The glycan chains consist of individual monosaccharides, which are 
polymerized into oligosaccharides (up to 20 residues) or polysaccharides. 
Individual monosaccharides are joined by glycosidic linkage, which can be in 
either α or ß form. Glycosylation is the process whereby glycan chains are 
enzymatically attached to core molecules and it represents the most common 
post-translational modification of eukaryotic proteins. In this glycosylation 
reaction the glycan can be linked to either an asparagine residue of the protein 
(N-glycans) or a hydroxyl group of a serine or threonine residue (O-glycans). N-
glycosylation occurs during protein biosynthesis in the ER whereas O-
glycosylation is a post-translational modification occurring in the Golgi 
compartment.  
Due to variable saccharide composition, differential linkage, chain length and 
branching as well as modification, glycoproteins are highly complex, information 
rich molecules. The field of glycobiology is a rapidly growing research area; 
publications have more than doubled over the last 10 years (based on 
publications containing the word glycobiology in PubMed). 
1.4.1 Proteoglycans and Glycosaminoglycans 
Proteoglycans (PG) are glycoproteins, where glycosaminoglycan (GAG) chains 
are covalently attached to serine residues of a core protein. The protein core 
determines where the proteoglycans are localized. Proteoglycans are found on 
cell surfaces, in extracellular matrix (ECM) or intracellularly, as in granules of 
mast cells (Kjellen and Lindahl, 1991). There is no mammalian cell known 
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without proteoglycans. GAGs are highly negatively charged linear 
heteropolysaccharides consisting of up to 150 characteristic disaccharide 
repeats. GAGs forming proteoglycans can be divided into four different families: 
keratan sulphate (disaccharide unit: N-acetylglucosamine and galactose), 
heparan sulphate and heparin (disaccharide unit: N-acetylglucosamine and 
glucuronic acid), chondroitin sulphate and dermatan sulphate (disaccharide unit: 
N-acetylgalactosamine and glucuronic acid).  Another member of the GAG 
family is hyaluronic acid (disaccharide unit: N-acetylglucosamine and glucuronic 
acid), which is secreted into the ECM (Taylor and Gallo, 2006). The GAG 
chains can be sulphated to different extents on specific positions on the chain 
and the glucuronic acid in heparan sulphate and heparin can be converted into 
iduronic acid via C-5-epimerization (Sugahara and Kitagawa, 2000). 
1.4.2 Heparan sulphate proteoglycans (HSPGs) 
Proteoglycans carrying heparan sulphate chains can be divided into different 
groups, depending on their occurrence. They can be located in the ECM, on the 
cell surface and intracellularly (Parish, 2006). 
1.4.2.1 Extracellular Matrix HSPGs  
HSPGs in the ECM comprise a variety of molecules including perlecan, 
collagen XVIII and agrin.  
 
Perlecan (~470kDa molecular weigth) can be found in basal membranes as well 
as the interstitial matrix and carries attachment site for 3 HS chains close to the 
N-terminus with one additional GAG attachment site near the C-terminus (Iozzo, 
2005). It is involved in embryogenesis, tissue morphogenesis and cartilage 
development (Melrose et al., 2003, Farach-Carson and Carson, 2007). 
 
Collagen XVIII (~180kDa molecular weight) can be found in almost all 
basement membranes and offers 3 HS attachment sites (Iozzo and San 
Antonio, 2001). Proteolytic cleavage leads to the release of endostatin, a 
fragment shown to have anti-angiogenic properties (O'Reilly et al., 1997, 
Marneros and Olsen, 2005). 
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Agrin, another large HSPG (214kDa molecular weight) aggregates acetylcholine 
receptors in neuromuscular junctions during synaptogenesis (Cole and Halfter, 
1996) and plays an important role in glomerular filtration of the kidney (Groffen 
et al., 1999, Raats et al., 2000). 
1.4.2.2 Cell surface HSPGs 
Cell surface bound HSPGs are syndecans (4 members), which have a 
transmembrane domain and glypicans (6 members), which are bound via a 
glycosylphosphatidylinositol (GPI) anchor. Despite these „full time‟ HSPGs, 
which always carry HS chains, so called „part time‟ HSPG have been described, 
which only carry HS chains under specific conditions, including betaglycan, 
splice variants of CD44 and testican (Parish, 2006). 
1.4.2.2.1 Syndecans 
Syndecans comprise a family of 4 core proteins (~33kDa molecular weight). 
They are type I transmembrane proteins with a small cytoplasmic region, a 
transmembrane domain and an extracellular domain with 3-5 of GAG 
attachment sites (Bernfield et al., 1992). Syndecans 1 and 3 can be substituted 
with CS chains whereas syndecans 2 and 4 only carry HS chains (Carey, 
1997). Syndecans are expressed in a tissue specific manner and upon 
interaction with an extracellular ligand they can transfer the signal via the 
membrane spanning domain into the cell (Woods, 2001). 
The extracellular domain of syndecans can also be shed by proteolytic 
cleavage, possible playing a role in tissue repair. Increased levels of syndecan-
1 ectodomain were found in dermal wound fluid (Fitzgerald et al., 2000) and 
shed syndecan-1 did indeed enhance cell migration and wound closure in a 
model of lung injury (Chen et al., 2009). 
1.4.2.2.2 Glypicans 
Glypicans, which are attached to the cell membrane via a GPI anchor at the C-
terminus, can be found associated with lipid rafts (Filmus et al., 2008). There 
are 6 mammalian glypicans (~60kDa molecular weight) which each having 2 to 
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3 GAG chains (HS exclusively) attached to the extracellular region. Most 
importantly they play a role in regulating morphogens, thus controlling 
development and growth (Filmus and Selleck, 2001, Filmus et al., 2008). As 
shown for syndecans, glypicans can also be shed via the action of an 
extracellular lipase which cleaves the GPI anchor and glypican fragments have 
been demonstrated to play a role in the transport of morphogens (Belenkaya et 
al., 2004, Traister et al., 2007). 
1.4.2.3 Intracellular PGs 
Intracellularly, heparin is stored in secretory granules of connective-tissue-type 
mast cells linked to the core protein serglycin (~18kDa molecular weight). 
Heparin can be seen as a highly sulphated, highly epimerized form of HS 
(Kolset and Tveit, 2008). 
 
 
Figure 1-2 Schemativ representation of four types of common HSPGs 
 
Overall, HSPGs are involved in the regulation of various cellular processes, 
including cell-matrix interaction, coagulation, binding of growth-factors, 
angiogenesis and inflammation depending on the interaction with a GAG-
binding protein (Bernfield et al., 1999, Bishop et al., 2007). 
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1.5 Glycosaminoglycans and protein interactions 
A vast number of proteins that bind to GAGs have been described in the 
literature (Table 1-2). Initially, it was thought that HS-protein interactions are 
non-specific. However, there is increasing evidence that these interactions 
require a certain level of specificity (Turnbull et al., 2001, Whitelock and Iozzo, 
2005). In addition to ionic forces between basic amino acids of the proteins 
(lysine and arginine) and carboxyl and sulphate groups of the GAGs, van der 
Waals forces, hydrogen bonds and hydrophobic interactions with the 
carbohydrate backbone also seem to be involved (Mulloy and Rider, 2006). 
Most likely the interaction of HS and its ligands depends on the modification 
status of the chain and the spatial distribution of the groups involved. 
 
Table 1-2 Examples of GAG binding proteins 
Protein 
function 
Examples References 
Cell adhesion 
molecules 
L-selectin, P-selectin  (Celie et al., 2005, Koenig et al., 1998, 
Parish, 2006) 
Extracellular 
matrix proteins 
fibronectin, laminin, collagens  (Battaglia et al., 1992, Bernfield et al., 
1999, Isemura et al., 1987, LeBaron et 
al., 1989) 
Growth factors FGFs, HGF, VEGF  (Bashkin et al., 1989, Iozzo and San 
Antonio, 2001, Lyon et al., 1994b) 
Morphogens TGFß superfamly  (Lyon et al., 1997, Rider, 2006) 
Cytokines IL-2,-3,-4,-5,-7,IFNγ, TNFα, 
chemokines 
 (Bernfield et al., 1999, Lortat-Jacob, 
2006, Lortat-Jacob et al., 1990, 
Proudfoot, 2006, Webb et al., 1993) 
Viral envelope 
proteins 
Herpes simplex virus, human 
immundeficiancy virus, hepatitis 
C virus 
 (Chen et al, 2008) 
Plaque proteins Prion proteins, amyloid proteins  (Scholefield et al., 2003, Warner et al., 
2002) 
Lipid binding 
proteins 
Apolipoprotein E and B  (Mac Arthur et al, 2007) 
 
So far, the only example of a specific GAG-protein interaction is the binding 
between antithrombin III and heparin (Petitou et al., 2003). This interaction is of 
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great medical interest as heparin is widely used as an anticoagulant. This 
binding causes conformational changes in the protein, which enhances the 
neutralization of thrombin leading to anticoagulant effects. As not only 
antithrombin but also thrombin has heparin binding sites, heparin does not only 
activate the protease but also helps to hold both molecules in close proximity. 
Structural analysis revealed a unique pentasaccharide sequence containing a 
very rare 3-O-sulphation required for high affinity binding.  
Well known interaction partners of HS are fibroblast growth factors (FGFs) and 
their receptors (FGFRs). Two FGF molecules and two FGFR must bind to HS 
forming a ternary complex in order to signal properly (Kan et al, 1993, 
Rapraeger et al, 1994). Although there is an oligosaccharide which is 
recognised preferentially, no unique or specific binding site has been described. 
The most favourable sequence is composed of N-sulphation on the non-
reducing end glucosamine, 2-O-sulphation on iduronic acid and 6-O-sulphation 
on the reducing end glucosamine (Kreuger et al., 2001). The minimal FGF 
binding domain has been described as terasaccharide recently (Guglieri et al., 
2008). 
IFNγ has also been identified as a GAG ligand on the basement membrane.  
The structural domain of HS that is responsible for IFNγ binding has been 
investigated and is composed of a predominantly N-acetylated and GlcA-rich 
(NA-domain) fragment flanked by two small N-sulphated oligosaccharides 
(Lortat-Jacob et al., 1995, Lortat-Jacob et al., 1996). It is thought that this 
interaction limits the extent of its C-terminal domain degradation, thus 
increasing its activity. In addition, IFNγ can also bind to soluble heparin, thus 
preventing sequestration onto the cell surface HS and inhibiting its function 
(Fritchley et al., 2000). 
 
As seen from these few examples, protein-GAG interaction has great 
physiological significance, as binding of proteins to GAGs can result in 
immobilisation and/or  activation (antithrombin III),  building of ligand-receptor 
complexes (FGF-FGFR) and protection against degradation (IFNγ). 
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1.6 Heparan sulphate biosynthesis 
HS is produced by almost any cell type and in contrast to other biomolecules, 
such as proteins, no code or template for the polysaccharide structure exists. 
The biosynthesis of HS takes place in two compartments: in the endoplasmic 
reticulum and the Golgi compartment. It is a complex reaction which can be 
divided into the stages of chain initiation, polymerisation and modification, with 
each involving a set of enzymes (Figure 1-3).  
1.6.1 Protein linkage 
The attachment site for GAGs consists of a central serine-glycine dipeptide 
flanked by one or more acidic amino acids (Esko and Zhang, 1996).This first 
step occurs in the ER. A tetrasaccharide consisiting of glucuronic acid-
galactose-galactose-xylose is linked to a hydroxyl group of the selected serine 
residue in the core protein (Sugahara and Kitagawa, 2000). The first 
monosaccharide, xylose, is transferred from its nucleotide sugar carrier UDP 
(uridine diphosphate)-xylose to the serine residue of the core protein in a 
reaction catalyzed by the enzyme UDP-xylotransferase (Esko and Zhang, 
1996). Two human xylosyltransferase isoforms have been identified, XT-I and 
XT-II, but only XT-I has been shown to be active (Gotting et al., 2000). After the 
transport of the molecule to the Golgi compartment, the first galactose is 
transferred to the molecule by galactosyltransferase I, the second galactose by 
the galactosyltransferase II. Both galactose residues can be sulphated (Silbert 
and Sugumaran, 2002), which does not happen for HS/heparin but may for 
CS/DS (Ueno et al., 2001). Then the fourth monosaccharide, glucuronic acid, is 
added by glucuronyltransferase (Kitagawa et al., 1998). 
1.6.2 Polymerization 
After the addition of an N-acetylglucosamine residue to the tetrasaccharide by 
N-acetylglucosaminyltransferase I  (Lidholt and Lindahl, 1992) the fate of the 
chain as HS is sealed and  chain elongation occurs on the non-reducing end by 
addition of alternating glucuronic acid and N-acetylglucosamine residues from 
UDP-sugar donors by EXT1 and EXT2 (Esko and Zhang, 1996). 
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1.6.2.1 EXTs 
Although EXT1 is capable of elongating the chain in vitro on its own, the chain 
elongation enzymes EXT1 and EXT2 have been shown to form a hetero-
oligomeric complex in the Golgi compartment, which is the biologically active 
form of the chain elongation machinery (Nilsson et al., 1994, Munro, 1998, 
Busse and Kusche-Gullberg, 2003). In addition, there are three EXT-like 
proteins (EXTL1-3) which also have glycosyltransferase activities, but their 
contribution to chain polymerisation is not clear (Kim et al., 2001). 
1.6.3 Modification 
Chain modification targets the glucuronic acid part as well as the glucosamine 
and can occur during chain elongation (Esko and Lindahl, 2001). The initial 
modification step is catalyzed by the N-deacetylase/N-sulphotransferase 
(NDST) enzyme. This bifunctional enzyme is responsible first for the removal of 
acetyl groups from N-acetylglucosamine. The created free amine group than 
generally gets sulphated through the sulphotransferase activity of the enzyme. 
Further modification includes the epimerization of glucuronic acid to iduronic 
acid by C-5-epimerase (Li et al., 1997). Iduronic acid (to a lesser extent 
glucuronic acid) can be further O-sulphated at the C2 position by uronosyl-2-O-
sulphotransferase (Rong et al., 2001).  
6-O-sulphation of both uronic acid and glucosamine can occur on the C6 
position by various glucosaminyl 6-O-sulphotransferases (6-OST) and the 
glucosamine can be further sulphated by glucosaminyl 3-O-sulphotransferase 
(3-OST) (Habuchi et al., 2004) (Figure 1-4). 
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Figure 1-3 Schematic representation of HS biosynthesis 
 
The synthesis of heparan sulphate is initiated by the attachment of xylose to a core 
protein, catalysed by xylotransferase. Two D-galactose residues and a glucuronic acid 
are then added sequentially by the enzymes galactosyltransferases I and II, and 
glucuronyltransferase I, respectively. Chain elongation then continues with addition of a 
single N-acetyl-glucosamine to the linkage tetrasaccharide, catalysed by N-
acetylglucosaminyltransferase I followed by the addition of alternating D-glucuronic acid 
and N-acetyl-glucosamine residues, catalysed by glucuronyltransferase II (EXT1) and N-
acetylglucosaminyltransferase II (EXT2). The chain is then modified through N-
acetylglucosamine N-deacetylation/N-sulphation, epimerisation, and O-sulphation. 
Adapted from Esko et al, 2001. 
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Figure 1-4 Schematic represenaton of HS chain modifications 
 
It was shown that epimerization and O-sulphation are all dependent on prior N-
sulphation. N-sulphation therefore predicts the overall struture of HS and 
without N-sulphation further modification will not occur (Unger et al., 1991). Due 
to this finding NDSTs are regarded as key regulators of HS biosynthesis. 
1.6.3.1 N-deacetylase/N-sulphotransferase enzymes 
NDSTs perform the first modification of the chain. The NDST enzyme family 
consists of 4 mammalian isoforms (Table 1-3), which show 65-80% sequence 
identity (Grobe et al., 2002, Esko and Selleck, 2002). In 1991 it was shown for 
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the first time that both the N-deacetylase and the N-sulphotransferase activity 
were combined in one enzyme (Pettersson et al., 1991). However, they do not 
always work together as free amine groups can occur.  
Human NDST1 was first described by Dixon and colleagues (Dixon et al., 1995) 
and human NDST2 was cloned three years later (Humphries et al., 1998). 
NDST1 and 2 are expressed ubiquitously and abundantly at a transcriptional 
level, whereas NDST3 and NDST4, which have been identified later, are 
expressed in a more restricted manner in adult brain, kidney, liver and lung and 
during embryogenesis (Aikawa and Esko, 1999, Aikawa et al., 2001, Pallerla et 
al., 2008). 
All 4 isoforms show different ratios in N-deacetylase/N-sulphotransefrase 
activity, where in NDST1 and NDST2 the N-deactylase activity is higher than 
the N-sulphotransferase activity (Aikawa et al., 2001). 
 
Table 1-3 Comparision of human NDST isoforms 
Isoform Size 
(aa) 
Chromosomal 
location 
Potential glycosylation 
sites  
Site of 
expression 
1 882 5q33.1 4 ubiquitous 
2 883 10q22 6 ubiquitous 
3 873 4q26 6 tissue specific 
4 872 4q25-26 5 tissue specific 
 
As human NDST3 and 4 are located very close on chromosome 4 it can be 
speculated that they arise from the same ancestral origin and have diverged 
through duplication during evolution. This could also be true for NDST1 and 2 
because of their similar expression pattern though their chromosomal location is 
not too close.  
All 4 isoforms are found in the Golgi compartment and also analysis based on 
the hydrophobicity values (Yuan and Teasdale, 2002) confirmed Golgi 
localisation for all 4 NDSTs (Golgi localisation prediction tool: 
http://ccb.imb.uq.edu.au/golgi/documents/). 
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The N-deacetylase activity is located at the N-terminus of the enzyme and 
requires Mn2+ ions in vitro for its function (Riesenfeld et al., 1980). 
The N-deacetylase activity predicts the degree of N-sulphation and is therefore 
rate limiting. This was shown by mutant studies in HEK 293 cells, where either a 
deacetylase or a sulphotransferase mutant was overexpressed. The 
sulphotransferase mutant still acted as a deacetylase and an endogenous N-
sulphotransferase seemed to be responsible for the transfer of sulphate groups 
resulting in oversulphation of HS. Cells overexpressing the deacetylase mutant 
did not show any increase in N-sulphation, despite large amounts of N-
sulphotransferase, pointing out that the deactelyse activity is a prerequisite for 
sulphation (Bengtsson et al., 2003). 
These findings were further confirmed by a yeast system expressing rat 
NDST1. As yeast does not express GAGs, NDST1 could be analysed in a 
“clean room”, as no GAG synthesising or modifying enzymes could interfere 
with the enzymes activity (Saribas et al., 2004).   
Both NDST1 and NDST2 act on a low sulphated HS better than on a non-
sulphated one. Further it was shown that N-sulphated HS can inhibit NDST 
activity (van den Born et al., 2003). 
The N-sulphotransferase activity is located in the C-terminus of the enzyme. 
The sulphotransferase domain of human NDST1 was crystallized and lysine614 
was identified as catalytic residue. This lysine residue can interact with PAPS 
5‟phosphate (Sueyoshi et al., 1998). 
3‟-phosphoadenosine 5‟-phosphosulphate (PAPS) is the universal sulphate 
donor for various sulphotransferases, where the 5‟-sulphuronyl group is the 
sulphate donor. PAPS is synthesized by the bifunctional PAPS synthetase, 
which combines ATP sulphurylase and adenosinphosphosulphate kinase 
activity (Venkatachalam et al., 1998). As PAPS synthesis takes place in the 
cytoplasm, it is physically separated from the area where sulphation of GAGs 
takes place, which is the Golgi compartment. Therefore, the transport of PAPS 
from the cytoplasm to the Golgi is of importance. So far, two transporters have 
been identified, which are both located in the Golgi (Kamiyama et al., 2003, 
Kamiyama et al., 2006).  
NDSTs remove acetyl groups from N-acetylglucosamine and then transfer 
sulphate groups to the substrate. But not every N-acteylglucosamine group is a 
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substrate for NDSTs. N-sulphated GlcNAcs can be found in areas with N-
acetylated domains in between. A pattern consisting of NS (N-sulphated) 
domains, separated from NA (N-acetylated) domains by NA/NS transition zones 
can be observed (Grobe et al., 2002). 
1.6.3.1.1 Regulation of NDST1 
Not much is known about the regulation of NDSTs. In 2002 it was demonstrated 
that all 4 murine isoforms of NDST have unusually long and complex 5‟ 
untranslated regions (Grobe and Esko, 2002). These 5‟ UTR have a high 
degree of secondary structures and contain several upstream AUG codons 
which interfere with normal cap-dependent ribosome scanning and translation 
initiation. These Internal Ribosome Entry Sites (IRES) offer regulation on the 
translational level (Grobe and Esko, 2002).  
Another model of NDST regulation was suggested recently. Studies in 
embryonic mouse liver led to the assumption that no regulation at 
transcriptional, translational, or posttranslational level takes place at all. 
Regulation is rather due to the assembly of the enzyme complex and the 
selection of enzymes into the complex, called the GAGosome (Ledin et al., 
2006). This model offers a more flexible way of modification where enzymes 
involved in HS modification can act at the same time or before or after each 
other. The GAGosome is thought to offer restricted numbers of binding sites for 
NDSTs and that the affinity to the GAGosome will predict which isoform is 
incorporated. There have been studies supporting this new hypothesis. In 2004, 
it was demonstrated that HS synthesised by embryonic stem cells deficient in 
NDST1 and NDST2 lack N-sulphation, still contains 6-O-sulphate groups, 
indicating modification of HS without prior N-sulphation (Holmborn et al., 2004). 
Recently, it was shown that N-sulphated domains were created in apparent 
processive mode. Extended N-sulphated domains were generated by a coupled 
N-deacetylase/N-sulphotransferase activity in vitro, which was dependent on 
the availability of the sulphate donor PAPS (Carlsson et al., 2008). It seems 
however unlikely that a process as complex as HS biosynthesis is not regulated 
at the transcriptional, translational or post-translational level at all and should be 
solely regulated by the assembly of the enzyme complex. 
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1.6.3.2 C-5-Epimerase 
The uronyl C-5-epimerase is responsible for the conversion of D-glucuronic acid 
into L-iduronic acid by switching the COO- group from above the ring to below 
the ring. So far this is the only epimerase known which acts on HS and heparin 
chains. Epimerisation seems to play an important role for protein binding to 
GAGs as almost all binding sites identified so far contain L-iduronic acid. 
Epimerisation itself is a reversible process. However, following 2-O-sulphation 
of the uronic acid and 6-O-sulphation of glucosamine the epimerisation state 
seems to be locked (Lindahl et al., 1989, Hagner-Mcwhirter et al., 2000). 
1.6.3.3 O-Sulphotransferases 
2-O-sulphotransferase is responsible for sulphate substitution on the C2 
position of both iduronic and glucuronic acid, although iduronic acid seems to 
be the preferred target (Rong et al., 2001). O-sulphation can be found in NS 
and NS/NA domains, with a tendency to act more in N-sulphated regions 
(Maccarana et al., 1996). 
3-O-sulphotransferases transfer sulphate to the C3 position of the glucosamine 
and seven different isoforms have been identified so far with distinct 
preferences for modification depending on disaccharide composition. All 
isoforms have restricted expression pattern in various tissues and not all of 
them are capable of creating anticoagulant HS (Shworak et al., 1999, Xia et al., 
2002, Girardin et al., 2005). Three 6-O-sulphotransferases have been identified 
until now and they are responsible for the sulphation of the N-
sulphoglucosamine residues. Similar to 3-O-sulphotransferases, their 
expression appears to be tissue specific (Habuchi et al., 2000, Habuchi et al., 
2003, Habuchi et al., 2006). 
1.6.3.4 Sulphatases 
Recently, another class of enzymes which modify the HS chain have been 
discovered. They are a family of 6-O-endosulphatases whose action is distinct 
from the exosulphatases, which are responsible for HS breakdown. The two 
human endosulphates SULF1 and SULF2 remove specific 6-O-sulphate groups 
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and were discovered first in quail (Dhoot et al., 2001). Even though both SULF 
enzymes have redundant function, the loss of either form leads to a specific 6-
O-sulphation pattern, possibly due to different preferred disaccharide 
composition (Ai et al., 2006). Despite the direct removal of the 6-O-sulphate 
groups, SULFs are also capable of influencing other modifications, such as 2-O-
sulphation and N-sulphation. This observation would support the GAGosome 
model, where a balanced cross talk between individual biosynthetic enzymes 
occurs rather than action independent of other (Lamanna et al., 2007). 
1.6.3.5 Heparanase 
Mammalian heparanase is another enzyme important in HS biology. It is not 
involved in HS biosynthesis, but is a HS degrading endoglycosidase (Bame, 
2001). It is highly expressed in placental tissue, but its role in normal 
development is not well understood (Haimov-Kochman et al., 2002). It seems to 
be important in pathological situations such as inflammation, whereby disruption 
of the ECM by heparanase helps immune cells to migrate into inflamed tissue, 
and cancer metastasis. HS breakdown by heparanase is required for 
angiogenesis and tumour growth and HS fragments can enhance FGF2 binding 
and signalling (Nasser, 2008). Expression of heparanase also correlates with 
the metastatic potential of tumours (Vlodavsky and Friedmann, 2001). High 
levels of heparanase were found to increase levels of overall sulphation, maybe 
compensating the loss of full chain length by „over‟sulphating shorter fragments 
(Escobar Galvis et al., 2007). 
1.7 HS in normal physiology 
HSPGs are expressed universally and ubiquitously and regulate many 
physiological and pathophysiological processes by facilitating interaction 
between ligands and their receptors on the cell surface and the ECM (Figure 1-
5). Both core proteins and the modified HS chains influence ligand binding in a 
cell/tissue and development specific manner.  
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Figure 1-5 Physiological processes modulated by HS-protein interaction 
 
 
The various functions of HS have been explored using mouse mutant models 
by either targeting the HS biosynthetic enzymes or the core proteins and a 
range of phenotypes have been described, as below.  
1.7.1 Mice deficient in HS biosynthetic enzymes 
1.7.1.1 EXT deficient mice 
In humans, EXTs are linked to autosomal dominant hereditary multiple 
exostosis, a particular benign bone tumour type. EXT1 and EXT2 null mutants 
in mice are not viable and die during gastrulation most likely due to HS 
dependent morphogen signalling (Forsberg and Kjellen, 2001, Stickens et al., 
2005). This is not surprising, as the EXTs are responsible for HS chain 
elongation and without EXT activity only short stubs will be attached to the core 
protein.  A conditional inactivation of EXT1 in the brain revealed disturbed brain 
morphogenesis and axon formation in mice and zebrafish (Inatani et al., 2003, 
Lee and Chien, 2004). 
1.7.1.2 NDST deficient mice 
1.7.1.2.1 NDST1 
Mice lacking NDST1 die perinatally due to respiratory failure. HS deficient 
epithelial cells are incapable of producing surfactant, thus resulting in lung 
failure (Ringvall et al., 2000, Fan et al., 2000). Additionally, defects of skull and 
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brain development have been observed due to disturbed growth factor 
signalling (Grobe et al., 2005). 
1.7.1.2.2 NDST2 
NDST2 deficient mice display hardly any structural alterations of HS. Defective 
connective tissue-type-mast cells lacking correctly sulphated heparin, reduced 
amounts of histamines and mast cell proteases are the only consequence of 
NDST2 loss. This relatively mild effect can be explained since NDST2 is the 
predominant form of NDSTs in mast cells whereas NDST1 appears to be the 
predominant isoform in other cells and tissues  (Humphries et al., 1999, 
Forsberg et al., 1999). 
1.7.1.2.3 2-O-sulphotransferase deficient mice 
A gene trap mutation in mouse 2-O-sulphotransferase resulted in perinatal 
death and displayed severe renal, skeletal and neuronal defects (Bullock et al., 
1998, Wilson et al., 2002). 
1.7.1.2.4 C-5-epimerase deficient mice 
Mice deficient in C-5-epimerase die perinatally possibly due to respiratory 
failure. These mice also lacked kidneys while other abdominal organs were 
unaffected (Li et al., 1997, Jia et al., 2009). 
1.7.1.2.5 3-O-sulphotransferase deficient mice 
Isoform 1 of the 3-O-sulphotransferase family has been inactivated in a mouse 
model with only mild effects such as intrauterine growth retardation (Shworak et 
al., 2002). 
1.7.2 Mice deficient in HS core proteins 
1.7.2.1 Syndecans 
Mice lacking syndecans 1, 3 and 4 have been described in the literature and 
have only subtle effects, all being viable and healthy (Ishiguro et al., 2002, 
Ledin et al., 2004). Syndecan 1 deficient mice develop normally and 
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crossbreeding studies have revealed a genetic interaction between syndecan 1 
and Wnt-1, indicating a role in tumorigenesis (Alexander et al., 2000).  
Syndecan 3 regulates feeding behaviour in the hypothalamus as mice lacking 
syndecan 3 eat less and are partially resistant to obesity (Reizes et al., 2001, 
Strader et al., 2004). 
Syndecan 4 deficient mice are healthy despite a delayed wound repair and 
impaired coagulation in fetal vessels in the placenta (Ishiguro et al., 2000, 
Echtermeyer et al., 2001). 
1.7.2.2 Glypicans 
The only glypican isoform inactivated in mice is glypican 3 and loss of function 
has major consequences. These mice exhibit developmental overgrowth and 
cystic and displastic kidneys (Pilia et al., 1996, Cano-Gauci et al., 1999). A 
similar phenotype is displayed by humans with the Simpsom-Golabi-Behmel 
syndrome, an X-linked disorder with mild phenotypes in females to lethal forms 
in some males (Filmus and Selleck, 2001). 
1.7.2.3 Perlecan 
Loss of perlecan is lethal in mice. Some mice die during embryonic 
development due to the rupture of the basement membrane of the heart 
whereas others die perinatally as a result of brain defects and skeletal 
abnormalities (Arikawa-Hirasawa et al., 1999). The Schwartz-Jampel syndrome 
in humans, which is also characterised by skeletal and developmental defects 
mutations, has been recently linked to mutations in the perlecan gene (Nicole et 
al., 2000). 
1.7.2.4 Collagen XVIII 
Loss of collagen XVIII affects the eye development in mice, similar to the 
reported Knobloch Syndrome in humans which harbour a mutation in the 
collagen XVIII gene (Sertie et al., 2000, Fukai et al., 2002). 
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1.7.2.5 Agrin 
Agrin is present in neuromuscular junctions and the central nervous system. 
Mice devoid of agrin show defective synaptogenesis (Gautam et al., 1996). 
These are the mutants of HS biosynthetic enzymes and core proteins 
investigated so far and phenotype analysis confirms the cell/tissue and 
time/developmental specific existence of HS species. This idea is strengthened 
by the observation that lack of one enzyme affects mainly one organ, whereas 
others are unaltered and vice versa, as it can be seen for C5-epimerase with 
loss of kidneys and NDST1 with impaired lungs.  Also not surprising are the 
subtle effects of 3-O-sulphotransferase mutants as only one isoform is targeted 
and others may be capable of compensating the loss depending on their 
expression throughout the tissue. Common for all phenotypes investigated is 
that the individual defects are very distinct and specific and human and mouse 
data are coherent.  
1.7.3 Tissue specific inactivation of NDST1  
Inactivation of NDST1 affects a multitude of organ systems and thus confirms 
the vital role of this enzyme. A few examples can be seen listed below (adapted 
from (Bishop et al., 2007). 
 
Digestive system: Inactivation of NDST1 in mouse liver revealed that HS acts a 
co-receptor for lipoprotein uptake (MacArthur et al., 2007). 
 
Nervous system: NDST1 inactivation in mice leads to cerebral hypoplasia, 
neural tube closure defects and eye and lens defects (Grobe et al., 2005, Pan 
et al., 2006). 
 
Skeletal system: craniofacial defects and delayed or even missing ossification 
(Grobe et al., 2005, Hu et al., 2007). 
 
Immune system: endothelial and leukocyte specific NDST1 inactivation resulted 
in decreased chemokine transcytosis and presentation and neutrophil infiltration 
(Wang et al., 2005). 
Chapter 1 Introduction 
 28 
 
 
Respiratory system: Lung hypoplasia and surfactant insufficiency in mice 
resulting from NDST1 inactivation (Ringvall et al., 2000, Fan et al., 2000). 
1.8 Transplant Biology  
Transplantation is often the only therapy for end-stage organ failure. In 1954, 
the first successful renal transplantation was performed between identical twins 
in Boston, USA, by Dr. Murray (Murray, 2002). More than a decade later in 
1967, the first liver transplant followed in Denver, USA, by Dr. Starzl (Penko and 
Tirbaso, 1999). Due to sophisticated surgical procedures nowadays organ 
transplantation is carried out routinely, but as most organs arise from genetically 
different donors (with the exception of identical twins), the immunological 
response against the graft can lead to rejection (Sayegh and Carpenter, 2004).  
Rejection is mostly due to the different major histocompatibility complex 
antigens (HLA, which exist in many different allelic forms), and AB0 blood 
groups of the donor and the recipient. Based on the onset and aetiology, the 
rejection process can be divided into three different types (Terasaki, 2003).  
1.8.1 Hyperacute rejection  
This type of rejection occurs within minutes of transplantation in patients with 
pre-existing host antibodies (such as blood type antibodies) that recognize 
antigens presented by the graft, which in turn activate the complement system 
(Fodor et al., 1994). Due to standard cross-matching and MHC tissue typing this 
process poses only limited risk in clinical settings. 
1.8.2 Acute rejection 
Acute rejection usually develops within weeks of transplantation and is caused 
by mismatched HLA antigens.  It can take place on both the cellular 
(lymphocyte mediated) and the humoral (antibody mediated) level (Le Moine et 
al., 2002, Colvin, 2007). Donor dendritic cells migrate to the lymphoid tissue of 
the recipient (Nelson and Krensky, 2001a) and activate allo-reactive 
lymphocytes, which in turn react with the vascular endothelium of the graft, 
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guided by chemotactic cytokines (el-Sawy et al., 2002). Apart from the cytotoxic 
effect of graft infiltrating lymphocytes, other inflammatory cells can be involved 
leading to necrotic cell death in the allograft. 
1.8.3 Chronic rejection 
Chronic rejection occurs within months up to several years after transplantation. 
It is often thought of to be the consequence of a multitude of acute rejections. 
Generally it is characterised by vasculopathy and fibrosis (Cornell et al., 2008). 
1.9 Heparan sulphate and chemokines in transplantation  
Chemokines presented by HS of the activated endothelium initiate the first step 
of leukocyte extravasation. This process is based on the interaction of 
chemokines presented on the endothelium and their corresponding receptors 
on leukocytes. Once leukocytes have invaded the graft, the pattern of 
chemokines secreted and displayed by HS within the tissue determines the 
positioning of the infiltrating cells. The structural heterogeneity of the HS chains 
allows HS to interact with a multitude of biomolecules. Apart from rather 
unspecific charge dependent interactions, one structurally unique HS motifs has 
been reported for antithrombin III. The existence of specific HS-protein 
interaction implies that cells and tissues can change and adopt their HS 
structure in order to interact with different HS-binding partners. Indeed, it was 
shown recently that stimulation of endothelial cells with proinflammatory 
cytokines leads to an increase of N-sulphated HS on the cell surface and 
matrix, possibly offering new binding sites (Carter et al., 2003, Ali et al., 2005a).  
1.10 Renal transplantation 
The kidney is a paired organ which serves the excretion of waste products and 
toxins from the blood. The main components of the urine are urea and uric acid 
(break down products of proteins and nucleic acids). The kidney is further 
involved in homeostasis by regulating electrolytes, acid-base balance and blood 
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pressure. In addition, it acts as an endocrine organ producing several hormones 
and processing vitamin D. 
Each kidney is a bean shaped organ with a concave and a convex side. 
Functionally, it can be divided into 3 anatomically distinct parts: the cortex, the 
medulla and the pelvis (which extends into the ureter). Blood is collected and 
filtered into the cortex, whereas the medulla concentrates the urine which in the 
end is excreted by the pelvis. The smallest structural and functional unit of the 
kidney is the nephron. The nephron consists of the renal corpuscle and the 
renal tubular structure. In the renal corpuscle the glomerulus, which is 
responsible for the blood filtration from capillaries, is embedded in a 
membranous structure, the Bowmen‟s capsule. The tubular structure has its 
origin in the cortex at the Bowmen‟s capsule and is divided into proximal tubule, 
loop of Henle and distal tubule. The proximal tubule has microvilli, the so called 
brush border, which increases the surface area for the absorption of nutrients 
(amino acids or glucose) and electrolytes (salts). The tissue surrounding the 
loop of Henle concentrates the urine by increasing the osmolarity, before the 
distal tubule reabsorbs salts for the maintenance of the appropriate pH. Finally, 
the fluid passes via the collecting ducts to the ureter and the bladder.  
1.10.1 Kidney rejection 
Renal transplantation has become the method of choice for end stage renal 
disease (ESRD) patients. There are many different causes for ESRDs, including 
diabetes, hypertension, glomerulonephritis or polycystic kidney disease. In 
general, patients in need for a renal transplant have a good prognosis with one 
year survival rates lying above 90% (Nguan and Du, 2009). Before 
transplantation, ABO blood antigens and partial HLA matching is carried out. 
Due to the shortage of donors a perfect match can rarely be found, which can 
lead to hyperacute rejection. It mainly targets the endothelium and complement 
activation results in vascular thrombosis and necrotic death of the renal tissue 
(Trpkov et al., 1996). Once this type of rejection is in full swing, which can 
happen within the first few minutes to hours after transplantation, it can be 
resistant to immunosuppressive therapy and therefore better cross matching 
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and panel reactive antibody titre tests (describing the level of sensitisation to 
donor antigens) should be carried out (Jordan and Pescovitz, 2006).  
Acute rejection occurs within weeks up to months following transplantation and 
can be reoccurring throughout the entire lifespan of the graft, thereby increasing 
the chances of developing chronic rejection. It can be antibody mediated as well 
as T-cell mediated. Acute antibody mediated rejection (AMR) makes up for 25% 
of acute rejection episodes (Cornell et al., 2008) and resembles the histological 
changes described for hyperacute rejection. As compared to hyperacute 
rejection, its onset is days up to weeks after transplantation of the graft, which 
has been working before (Halloran et al., 1990). It is defined by injury to the 
endothelium and the existence of C4d, a cleavage product of the complement 
system that becomes bound to peritubular arteries at the site of activation 
(Racusen and Haas, 2006). Today, high dosage of intravenous Ig, 
plasmapheresis and immunoadsorption allow a reversal rate of up to 90% of 
AMR (Bohmig et al., 2001, Crespo et al., 2001, Racusen and Haas, 2006).  
T-cell mediated rejection (acute cellular rejection) can occur alone or in 
conjunction with AMR. It is characterised by the infiltration of the allograft 
interstitium with mononuclear cells. This leukocyte recruitment is controlled by 
chemokines, which are present on endothelial cells and corresponding 
chemokine receptors, present on the leukocytes. After chemokine-mediated 
penetration of the graft tissue, the leukocytes can secrete cytokines which 
activate graft resident tubular epithelial cells which in turn can produce 
chemokines directing leukocyte subpopulations to tubular epithelial 
compartments within the graft. A number of chemokines have been shown to be 
expressed during acute cellular rejection, such as CCL2, CCL3, CCL4 and 
CCL5 (Robertson et al., 1998, Nguan and Du, 2009). The infiltration of CD4 and 
CD8 lymphocytes as well as monocytes to the tubules is called tubulitis. The 
number of T cells infiltrating the tubules correlates with long term survival of the 
graft and identification of the leukocyte subsets infiltrating the tubules could 
strengthen the diagnosis of acute rejection and could help to predict further 
outcome (Racusen et al., 1999, Robertson and Kirby, 2003). In most severe 
cases the arterial endothelium becomes a target and can undergo necrosis.   
Acute rejection can be divided into different stages of disease according to the 
Banff Schema, a universal classification of renal allograft pathology (Table 1-4, 
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adapted from (Solez et al., 2007). This schema was introduced in 1995 
(Racusen et al., 1995) and has been updated ever since (Racusen et al., 1999, 
Solez et al., 2007, Solez et al., 2008, Sis et al., 2010). 
 
Table 1-4 Grading of acute renal allografts 
Type 
(grade) 
Histopathological findings 
IA Cases with significant interstitial infiltration (>25% of parenchyma affected) and 
foci of moderate tubulitis 
IB Cases with significant interstitial infiltration (>25% of parenchyma affected) and 
foci of severe tubulitis 
IIA Cases with mild to moderate intimal arteritis 
IIB Cases with severe intimal arteritis comprising >25% of the luminal area 
III Cases with transmural arthritis and/or fibrinoid changes and necrosis of medial 
smooth muscle cells with accompanying lymphcytic inflammation 
Adapted from Banff 97 (Solez et al, 2007) 
 
Chronic rejection is often thought of as the result of cumulative individual acute 
rejection episodes. It is still poorly understood, but there is evidence that chronic 
rejection correlates with the severity of the acute rejection (Robertson et al., 
2004). It can be caused by both antibody or T-cell mediated rejection and is not 
curable at the time. Histological features of chronic rejection are transplant 
glomerulopathy (duplication or multilamination of the glomerular basement 
membrane; if accompanied by C4d deposits referred to as chronic humoral 
rejection), peritubular capillaropathy (duplication or multilamination of basement 
membrane), transplant arteriopathy (neointimal thickening with scattered 
mononuclear cells), interstitial fibrosis and tubular atrophy (Colvin, 2006, Cornell 
et al., 2008). Tubular epithelial cells undergo epithelial to mesenchymal 
transition (EMT) in response to TGFß and migrate to the interstitium where they 
transform into myofibroblasts (Liu, 2004). Myofibroblasts together with 
fibroblasts in the interstitium produce excessive amounts of ECM. Excessive 
production with reduced degradation of ECM can result in massive ECM 
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deposition and fibrosis (Qi et al., 2006). Chronic rejection can be graded 
semiquantitatively as mild, moderate or severe according to interstitial fibrosis 
and tubular atrophy. 
1.11 Liver transplantation  
The liver is the largest solid organ of the body and is highly metabolically active. 
It is involved in the production, the break down and the storage of glucose; the 
synthesis of various proteins including blood clotting factors and acts as a store 
for a range of molecules, including vitamins and minerals. It is also responsible 
for regulating lipid metabolism.  
Another important feature of the liver is its capacity to remove impurities from 
the blood and the detoxification of undigested or harmful substances. Bile, a 
substance essential for the absorption of fat and fat soluble vitamins, is also 
produced and secreted by the liver. It is produced by hepatocytes and then 
transported to the gallbladder and small intestine, where it exerts its function.  
The smallest functional unit of the liver are the lobules. A single lobule has a 
roughly hexagonal shape with the hepatic vein in the centre. At the corners of 
the lobule the portal tract (or portal triad) is located, consisting of the hepatic 
artery, the portal vein and the bile duct, which are covered by connective tissue 
and hepatocytes. The hepatic artery and portal vein bring blood, carrying 
oxygen and nutrients, to the sinusoids. Sinusoids are very thin blood vessels 
with a discontinuous endothelial cell layer, allowing an easy exchange of 
proteins, also closely associated with Kupffer cells. 
1.11.1 Liver rejection 
Transplantation has been proven to be very efficient treatment for endstage 
liver disease with excellent survival rates (90% one year after transplant and 
75% long term survival (Desai and Neuberger, 2009). In the UK, the most 
common reasons for a liver transplant are alcoholic cirrhosis, chronic hepatitis 
and primary biliary cirrhosis (www.uktransplant.org.uk). Before transplantation, 
ABO blood group matching between donor and recipient is performed. Of minor 
importance is HLA cross-matching, as the liver is not very immunogenic.   
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In contrast to renal transplantation, hyperacute rejection, which is dependent on 
preformed antibodies and activation of the complement system, does rarely 
occur in hepatic rejection. It is not completely understood why livers hardly 
develop hyperacute rejection (also referred to as humoral rejection) but it could 
be due to the binding and inactivation of damaging antibodies to Kupffer cells or 
soluble histocompatibility antigens (Demetris and Markus, 1989).  
The basis of the cellular rejection is lymphocyte infiltration into the allograft.  
These activated lymphocytes are guided into the graft by chemokines, which 
are expressed and presented by the endothelium of both sinusoids and portal 
vessels. After entering the graft, the pattern of chemokine secretion and 
retention determines the positioning of the infiltrating T-cells. Biliary epithelial 
cells have been shown to secrete a number of chemokines, such as CCL2 and 
CCL5, which direct lymphocytes in the proximity of bile ducts (Goddard et al., 
2001).  
Acute cellular rejection is characterized by mainly three pathological features. 
Firstly, a massive infiltrate of inflammatory cells. Cells infiltrating the portal tract 
usually comprise a mixture of inflammatory cells, but mononuclear cells are the 
most prominent. Secondly, bile duct inflammation and injury (Vierling and 
Fennell, 1985) and finally, inflammation of the portal or terminal hepatic veins, 
caused primarily by lymphocytes (Ludwig, 1989, Batts, 1999). At least two of 
the three above described features have to be displayed to establish the 
diagnosis of an acute rejection (together with other evidence, such as 
biochemical markers).  Once this diagnosis has been established, the rejection 
can be graded according to severity based on the Banff Schema developed for 
liver rejection based on the Banff schema for renal rejection. It is based on the 
severity of inflammation plus morphological changes due to rejection related 
ischemia (Table 1-5). 
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Table 1-5 Grading of acute liver allogarfts 
Global 
Assessment 
Criteria 
indeterminate Portal inflammatory infiltrate fails to meet criteria for the diagnosis of acute 
rejection 
mild Rejection infiltrate in a minority of triads, generally mild and confined within 
the portal spaces 
moderate Rejection infiltrate, expanding most or all of the triads 
severe As moderate, with spillover into periportal areas and moderate to severe 
pervenular inflammation that extends into the hepatic parenchyma and is 
associated with pervenular hepatocyte necrosis 
Adapted from Banff Schema for Grading Liver Allograft rejection, 1995 
 
After the descriptive global assessment, a semi-quantitative scoring of the three 
specific features: portal-, bile duct- and venular inflammation, can be conducted 
if necessary. Acute hepatic rejection affects almost two thirds of the patient 
population (Tippner et al., 2001) and typically develops within the first 30 days 
(Neuberger and Adams, 1998) after transplantation. The early onset generally 
corresponds with a good prognosis and is susceptible to additional 
immunosuppression (Anand et al., 1995). Late acute rejection (onset after 6 
months) affects up to 20% of transplant patients (Uemura et al., 2008) has a 
poorer prognosis and has been associated with reduced survival of the liver 
(D'Antiga et al., 2002). 
Chronic hepatic rejection is a rare event, most likely due to the specific 
immunological characteristics of the organ and its regenerative capacity (Tiegs 
and Lohse, 2010) and the good recognition and treatment options of acute 
rejection. If acute rejecting liver is resistant to immunosuppression, chronic 
rejection, often linked to chronic graft failure, can develop. It is characterized by 
persistent inflammation of the portal tract and a severe damage and loss of 
intrahepatic bile ducts and hepatic arteriolar thickening (Demetris et al., 2000).  
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1.12 Heparan sulphate in tissue remodelling  
Whilst tissue remodelling is an important physiological process which is crucial 
and beneficial during development or wound healing after injury, sustained 
tissue remodelling caused by persistent injury or chronic inflammation after 
transplantation can lead to fibrosis and ultimately results in graft failure. Fibrosis 
is characterized by excessive accumulation and reduced degradation of ECM 
(Qi et al., 2006). As HS facilitates cell-cell and cell-matrix interaction by binding 
many factors involved in this process it is not surprising that HS is thought to 
play an important role in tissue homeostasis in general and the development of 
fibrosis in particular. 
 
Liver Fibrosis 
Liver fibrosis is characterized by the accumulation of myofibroblasts which 
produce excessive amounts of ECM such as collagens I, III and IV, fibronectin, 
laminin, hyaluronan and HSPGs (Gressner and Haarmann, 1988, Schuppan, 
1990).This ongoing deposition of ECM leads to the formation of a scar and 
ultimately leads to cirrhosis, characterized by abnormal nodule formation and 
organ contraction (Lotersztajn et al., 2005).  
Inflammatory lymphocytes infiltrate the liver parenchyma upon persistent injury, 
guided by chemokines presented by HSPGs. After the apoptotic cell death of a 
fraction of hepatocytes, Kupffer cells release fibrogenic mediators, which in turn 
activate hepatic stellate cells (HSC) (Bataller and Brenner, 2005). In normal 
liver, HSC function as Vitamin A storage. They are found in the space of Disse, 
but upon activation after chronic injury they lose Vitamin A and differentiate into 
myofibroblasts (Gabele et al., 2003), synthesizing collagen I rich matrix 
(Friedman et al., 1985). Platelet derived Growth factor (PDGF), mainly 
produced by Kupffer cells is the main mitogen for activated HSC. PDGF-B has 
been shown to bind to HS (Lindblom et al., 2003) and studies in mice revealed 
that N-sulphation and 6-O-sulphation are required for PDGF-B binding and 
subsequently for pericyte recruitment (Abramsson et al., 2007). 
Other sources of ECM apart from HSC are portal fibroblasts (Beaussier et al., 
2007) and also epithelial cells, which undergo epithelial-to mesenchymal 
transition, have been implicated as potential source, with TGFβ being a main 
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inducer of the EMT process (Liu, 2004, Rygiel et al., 2008).TGFβ also 
stimulates ECM production and inhibits its degradation in the liver (Shek and 
Benyon, 2004). Elevated levels of TGFβ are often found in fibrotic livers (Liu et 
al., 2006). Hepatocyte growth factor (HGF), which also requires HS as a 
cofactor (Catlow et al., 2008) can attenuate fibrosis by inhibiting TGFβ driven 
EMT (Xia et al., 2006). Fibrogenic liver tissue derived from chronic cholestatic 
diseased human livers revealed an increase of syndecan-1 and perlecan in 
ductular cells whereas HSC showed enhanced syndecan-3 expression; cultured 
HSC even showed increased expression of all 4 syndecans, perlecan and 
glypican, pointing out the important role of these matrix components in liver 
fibrogenesis (Roskams et al., 1996). Increased levels of perlecan have also 
been found in the ECM from chronically damaged livers of rats (Gallai et al., 
1996). Another HSPG found overexpressed in cirrhotic livers is agrin (Tatrai et 
al., 2006). Recently, a study investigated changes in HS related to fibrogenesis 
in humans and rats and revealed an overall increase HS, specifically an 
increase in N-sulphation, 2-, 3- and 6-O-sulphation for both species. Also, levels 
of syndecan and perlecan were elevated in human cirrhotic livers (Tatrai et al., 
2010). 
 
Renal fibrosis 
 Chronic injury in kidneys, like chronic rejection, often leads to fibrosis, which is 
characterized by excessive accumulation and deposition of ECM, such as 
collagens I, III and IV, fibronectin, laminin and HSPGs (Klahr and Morrissey, 
2002, Miyazaki et al., 2003). Ongoing deposition of ECM leads to fibrous 
scarring of the tissue and ultimately to graft dysfunction and failure (Liu, 2006). 
Following injury, inflammatory lymphocytes, guided by pro-inflammatory 
chemokines presented by HSPGs, infiltrate the kidney. Proninflammatory 
cytokine and fibrogenic factors are released by inflammatory cells which in turn 
activate mesangial cells and fibroblasts and trigger EMT of tubular epithelial 
cells, which leads to the excessive production of ECM. TGFβ  has been 
identified as main inducer of EMT  (Schnaper et al., 2003). In vitro, TGFβ on its 
own can induce activation of mesangial cells and fibroblasts or activation of 
tubular epithelial cells (Yang and Liu, 2001). Elevated levels of both TGFβ-1 
and its receptor have been found in renal tubular epithelial cells upon injury 
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(Yang and Liu, 2002). Hepatocyte growth factor can prevent renal fibrosis by 
inhibiting TGFβ-1 expression (Liu, 2002).  
Recently, also endothelial cells were identified as origin of fibroblasts, after they 
underwent so called „endothelial to mesenchymal transition‟ (Zeisberg et al., 
2008). 
Increased expression of HSPGs has been observed in renal fibrotic lesions 
(Born et al., 1996), which was accompanied by increased chemokine binding 
capacity by HS (Ali et al, 2005; Celie et al, 2007). Increased binding of L-
selectin and CCL2 to tubulointerstitial HSPGs has been observed in an array of 
renal diseases; upregulation of syndecan 1 on tubular epithelial cells co-
localizing with L-selectin and CCL2 binding HSPGs was shown (Celie et al, 
2007). Recently, the role of HSPGs in tissue remodelling in chronic transplant 
dysfunction was demonstrated. Increased expression of HS was found in 
intrarenal arteries, glomeruli and the tubulointerstitium. Collagen XVIII and 
perlecan expression was induced in arteries with vasculopathy and sclerotic 
glomeruli, whereas versican, a chondroitin sulphate proteoglycan, was 
predominant in interstitial fibrosis. Glomerular remodelling was defined by 
pronounced expression of perlecan in the glomerular basement membrane. 
Collagen XVIII production was further induced in corticular tubular basement 
membranes (Rienstra et al, 2010). 
As HS binds to growth factors, profibrogenic cytokines and also matrix 
metalloproteases (Yu and Woessner, 2000), which are involved in the 
degradation of the ECM, the changes in HSPG expression as well as HS 
modification are likely to modulate the tissue remodelling process. 
1.13 Specific aims of this study 
The endothelium can be regarded as a gatekeeper as its function is to separate 
tissues from peripheral blood leukocytes. The resting endothelium provides an 
anti-inflammatory environment. Therefore leukocyte infiltration can only occur if 
the endothelium is activated and promotes this process. During transplantation, 
ischemia/reperfusion syndrome and mechanical stress targets leukocytes into 
microvascular spaces (Ambrosio and Tritto, 1999, Linfert et al., 2009). The 
multistep process of leukocyte recruitment into the allograft is based on 
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interactions between adhesion molecules expressed both on the leukocyte as 
well as on the endothelium (Barreiro et al., 2010). Inflammatory mediators, such 
as TNFα, are produced and lead to an upregulation of adhesion molecules, 
which are responsible for leukocyte rolling and firm adhesion. The activation of 
leukocyte-expressed integrins by chemokines, bound to endothelial GAGs, 
leads to firm adhesion of the leukocyte on the endothelium (Middleton et al., 
2002). Finally, chemokines promote the diapedesis of leukocytes. Once the 
leukocytes have entered the graft specific subpopulations can be further guided 
into the tissue by HS-immobilised chemokines.   
The activation of these pro-inflammatory pathways can then lead to irreversible 
injury of the endothelium and of the graft, resulting in graft rejection.  
 
This study aims to further elucidate the current understanding of Heparan 
Sulphate Proteoglycans during inflammation.  
 
The specific aims of this study are as follows: 
 
 Analysis of HS expression pattern in healthy   tissues and tissues derived 
from organs undergoing rejection 
 
 Investigation of the regulation of Heparan Sulphate biosynthesis  at the 
protein level targeting  the key enzyme NDST1 
 
 Examine the consequence of modulation of NDST1 expression on HS 
structure and function 
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2 General Materials and Methods 
2.1 General laboratory practice 
All experimental procedures were conducted in accordance with „Newcastle 
University safety policy‟ and „Institute of Cellular Medicine safety policy‟. 
Laboratory work was performed in accordance with University publication „Safe 
working with biological hazards‟ and „Safe working with chemicals in the 
laboratory‟. Tissue culture was carried out in compliance with regulations for 
containment of class II pathogens and BIOCOSHH and COSHH risk 
assessments were conducted before commencing any work. 
2.2 Cell culture 
2.2.1 Culture media 
Culture media used in this study included Dulbecco‟s Modified Eagle Medium 
(DMEM, 4.5g/l Glucose, 110mg/l sodium pyruvate, Cambrex); Roswell Park 
Memorial Institute 1640 (RPMI, Cambrex); Dulbecco‟s Modified Eagle 
Medium:Nutrient F12 Ham (DMEM-F12, Cambrex) and endothelial basal 
medium (MCDB-131, Sigma; supplemented with 10ng/ml epidermal growth 
factor (EGF) and 1µg/ml Hydrocortisone) . All media were supplemented with 
2mM L-glutamine, 100U/ml Penicillin, 100μg/ml Streptomycin and 10% heat 
inactivated foetal calf serum (FCS) (all supplied by Sigma). 
The antibiotic G418 sulphate (Calbiochem) was added in varying concentrations 
for transfectant selection (800μg/ml) and propagation (400μg/ml). 
 
2.2.2 Cell lines 
2.2.2.1 HEK 293  
The human embryonic kidney cell line was obtained from the American Type 
Culture Collection (ATCC) and cultured in complete DMEM. Cells have been 
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transformed with adenovirus 5 DNA. They have epithelial appearance and are 
semi-adherent. 
2.2.2.2 THP1  
The monocytic suspension cell line was obtained from ATCC and cultured in 
complete RPMI. This cell line can easily differentiate into macrophages 
following stimulation. Cells were originally isolated from peripheral blood of a 
one year old boy with acute monocytic leukaemia.  
2.2.2.3 PBMC 
Peripheral blood mononuclear cells were extracted from fresh blood provided by 
healthy volunteers. After adding heparin (0.5U/ml) to the blood, an equal 
volume of serum-free medium was added. Density gradient separation was 
performed by underlaying the diluted blood with 3ml of Lympholyte-H 
(Cedarlane) and centrifuged it at 800 x g for 20 minutes. The interface layer 
containing PBMCs was carefully removed and washed once in serum free 
RPMI before being cultured in complete RPMI. 
2.2.2.4 CHO 
The Chinese hamster ovary cell line was cultured in complete DMEM-F12. Wild 
type cells are referred to as CHO-K1 whereas the CHO-745 cells refer to a 
glycosaminoglycan deficient strain lacking of xylosyltransferase, a key enzyme 
in HS biosynthesis. These cells were kindly provided by Prof. Jeff Esko, 
University of San Diego La Jolla, USA. 
2.2.2.5 HMEC-1 
The human microvascular endothelial cell line was obtained from ATCC and 
cultured in complete MCDB-131. 
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2.2.2.6 HK-2 
This renal proximal tubular epithelial cell line has been isolated from normal 
human adult kidney and was immortalized by transduction with human 
papilloma virus 16 DNA. Cells were obtained from ATCC and cultured in 
complete DMEM-F12. 
2.2.2.7 HepG2 
The hepatocellular carcinoma cell line with epithelial morphology was obtained 
from ATCC and cultured in complete DMEM. 
All cells were grown at 37ºC and 5% CO2. 
2.2.3 Sub-culturing of cells 
Adherent cells were grown horizontally in tissue culture flasks (Corning) of 
variable sizes (25, 75, and 150 cm2). Subculturing was performed in a ratio of 
1:3 depending on cell density every 3 to 4 days. 
Culture medium was removed and cells were washed with PBS (Sigma). 
Sufficient amounts of Trypsin-EDTA solution (Sigma) was added and cells were 
incubated at 37ºC for 5 minutes. The Trypsin/EDTA solution was then 
inactivated by addition of the same volume of culture media. This mixture was 
then transferred to a universal centrifuge tube (SLS).  Cells were centrifuged at 
500 x g for 5 minutes and the pellet was resuspended in fresh culture media. 
Suspensions cells were grown vertically in tissue culture flasks and subcultured 
when necessary.  
2.2.4  Cell counting 
Cells were counted using an improved Neubauer chamber Haemocytometer 
(Reichert). Typically, 10µl of resuspended cells were allowed to diffuse beneath 
the coverslip. Cells in the 25 central squares of the grid were counted and the 
total multiplied by 1x104 to obtain the number of cells per millilitre.  
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2.2.5 Cryopreservation of cells 
Cells were cryopreserved in liquid nitrogen. Cells were detached from tissue 
culture flasks, pelleted and resuspended in 0.5ml of culture medium. To this 
0.5ml of freezing medium was added, consisting of 20% dimethylsulfoxide 
(DMSO, Sigma) in FCS, resulting in a final DMSO concentration of 10%. This 
mixture was transferred into a cryovial (Corning) and slowly cooled at 
1ºC/minute in a freezing vessel (Nalgene) containing isopropanol at -80ºC at 
least over night prior to final storage in liquid nitrogen.  
Recovery of the cells was achieved by rapid thawing of the cryovial contents in 
a waterbath at 37ºC and their addition to 5-10ml of culture media in a 25cm2 
flask. After 24 hours DMSO-containing media was replaced with fresh culture 
media. 
2.2.6 Mycoplasma testing and treatment 
Mycoplasma sp. infection can affect a variety of cellular processes, including 
reduced cell proliferation and changes in gene expression. The origin of 
contamination is often the researcher himself, as one subspecies of 
Mycoplasma lives in the respiratory tract. Apart from fluorescence microscopy, 
which can detect the nuclei of Mycoplasma after 4',6-diamidino-2-phenylindole 
(DAPI) staining, a selective biochemical test was used in this study. The 
MycoAlert kit (LONZA) relies on the activity of certain mycoplasmal enzymes. 
After lysing mycoplasma the enzyme can react with the MycoAlert substrate 
catalyzing the conversion of ADP to ATP. This increase in ATP can be 
measured in a bioluminescent reaction, where the emitted light is linearly 
related to the ATP concentration. Mycoplasma testing was performed according 
to the manufactures instructions. In short, 100µl of culture supernatant were 
mixed with 100µl of MycoAlert reagent and after 5 minutes the first 
luminescence reading was taken (reading A). After the addition of 100µl of 
MycoAlert substrate a further 10 minutes of incubation time followed, after 
which the final luminescence reading was taken (reading B). The ratio of 
reading B to reading A was determined and ratios smaller than 1 were 
considered mycoplasma negative. If readings greater than 1 were obtained, 
cells were either replaced with healthy cells or if necessary cleaned up with 
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mycoplasma removal agent (MRA, Serotec). MRA shows strong anti-
mycoplasma activity against many types of mycoplasma, including Mycoplasma 
orale, M. arginini, M. hyorhinis and Acholeplasma laidlawii. Cell culture media 
was supplemented with 0.5µg/ml MRA and cells were incubated for up to 10 
days. Testing with the MycolAlert kit was repeated after removal of the agent. 
2.3 General molecular biology techniques  
2.3.1 Bacterial culture 
E. coli were grown in LB-media (10g/L Bacto-tryptone, 5g/L Bacto yeast extract 
and 10g/L Sodium chloride; Sigma) at 37ºC in an orbital shaker. When grown 
on plates, LB Agar was used. After transformation of the bacteria the media was 
supplemented with antibiotics for selection of transformants. In these studies 
transformants were selected with Ampicillin (Sigma) at a final concentration of 
100µg/ml or Kanamycin (Sigma) at a final concentration at 50µg/ml. For the 
stock solution, antibiotics were dissolved in sterile ddH2O (100mg/ml ampicillin 
and 50mg/ml kanamycin). 
For long term storage, 0.5ml of an overnight culture was mixed with 0.5ml 40% 
glycerol (Sigma), resulting in a final concentration of 20% glycerol. Cells were 
kept at -80ºC.  
2.3.2 Preparation of competent cells and transformation 
Transformation describes the uptake of foreign DNA into a prokaryotic cell. 
Cells which are capable of DNA uptake are naturally competent; other cells are 
not naturally competent or not competent under certain conditions (e.g. E.coli 
grown in full media in the labratory) and have to be treated in a certain way to 
gain competence.  
In this study CaCl2 competent E.coli JM109 cells were used, which were 
obtained from Promega or competent cells were prepared as described: 
A single colony of E.coli XL-1-Bue was inoculated in 2ml of LB media and 
grown over night. 1ml of this suspension was transferred into 50ml of fresh LB 
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media. Cells were incubated in an orbital shaker until they reached an OD600 of 
0.3-0.4. Cells were then chilled on ice for 10 minutes before harvesting at  
2500 x g for 7 minutes at 4ºC. Cells were kept on ice all the time. 
The pellet was carefully resuspended in 10ml of 100mM CaCl2 solution and 
spinned at 2000 x g for 5 minutes at 4ºC. Again the pellet was carefully 
resuspended in 10ml of 100mM CaCl2 solution and kept on ice for 30 minutes. 
After spinning at 2000 x g for 5 minutes at 4ºC the pellet was resuspended in 
ice cold CaCl2 with 15% glycerol (Sigma). Cells were then aliquoted and frozen 
in liquid nitrogen. Until use, cells were stored at -80Cº. 
 
Plasmid DNA (1-10µl; 10-100ng) was kept on ice for 5 minutes before 100 µl of 
chilled bacteria were added. After 30 minutes of incubation on ice the mixture 
was heat shocked at 42ºC for 2 minutes in a water bath. 0.9ml of LB media was 
added and after 30 minutes of regeneration time at 37ºC cells were plated onto 
LB-Agar plates containing appropriate antibiotics. 
The plates were incubated upside down at 37ºC over night to allow single 
colonies to grow. 
All strains used in these studies are listed in Table 2-1. 
Table 2-1 Comparision of E. coli strains used in this study 
Strain Genotype Origin 
E. coli XL-1-Blue endA1 gyrA96(nalR) 
 thi-1 recA1 relA1 lac glnV44 
F'[ ::Tn10 proAB+ lacIq 
Δ(lacZ)M15] hsdR17(rK- 
mK+) 
Stratagene 
E. coli JM 109 endA1 glnV44 thi-1 relA1 
gyrA96 recA1 mcrB+ Δ(lac-
proAB) e14- [F' traD36 
proAB+ lacIq lacZΔM15] 
hsdR17(rK-mK+) 
Promega 
E. coli Solo pack tetr ∆(mcrA)183 ∆(mcrCB-
hsdSMR-mrr)173 endA1 
supE44 thi-1 recA1 gyrA96 
relA1 lac 
Hte [F´ proAB lacIqZ∆M15 
Tn10 (Tetr) Amy Camr] cre 
Stratgene 
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2.3.3 Plasmid DNA extraction 
Plasmid DNA isolation from transformed bacteria was performed using kits 
based on the modified alkaline lysis method. Dependent on the required amount 
of DNA, DNA-Mini-, Midi- or Maxiprep kits (Qiagen) were used. When DNA was 
required for transfection an endotoxin free kit was used (Sigma). 
Endotoxin consists of lipopolysaccharides and which are a major constituent of 
the outer membrane of gram-negative bacteria (E. coli). When they are 
released they initiate a host response in mammals which should be avoided. 
DNA isolation was performed according to the manufactures instructions.  
Briefly, transformed bacteria were grown over night under selection pressure. 
Cells were pelleted and resuspended and lysis was induced by the addition of 
NaOH and SDS.  The addition of RNase to the buffer assured the degradation 
of all RNAs. The reaction was then neutralised and precipitated denatured 
proteins, chromosomal DNA and cell debris were removed. In the presence of a 
high salt concentration plasmid DNA was bound to a silica membrane and later 
eluted in a low salt buffer or H2O.  
2.3.4 Nucleic acid quantitation 
DNA was quantified either using spectrophotometry at 260nm wavelength 
(Eppendorf BioPhotometer, Eppendorf or Nanodrop, Thermo Scientific) or by 
running an agarose gel and comparing the intensity of the bands to bands of a  
Hyperladder  with known DNA concentrations.   
When DNA or RNA were quantified spectrophotometrically, only samples with 
OD 260/280 and OD 260/230 ratios >1.8 were considered good quality. 
Measurements with 260/280 ratios <1.8 are indicative for protein contamination 
whereas 260/230 readings <1.8 indicate the presence of salts, solvents or 
proteins. 
2.3.5 Precipitation of DNA 
To increase the concentration of DNA and to remove impurities ethanol 
precipitation was performed. 3M Sodium Acetate (pH 5.2) was added to the 
DNA with a resulting final concentration of 0.3M. 2.5 volumes of ice-cold ethanol 
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absolute were added and this mixture was incubated at -80ºC for at least 20 
minutes. The absolute ethanol precipitates DNA as well as salts. After a 
centrifugation step the pelleted DNA was washed in 70% ethanol to remove 
residual salts. The pellet was air dried and resuspended in an appropriate 
volume of sterile H2O. 
2.3.6 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate nucleic acid fragments 
according to their size. An electric field is applied to the gel and the negatively 
charged DNA molecules migrate through the matrix towards the positive 
electrode. Gels were routinely run at 85V with 1 x TAE (40mM Tris, 20mM 
acetic acid, 1mM EDTA; pH 8) as running buffer. The agarose (Bioline) was 
dissolved in 1 x TAE buffer whilst heating in a microwave. Dependent on the 
expected size of the DNA fragments 0.8 – 1.7% gels were used. The rate of 
migration is dependent on the size and form of the DNA. Smaller fragments 
migrate more quickly than larger ones and linear DNA migrates slower than 
supercoiled DNA. To determine the size of DNA fragments molecular weight 
markers with known fragment sizes are run on each gel. In this study either a 
100bp ladder with fragments from 100bp to 1500bp (Promega) or Hyperladder 1 
(200bp -10000bp) from Bioline were used. To allow the DNA to sink into the 
wells of the gel and for visualisation a DNA loading buffer was added, e.g. 
Orange G buffer (30% glycerol, 0.25% Orange G). For visualisation of the DNA 
on a UV screen the intercalating agent ethidium bromide was added to the gel 
at a final concentration of 0.5µg/ml. 
2.3.7 Isolation of DNA fragments  
DNA fragments were excised from agarose gels following electrophoresis 
separation using a sterile scalpel. The DNA was purified using the Wizard SV 
Gel and PCR Clean-up System (Promega).  The gel slice was incubated with 
membrane Binding Solution at 60ºC until it was completely dissolved. This 
mixture was applied to a Minicolumn and the DNA bound to the silica 
membrane. After two washing steps with membrane Wash Solution the DNA 
was eluted in nuclease-free water. The DNA was then stored at -20ºC.   
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2.3.8 Cloning and use of restriction enzymes 
Restriction enzymes are a group of endonucleases isolated from bacteria. They 
are able to hydrolyse DNA in a sequence specific manner. In the lab type II 
restriction endonucleases are of common use as they cleave DNA within the 
target sequence and do not posses methyltransferase activity. Target 
sequences are predominantly palindromic sequences consisting of 4, 6 or 8 
basepairs. Hydrolysis of target DNA can result in blunt ends or single stranded 
3‟ or 5‟ overhangs, so called sticky ends. All the restriction enzymes used in this 
study were obtained from Promega and were used according to the 
manufacture‟s guidelines. Per definition, one unit of restriction enzymes can 
cleave one µg of Lambda-DNA under optimal buffer conditions in one hour at 
37ºC.  
In general, restriction digestions were incubated for at least 2 hours at 37ºC or 
over night. If double digestions were performed, enzyme buffers which offered 
both enzymes the best conditions, were chosen. 
Dependent on the enzyme heat inactivation was performed if necessary. 
For the ligation of insert DNA into an appropriate vector a molar ratio of insert to 
vector of 3:1 was used. The T4 ligase (Promega) from Bacteriophage T4 
catalyzes the formation of a phosphodiester bond between 5' phosphate and 3' 
hydroxyl termini in duplex DNA. Ligation reactions were generally performed 
over night at 16ºC. 
2.3.9 DNA sequencing 
Automated DNA sequencing was used to determine the sequence of the 
created construct. Sequencing was performed at Geneservice, Cambridge 
using the chain termination method originally developed by Sanger. 
2.4 DNA transfection 
Transfection of eukaryotic cells is a technique used to deliver foreign DNA 
molecules into cells to study gene expression. 
It can be discriminated between two different types of transfection, transient and 
stable transfection.  
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Transiently transfected cells do not integrate foreign DNA into their genome 
therefore many copies of the gene of interest must be present in the cells. 
Transient transfection leads to high expression levels of the gene of interest, but 
this effect only lasts for a few days. Transiently transfected cells must be 
analysed within 24 to 96 hours after transfection, because cells lose their 
plasmids with every cell division. 
Stable transfection is used to achieve a permanent expression of the gene of 
interest. Foreign DNA can either be incorporated into the host genome or the 
vector can be maintained episomally. Transfectants can be selected due to the 
antibiotic resistance marker of the plasmid. To avoid mixed populations, single 
clones must be picked and expanded. 
Many different transfection kits are commercially available. In this study, the 
Effectene transfection kit (Qiagen) was used.  At first, the DNA is condensed by 
interaction with the positive charged enhancer. Then, the condensed nucleic 
acid is coated with a cationic lipid micelle. This transfection complex is finally 
taken up into the cells by endocytosis.  
Transfection was performed according to the manufacturer‟s instructions.  
Briefly, 2 x 106 HEK 293 cells/100mm dish were seeded the day before 
transfection. On the day of transfection cells were 60-70% confluent. 2μg of 
DNA were mixed with the DNA condensation buffer EC and supplemented with 
enhancer to allow DNA condensation. This mixture was incubated at RT for 25 
minutes and Effectene Transfection Reagent was added. In order to form 
transfection complexes, the sample was incubated for 10 minutes at RT. 
Different DNA:Effectene Transfection Reagent ratios were used (1:10, 1:30, 
1:50). Culture medium was gently removed from the dishes, cells were washed 
with PBS and fresh culture media was added. The transfection complex was 
mixed with growth media and then added drop-wise onto the cells in the 100mm 
dishes. 48 hours after transfection antibiotics were added. The vector used has 
a neomycin resistance cassette. As neomycin is toxic, an analogous antibiotic, 
G418 sulphate (Calbiochem) was added (800µg/ml). Both antibiotics inhibit the 
protein biosynthesis by interfering with the 80S ribosome.  
Single clones were selected and during expansion cells were kept under 
antibiotic selection (400µg/ml).  
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2.5 Protein chemistry 
2.5.1 Protein extraction 
For protein extraction cells from 1 subconfluent 75cm2 flask were detached by 
trypsinisation. The cell suspension was washed twice in PBS. After 
centrifugation the pellet was resuspended in 200μl lysis buffer (50mM Tris, 
150mM NaCl, 10mM Na3VO4 and 0.5-1%NP40; all supplied by Sigma, 
supplemented with Complete Mini Protease Inhibitor Cocktail tablet (Roche)). 
One tablet was added per 10ml of lysis buffer. Lysis occurred on ice for 30 
minutes. If the cell pellet did not dissolve by mixing, the suspension was 
sheared mechanically by passing the lysate several times through a 21G 
needle. Cells were then sonicated until the DNA was disrupted. The sample 
was centrifuged at 20.000 x g for 20 minutes and the supernatant was collected. 
Proteins were stored at -80ºC prior to protein concentration estimation.  
2.5.2 Protein precipitation 
In order to increase protein concentration Trichloroacetic acid (TCA) 
precipitation was performed. In brief, TCA was added to the protein lysates to a 
final concentration of 25%. After incubating the mixture on ice for 10 minutes 
the sample was centrifuged at 14.000 x g for 5 minutes. Two washing steps with 
ice-cold acetone followed before the sample was left at 95°C degree to dry. To 
solubilise the proteins before SDS-PAGE, proteins were resuspended in loading 
buffer and incubated at 37°Celsius for further 30 minutes. 
2.5.3 Protein concentration estimation 
The protein concentration was determined by using the BCA kit from Pierce. 
This kit is based on the Biuret reaction, where Cu2+ gets reduced to Cu+ by 
proteins in an alkaline medium. The cuprous cation is selectively detected using 
a reagent containing BCA (bicinchoninic acid). A coloured chelate complex 
consisting of 2 BCA molecules and 1 cuprous ion is formed which exhibits 
absorbance at 562nm wavelength. The protein concentration is determined by 
spectrophotometry. To estimate the protein concentration of the sample its 
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absorbance is compared to the absorbance of the standard curve (made of 
serial dilutions of BSA with known concentration).  
An appropriate amount of working reagent was prepared by mixing solution A 
and B in a ratio of 50:1. 10µl of protein sample were mixed with 200µl of 
working reagent, incubated for 30 minutes and absorbance was measured 
using a spectrophotometer (Eppendorf). 
2.5.4 Sample preparation 
The protein sample was made up to a concentration of 20 to 80μg/sample by 
adding H2O. After adding 10x loading buffer (0.125M Tris-HCl, 2% (w/v) SDS, 
10% (w/v) glycerol, 0.001% (w/v) bromophenolblue) and 10% β-
mercaptoethanol the sample was boiled for 5 minutes at 100ºC and an aliquot 
was loaded onto a SDS-PAGE. The rest was kept at -80ºC. 
2.5.5 SDS-PAGE 
Proteins can be separated according to their size by SDS-PAGE. This protocol 
has been adopted from the original by Laemmli. Sodium dodecyl sulfate (SDS) 
is an anionic detergent which destroys secondary and non disulfide linked 
tertiary structures. SDS binds to the protein and gives the molecule an overall 
negative charge, so that the separation is solely dependent on the size of the 
protein. For SDS-PAGE a reducing agent such as dithiothreitol (DTT) or β-
mercaptoethanol is added, which reduces disulfide linkages, which are 
responsible for some tertiary structures (typical composition of SDS-PAGE see 
Table 2-2). A molecular weight marker is run along side the protein to estimate 
its molecular size.  In this study the ProSieve pre-stained protein marker was 
used which has a size range from 10 to 179 kDa. 
SDS gels were run in a SDS-PAGE system from Bio-Rad which was filled with 
running buffer (0.025M Tris, 0.25M glycine pH 8.3, 0.1% (w/v) SDS). 
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Table 2-2 Composition of a typical SDS-PAGE 
compound resolving gel 10% stacking gel 4% 
H20 4ml 1.4ml 
Acrylamide 30% 3.3ml 0.33ml 
1.5 M Tris pH 8.8 2.5ml - 
1.0 M Tris pH 6.8 - 0.25ml 
SDS 10% 100μl 20μl 
APS 10% 100μl 20μl 
Temed 4μl 2μl 
 
10% acrylamide gels were used because the protein of interest has an 
expected size of 100 kDa and 10% gels allow the separation of proteins from 15 
to 100 kDa. APS (ammoniumpersulfate) and TEMED (tetramethyl-
ethylenediamine) catalyse the polymerisation of the acrylamide, where APS 
acts as a source of free radicals. 
Gels were run at 35mAMPs per gel with water cooling until the protein front 
reached the end of the gel. 
2.5.5.1 Coomassie staining  
In order to visualize protein bands on the SDS-PAGE gels were stained with 
Coomassie blue solution (10% acetic acid, 10% isopropanol, 0.1% Coomassie 
blue powder). Gels were immersed in stain for 24 hours before being destained 
in water. 
2.5.6 Western Blot 
Following SDS-PAGE the proteins were transferred to a HiBond-P PVDF 
(polyvinylidene) membrane (Amersham).  
To activate the membrane it was soaked in methanol for 30 seconds and then 
washed in transfer buffer (20mM Tris, 1.92M glycine, 20% methanol) for 3 
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minutes. The resolving gel and the membrane were placed in a „gel sandwich‟ 
in an immunoblotting cassette filled with transfer buffer. The transfer was 
carried out for 1 hour at 90V or over night at 20V with water cooling.  
After the transfer the membrane was incubated for 1 hour in 5% non fat milk 
(Marvel) in TTBS (5mM Tris, 150mM NaCl, 0.005% Tween-20 (BDH 
Chemicals), pH 7.4) in order to block non-specific binding sites. The 
membrane was then washed 3 times in TTBS for 10 minutes before the addition 
of the antibody. The primary antibody NDST1 (Santa Cruz) was raised in goat 
and is able to detect an N-terminal sequence of human NDST1. Different 
dilutions of primary antibody were made up in 5% non-fat dry milk in TTBS and 
were incubated for 1 hour at room temperature or over night at 4ºC. After three 
washing steps in TTBS for 15 minutes the secondary antibody, donkey anti-goat 
HRP-conjugated (Santa Cruz) was added at a 1:5000 dilution and incubated for 
1 hour at room temperature. Before antibody detection the membrane was 
washed again three times in TTBS.  
All washing and incubating steps were carried out under gentle constant 
shaking of the membrane. 
For the detection of the antibodies the ECL Plus system (Amersham) was used. 
In this system HRP and peroxide catalyse the oxidation of an acridan substrate 
to acridinium ester intermediates, which then further react with peroxide, 
producing high intensity chemiluminescence with maximum emission at 430nm.  
The resulting light was detected on an x-ray film (Kodak).  
2.5.6.1 Regeneration of the membrane 
Stripping was used to regenerate the membrane so it could be used for further 
detection. After washing twice in TTBS the membrane was incubated in 
stripping buffer (62.5mM Tris, 2% (w/v) SDS, 30mM β-mercaptoethanol, pH 6.7) 
for 20 minutes at 55º. Prior to reblocking, the membrane was washed twice in 
TTBS.  
Reprobing with antibodies was used to prove equal loading. 
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2.5.6.2 Staining of the membrane 
To visualize the proteins on the membrane and to ensure equal loading the 
membrane was stained in 0.05% copper-phtalocyanine in 12mM HCl for a few 
minutes (until bands appeared).  
2.6 Statistical evaluation 
Statistical analysis was performed using Graph Pad Prism 3.0 software. Data 
with normal distribution was analysed with student‟s t-test. One-way Anova with 
Tukeys post test was used to compare 3 or more independent groups. Tissue 
samples were analysed by non-parametric Krusak-Wallis test. Differences with 
p<0.05 were considered to be significant. 
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3 Role of Heparan sulphate in Transplantation  
3.1 Introduction 
HS regulates a variety of physiological as well as pathophysiological processes 
as it binds a plethora of growth factors, cytokines and other biomolecules.  Its 
involvement in disease is manifold. It acts as a coreceptor for the entry of 
viruses, such as herpes simplex virus type 1, hepatitis B and C and human 
immunodeficiency virus (O'Donnell et al., 2010, Schulze et al., 2007, Barth et 
al., 2006, Saphire et al., 2001), bacteria (Bacillus anthracis) and parasites 
(Toxoplasma gondii) (Chen et al., 2008). In Alzheimer‟s disease, a 
neurodegenerative disorder, HS plays a role in plaque pathogenesis and ß-
amyloid precursor protein processing (Scholefield et al., 2003, van Horssen et 
al., 2003). Evidence for a direct role in cancer was found by genetic analysis. 
Tumour suppressor genes which can lead to cancer once their function is 
impaired due to mutations were identified, namely the chain elongation 
enzymes EXT1 and EXT2 responsible for hereditary multiple exostoses, a 
benign bone tumour, and glypican 3, which is linked to Simpson-Golabi-Behmel 
syndrome. The HS degrading enzyme heparanase is also linked to cancer, as 
increased heparanase expression positively correlates with metastatic potential 
(Vlodavsky and Friedmann, 2001). Recently, an endothelial specific knock out 
of NDST1 in a lung carcinoma model resulted in decreased tumour 
angiogenesis and tumour growth, correlating with decreased association with 
FGF2 and VEGF (Fuster et al., 2007). 
In inflammation, the role of HS in chemokine transcytosis and presentation has 
been discussed already, but an additional feature of HS is its shedding during 
inflammatory events. After crossing the endothelial cell layer, the subendothelial 
basement membrane represents a major obstacle for migrating leukocytes. An 
array of proteases has been implicated in this degradation process, heparanase 
being one of them (Madri and Graesser, 2000). Most likely the degradation of 
the basement membrane  is accomplished in a collaborative process between 
endothelial cells, leukocytes and platelets; all contributing different enzymes 
involved in the breakdown of the  membrane (Parish et al., 1998).  Besides 
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helping leukocytes to migrate into the tissue, heparanase can bind to T cells in 
its enzymatically inactive proform presumably facilitating T cell migration 
through the basement membrane (Sotnikov et al., 2004). Heparanase is also 
involved in the inflammatory reaction by releasing cytokines, which would 
otherwise be inactive while bound to HS (Schonherr and Hausser, 2000). At the 
same time heparanase can also reduce inflammation, by decreasing chemokine 
levels on endothelial cells (Parish, 2006).  In the context of transplantation, 
heparanse shed HS can lead to a breakdown of anticoagulant environment in 
the transplanted organ, possibly causing intravascular coagulation and fibrin 
deposits in the rejecting allograft (Ali et al., 2003). 
3.1.1 Renal Heparan sulphate 
HSPGs have been studied for their role in glomerular filtration for a while. 
Glomerular HS has been proposed to be a charge-selective barrier for proteins 
filtered from the blood. Negatively charged proteins, like albumin, would not be 
able to cross the barrier due to the highly negative charge of HS itself (Kanwar 
and Farquhar, 1979a, Kanwar and Farquhar, 1979b, Reeves et al., 1980). This 
concept has been supported by different approaches: Enzymatic digestion of 
HS of the glomerular basement membrane (GBM) increased permeability to 
albumin (Groffen et al., 1998) and an antibody directed against HS of the GBM 
resulted in proteinuria (van den Born et al., 1992). In patients with advanced 
diabetic nephropathy (DNP), GBM HS was partly or completely lost 
accompanied by increased proteinuria (Tamsma et al., 1994). However, 
recently the electrostatic barrier function of HS was questioned, as in a model of 
early human diabetic nephropathy and experimental diabetic nephropathy in 
rats no changes in HS content or composition were found. It was proposed that 
loss of HS from the GBM may be secondary to proteinuria and the involvement 
of glomerular podocytes in the capillary wall permeability was suggested (van 
den Born et al., 2006). In line with the later model a recent publication showed 
that removal of HS from the GBM did not result in acute albuminuria (Wijnhoven 
et al., 2007). Changes in glomerular endothelial HS expression have also been 
reported for human and murine lupus nephritis, where increased level of both N- 
and O-sulphation could be observed (Rops et al., 2007). 
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Relatively new is the interest in renal HS with regards to inflammation, but there 
is increasing evidence suggesting it plays a pivotal role. Studies of human renal 
allografts showed increased HS expression in acute rejecting kidneys compared 
to normal controls. HS was found in blood vessel walls and tubules, with the 
highest expression in the basement membrane, and colocalisation studies 
revealed co-expression of N-sulphated HS with CCL5.  Apart from 
colocalisation, a positive correlation between HS and CCL5 expression levels 
was found (Ali et al., 2005a).  This observation gives evidence that chemokines 
presented by HS direct leukocytes subsets to specific sites within a graft. An 
inflammatory response was simulated by stimulating primary endothelial cells 
with proiflammatory cytokines and an increase in NDST1 enzyme, which in turn 
led to increased N-sulphation on the cell surface, was the consequence. When 
these cells were examined for their ability to present CCL5, a significant 
increase in chemokine presenting capacity of the stimulated cells was revealed 
when compared to the unstimulated control, which was in line with the results 
obtained from kidney allograft biopsy studies (Ali et al., 2005a).  
Murine renal HS has also been shown to be a ligand for L-selectin. This is 
interesting, as all leukocytes express this form of lectin. The interaction of L-
selectin on the leukocyte and its binding partner HS on the endothelium initiate 
the first step of leukocyte extravasation. Binding assays in mouse kidney 
revealed collagen XVIII as ligand in the tubular basement membrane. In 
addition to the core protein, the HS chain length and the sulphation status 
(namely O-sulphation) were crucial for L-selectin binding (Celie et al., 2005). 
Based on the results from mouse experiments, human renal biopsies from 
primary kidney diseased patients were investigated for their ability to bind L-
selectin and CCL2, a chemokine reported important in renal transplantation 
settings (Robertson et al., 1998, Ruster et al., 2004, Segerer et al., 2000). Both 
molecules showed increased binding to HS of the perivascular interstitial matrix 
which was associated with increased influx of leukocytes. Further more, 
increased binding of L-selectin and CCL2 to HS expressed on the basolateral 
side of tubular epithelial cells was observed (Celie et al., 2007). 
As it has been suggested for chemokines (Ali et al., 2005a, Robertson and 
Kirby, 2003), HS in tubular basement membranes could display signals 
(chemokines, cytokines, L-selectin) which cause the infiltrating cell to penetrate 
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the tubular epithelium, resulting in tubulitis, an important feature of acute renal 
rejection.  
3.1.2 Hepatic Heparan sulphate 
HSPGs are the predominant form of proteoglycans in the liver and have been 
found to be highly sulphated compared to other organs or tissues (Lyon et al., 
1994a, Vongchan et al., 2005). Changes in overall amounts of liver HS have 
been reported for cirrhosis (Murata et al., 1985), hepatocellular carcinoma 
(HCC) (Kovalszky et al., 1990) and cholestasis (Roskams et al., 1996). In 
addition to changes in the amounts of HS, a decrease in HS sulphation was 
observed in rats with experimental diabetes (Kjellen et al., 1983, Williams et al., 
2005). Furthermore, impaired lipoprotein uptake by diabetic livers has been 
reported by different research groups (Ebara et al., 2000, Olsson et al., 2001). 
Highly sulphated HS domains in the liver have been reported to act as 
coreceptors for apolipoprotein E (Libeu et al., 2001). Recently, an elegant study 
demonstrated in vivo that hepatic HS acts as a coreceptor for triglyceride- and 
cholesterol-rich lipoproteins independently of the LDL-receptor family. Specific 
inactivation of NDST1 in hepatocytes resulted in partially undersulphated HS 
and plasma triglyceride accumulation (MacArthur et al., 2007). Similar results 
supporting the model of HS as lipoprotein coreceptor were obtained from mice 
lacking uronyl-2-O-sulphotransferase (Stanford et al., 2010). In a recent 
investigation, topological changes in fibrogenic liver disease and HCC have 
been revealed. Changes in a range of HS biosynthetic enzymes were recorded 
which resulted in overall increased 3-O-sulphation and slight 6-O-
undersulphation in HCC (Tatrai et al., 2010). The role of liver HS with regards to 
transplantation has not been investigated so far, but as the bile duct is targeted 
during allograft rejection by inflammatory cells, which are guided into the tissue 
by chemokines, the role of ductular HS should be further explored.  
3.1.3 Chemokines in transplantation 
CCL2, formerly known as monocyte chemoattractant protein-1 (MCP-1), is a 
proinflammatory chemokine which binds to its receptor CCR2 and facilitates 
migration of subsets of leukocytes to sites of inflammation (Kruger et al., 2002). 
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CCL2 is produced by a range of cell types, including lymphocytes and vascular 
endothelial cells.  
Elevated levels of CCL2 have been reported for an array of diseases, including 
multiple sclerosis, rheumatoid arthritis and cancer (Deshmane et al., 2009). In 
the kidney, weak basal expression of CCL2 in tubular epithelial cells has been 
reported and CCL2 expression was induced during renal allograft rejection 
(Prodjosudjadi et al., 1995, Robertson et al., 1998). Renal collagen XVIII has 
been identified as CCL2 ligand (Celie et al., 2007, Kawashima et al., 2003). 
The amino acid residues representing the heparin-binding motif of CCL2 have 
been identified as Lys-58 and His-66 (Chakravarty et al., 1998), but less 
understood are the corresponding binding sites of HSPGs (Proudfoot et al., 
2001, Severin et al., 2010). In general, all chemokines bind preferentially to 
saccharides with increased sulphation. In addition to N-sulphation, 2-O-
sulphation has been shown to facilitate CCL2 binding (Sweeney et al., 2006). 
CCL2 also was shown to bind preferentially to N-acetylated residues among 
saccharides with constant sulphation (Schenauer et al., 2007). Recently, a 
heparin octasaccaride lacking 3-O-sulphate groups has been identified as 
minimal binding sequence (Meissen et al., 2009). 
 
Taken together these data suggest that HS structure is highly flexible and can 
be altered upon interaction with various inflammatory stimuli in a cell/tissue 
dependent fashion, resulting in altered/new HS epitope expression with 
functional consequences for binding partners in the inflammatory response.  
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3.1.4 Specific aims 
Organ and tissue specific HS have been described (Dennissen et al., 2002) as 
well as changes of HS between healthy and diseased organs (Ali et al., 2005a, 
Rops et al., 2007, Tatrai et al., 2010, Vongchan et al., 2005). However, most of 
the data (with the exception of findings by Ali and Tatrai and coworkers) does 
not include information about the structural changes and distribution of HS 
epitopes. This part of the work therefore aimed to investigate the changes in 
expression of differentially modified HS epitopes in human tissues during 
different stages of allograft rejection. Specific goals: 
 
 Optimisation of antibody staining for HS (10e4, phage display antibodies)   
and CCL2 in human renal and liver tissue 
 
 Staining of renal and liver human allograft biopsies for differentially 
modified HS and CCL2 
 
 Determining changes in HS epitope expression and correlation with 
grades of rejection 
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3.2 Specific Materials and Methods 
3.2.1 Human Tissue 
Normal human kidney and liver tissue and allograft biopsies were obtained as 
formalin-fixed paraffin embedded blocks from the local transplant tissue archive 
in accordance with the Local Research Ethics Committee approval 
06/Q0905/150. Samples were anonymised and coded before they were made 
available for the study. 
3.2.2 Immunohistochemistry 
Immunohistochemistry allows antigen visualisation within the tissue 
architecture. To analyze differences in HS composition and chemokine 
occurrence during rejection tissue samples from human kidneys and livers were 
examined immunohistologically.  
Paraffin embedded formalin-fixed tissue sections were dewaxed for 10 minutes 
in xylene prior to rehydration in serial alcohol concentrations (100%, 95% and 
70% ethanol) for 2 minutes each before immersing in water for 5 minutes.  
Antigen retrieval was optimised for each antibody, 2 different methods were 
used in this study. 
a) Antigen retrieval via heat (pressure cooking): After rehydration tissue 
sections were placed in a pressure cooker and antigens were retrieved whilst 
cooking for 1 minute in citrate buffer pH 6.  
b) Enzymatic antigen retrieval (Trypsin): tissue sections were pre-warmed in 
TBS to 37ºC and incubated in a trypsin/calcium chloride solution (Sigma, pH 
7.8) between 12 and 20 minutes at 37ºC. 
Following several washes in TBS, sections were incubated with 2% BSA/TBS to 
block nonspecific binding of antibodies. After blocking, sections were incubated 
with the primary antibody over night at 4ºC. 
Secondary antibodies were applied to the sections after a series of washes in 
TBS and incubated for 1h at room temperature. In order to visualize the cells 
nuclei DAPI solution (Sigma, 2µg/ml final concentration) was applied to the 
sections and they were incubated for 5 minutes.  
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In order to quench autofluorescent staining liver sections were further incubated 
in Sudan Black (0.3% Sudan black in 70% methanol). 
After extensive washing in TBS sections were finally mounted in fluorescent 
mounting media (Dako) and stored until confocal analysis in the dark at 4ºC. 
Each time staining was performed a control staining, omitting the incubation 
with the primary antibody using the secondary antibody only, was carried along. 
Antibody specifications can be seen in Table 3-1 and Figure 3-1 (Rops et al., 
2008, Smits et al., 2006). 
 
Table 3-1 Antibodies used in this study and their binding requirements 
Antibody Supplier Subtype Target 
sequence 
Dilution Secondary ab 
10e4 Seikagaku Monoclonal  
Mouse IgM 
GlcA-GlcNS- 
GlcA-GlcNAc 
1/100 Anti-mouse-
FITC 
(1/100), Dako 
HS3A8 Gift from  
Prof. Kuppevelt,  
Nijmegen, 
Netherlands 
Single chain  
phage 
display- 
derived 
GlcNS6S- 
IdoA2S 
1/6 Anti-VSV-Cy3  
(1/300), Sigma 
HS4C3 Gift from  
Prof. Kuppevelt, 
Nijmegen, 
Netherlands 
Single chain  
phage 
display- 
derived 
GlcNS3S6S- 
GlcA/Ido2S 
1/6 Anti-VSV-Cy3  
(1/300), Sigma 
MCP-1 R&D Monoclonal  
Mouse 
IgG2B 
Human CCL2 1/20 Anti-mouse-
FITC 
(1/100), Dako 
Abbreviations GlcA: glucuronate; GlcNac: N-acteylated-glucosamine; GlcNS: N-
sulphated-glucosamine; IdoA: iduronate; 2,3,6S: 2,3,6 sulphate (Smits et al, 2006; Rops 
et al, 2008) 
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Figure 3-1 Structural motifs for HS antibody recognition 
 
3.2.2.1 Confocal microscopy and data analysis 
All fluorescent labelled samples were analysed with the Leica TCS-SP2UV 
confocal laser scanning microscope (Leica Lasertechnik). The excitation and 
emission wavelengths were 488nm and 530nm for FITC, 543nm and 580nm for 
TRITC and 358nm and 461nm for DAPI. Cy3 labelled samples were also 
visualized using TRITC filter settings as excition and emission spectra are 
almost identical to those of TRITC. Images were collected sequentially, frame 
by frame and finally combined to produce the final image. 
Quantitative information of the renal sections analysed was obtained using 
COMOS software applying histogram analysis (as described by Wong et al, 
(Wong et al., 2003). ‟Colour banding‟ allowed calculation of the median 
fluorescence intensity excluding the unstained areas such as tubular lumens. 
Median fluorescence was calculated by taking all fluorescent readings into 
account which where in-between 1 (threshold set manually) and 255 (maximum 
fluorescence). Whenever fluorescence readings were needed for quantification, 
staining was performed in parallel and readings were taken on the same day 
with the same settings applied. 
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Fluorescence readings of bile-duct-like structures of the liver were taken with 
Leica software by manually circling around ducts, therefore excluding other 
areas of the tissue and duct lumen. 
3.2.3 Chemokine Binding 
A chemokine binding assay was developed to investigate the ability of 
differentially modified HS to retain chemokines on the surface of cells and 
tissues.  
For tissues, antigen retrieval was performed as described in materials and 
methods. The sections were blocked with 20% swine serum in TBS. In order to 
prevent binding of the secondary reagent avidin to endogenous biotin, an 
avidin-biotin blocking step (Vectorlabs) was introduced. Following this, 
chemokine was added to a final concentration of 100ng/ml in TBS and slides 
were incubated over night at 4ºC. Following two washing steps in TBS avidin-
FITC was added for 1h at RT (BD, 1/100 dilution) before the slides were finally 
mounted in fluorescent mounting media (Dako).  
In some cases cell surface HS was removed by heparinase III (Sigma) 
treatment. Therefore cells or tissues were incubated with 0.05U/ml of 
heparinase in a humified chamber for 1h at 37ºC. 
3.2.4 Statistical analysis 
Tissue samples were analysed by non-parametric Krusak-Wallis test with 
Tukey‟s post hoc test. Differences with p<0.05 were considered to be 
significant.  
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3.3 Results 
3.3.1 Renal rejection 
3.3.1.1 HS3A8 staining in kidney 
3.3.1.1.1 Optimisation of HS3A8 staining 
As the phage display derived antibodies have preferentially been used on 
frozen sections (personal communication Prof. van Kuppevelt, Harden 
conference, March 2009), antigen retrieval of formalin-fixed paraffin embedded 
tissues had to be optimised. Both enzymatic and heat mediated retrievals were 
used, with trypsin mediated antigen retrieval for 12 minutes resulting in precise 
and reliable staining results (Figure 3-2). 
 
 
Figure 3-2 Optimisation of HS3A8 staining in human renal biopsies 
 
HS3A8 antibody was used at 1/6 dilution and visualized by a Cy3-labelled secondary 
antibody. Fluorescent staining A, brightfield-fluorescent overlay B and control staining 
omitting the primary antibody C. Antigen retrieval was performed by trypsin digestion. 
Scale bar represents 75 µm. 
 
Once the staining was optimised, additional sections were stained to further 
investigate the distribution of the HS3A8 (representing N-sulphation, 6-O-
sulphation, C-5-epimerization and 2-O-sulphation) epitope in renal tissue. The 
most prominent staining was found on tubular epithelial cells and to some lesser 
extent in the interstitium and weak staining of the glomerulus (Figures 3-2 and 
3-3).  
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3.3.1.1.2 Distribution of HS3A8 in normal renal tissue 
 
 
Figure 3-3 Distribution of HS3A8 epitope in human renal biopsies 
 
HS3A8 antibody was used at 1/6 dilution and visualized by a Cy3-labelled secondary 
antibody. Antigen retrieval was performed by trypsin digestion. Scale bar represents 75 
µm. 
3.3.1.1.3 Changes in HS3A8 HS epitope expression during rejection 
A series of renal allograft biopsies was investigated for the expression of 
HS3A8 during different stages of rejection. Figures 3-4 and 3-5 show slightly 
increased expression of HS3A8, but not significantly during acute rejection 1a. 
During chronic rejection, HS3A8 staining increased significantly (p<0.05) within 
the tubules and the interstitium. 
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Figure 3-4 HS3A8 expression during renal allograft rejection 
 
HS3A8 antibody was used at 1/6 dilution and visualized by a Cy3-labelled secondary 
antibody. Kidney sections are representative for the indicated stages of rejection (acute 
rejection 1a, acute rejection 2a, chronic rejection) with normal tissue as control. Scale 
bar represents 75 µm. 
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Figure 3-5 Mean fluorescent expression of HS3A8 during renal rejection  
 
2-3 random fields per biopsy were chosen (dependent on size of the biopsy) and the 
mean fluorescence intensity analysis was performed using Comos software. Results 
represent data from 12 patients in total (5 normal, 3 acute rejection 1a, 2 acute rejection 
2a and 2 chronic rejection). Statistical analysis was determinded by non-parametric 
Kruskal-Wallis test with differences p<0.05 considered to be significant. 
 
In addition to the mean fluorescence intensity the median fluorescence intensity 
and the area covered by HS3A8 staining was determined. This was done to 
clarify if increased mean fluorescence was due to extremely intense staining of 
few, defined structures within the tissue or if staining also increased with 
regards to the area covered. This way it was believed to be able to distinguish 
between moderate staining covering large areas and intense staining of distinct, 
localised structures.  
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Figure 3-6 Median fluorescent expression of HS3A8 during renal rejection 
 
2-3 random fields per biopsy were chosen (dependent on size of the biopsy) and the 
median fluorescence intensity was calculated by using the ‘colour banding’ mode of 
Comos software. Results represent data from 12 patients in total. (5 normal, 3 acute 
rejection 1a, 2 acute rejection 2a and 2 chronic rejection). Statistical analysis was 
determinded by non-parametric Kruskal-Wallis test with differences p<0.05 considered to 
be significant. 
 
 
The analysis of median fluorescence intensity and area coverage confirmed the 
data from mean fluorescence intensity analysis in the way that both increased 
staining of individual structures as well as increased staining within the 
interstitial space covering an extended area was observed (Figures 3-6 and 3-7) 
during chronic rejection (all p-values < 0.05). 
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Figure 3-7 Graphic representation of area coverage by HS3A8 staining 
 
2-3 random fields per biopsy were chosen and stained area was measured with Comos 
software. Results represent data from 12 patients in total (5 normal, 3 acute rejection 1a, 
2 acute rejection 2a and 2 chronic rejection). Statistical analysis was determinded by 
non-parametric Kruskal-Wallis test with differences p<0.05 considered to be significant. 
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3.3.1.2 HS4C3 staining in kidney 
3.3.1.2.1 Optimisation of HS4C3 staining 
Antigen retrieval of formalin-fixed paraffin embedded tissue was performed both 
by enzymatic and heat mediated retrieval, with trypsin mediated antigen 
retrieval for 12 minutes (Figure 3-8) proving suitable for HS4C3 staining. 
 
Figure 3-8 Optimisation of HS4C3 staining in human renal biopsies 
 
HS4C3 antibody was used at 1/6 dilution and visualized by a Cy3-labelled secondary 
antibody. Fluorescent staining A, brightfield-fluorescent overlay B and staining control 
omitting primary antibody C. Antigen retrieval was performed by trypsin digestion. Scale 
bar represents 75 µm. 
3.3.1.2.2 Distribution of the HS4C3 in normal renal tissue 
 
Additional biopsies were stained to investigate the distribution of HS4C3 
(representing N-sulphation, 6-O-sulphation, 2-O-sulphation and 3-O-sulphtion) 
in renal tissue. 
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Figure 3-9 Distribution of HS4C3 epitope in human renal biopsies 
 
HS4C3 antibody was used at 1/6 dilution and visualized by a Cy3-labelled secondary 
antibody. Antigen retrieval was performed by trypsin digestion. Scale bar represents 75 
µm.  
 
Figures 3-8 and 3-9 show the staining pattern of HS4C3. Antibody HS4C3 
stained tubules in a similar fashion to antibody HS3A8. Glomerular staining 
appeared to be more prominent compared to HS3A8 staining and little 
interstitial staining was observed. In addition, nuclear staining was observed. 
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Figure 3-10 Nuclear staining of HS4C3 in human renal biopsies 
 
HS4C3 antibody was used at 1/6 dilution and visualized by a Cy3-labelled secondary 
antibody. Antigen retrieval was performed by trypsin digestion. Scale bar represents 75 
µm. 
 
Inclusion of DAPI staining in following experiments confirmed the staining of 
nuclei with antibody HS4C3 (Figure 3-10). However, this nuclear staining was 
found to be present in most, but not all cases. Due to different degrees of 
nuclear staining a quantitative analysis could not be carried out for antibody 
HS4C3.  
3.3.1.3 10e4 staining in kidney 
Optimal antibody retrieval for the 10e4 antibody showed that citrate buffer 
boiling resulted in superior results compared to enzymatic mediated retrieval 
(Figure 3-11). 
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Figure 3-11 Optimisation of 10e4 staining in human renal biopsies 
 
10e4 antibody was used at 1/100 dilution and visualized by a FITC-labelled secondary 
antibody. Fluorescent staining A, brightfield-fluorescent overlay B and control staining 
omitting primary antibody C. Antigen retrieval was performed by citrate buffer boiling. 
Scale bar represents 75 µm. 
 
10e4 staining was found predominatly within tubules, with hardly any interstitial 
staining. 
3.3.1.3.1 Changes in 10e4 HS epitope expression during renal rejection 
A series of renal allograft biopsies were investigated for the expression of 10e4 
HS epitope during different stages of rejection. Figures 3-12 and 3-13 show low 
level staining of 10e4 in normal kidney, whereas biopsies from patients with 
acute rejection 1a (cellular) exhibited much stronger staining throughout the 
tissue (p<0.05). Samples from acute rejection 2a (humoral) and chronic 
rejection patients revealed similar staining as the control. 
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Figure 3-12 Changes in 10e4 expression during renal rejection 
 
10e4 antibody was used at 1/100 dilution and visualized by a FITC-labelled secondary 
antibody. Kidney sections are representative for the indicated stages of rejection (acute 
rejection 1a, acute rejection 2a, chronic rejection) with normal tissue as a control. Scale 
bar represents 75 µm. 
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Figure 3-13 Mean fluorescent expression of 10e4 during renal rejection 
 
2-3 random fields per biopsy were chosen (dependent on size of the biopsy) and the 
mean fluorescence intensity analysis was performed using Comos software. Results 
represent data from 12 patients in total (5 normal, 3 acute rejection 1a, 2 acute rejection 
2a and 2 chronic rejection). Statistical analysis was determinded by non-parametric 
Kruskal-Wallis test with differences p<0.05 considered to be significant. 
 
The analysis of median fluorescence intensity and area coverage confirmed the 
data from mean fluorescence intensity analysis in the way that both increased 
staining of individual structures as well as increased staining within the 
interstitial space covering an extended area was observed during acute 
rejection 1a, while levels of staining during chronic rejection were comparable to 
normal tissue (Figures 3-14 and 3-15).  
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Figure 3-14 Median fluorescent expression of 10e4 during renal rejection 
 
2-3 random fields per biopsy were chosen (dependent on size of the biopsy) and the 
median fluorescence intensity was calculated by using ‘colour banding’ mode of Comos 
software. Results represent data from 12 patients in total (5 normal, 3 acute rejection 1a, 
2 acute rejection 2a and 2 chronic rejection). Statistical analysis was determinded by 
non-parametric Kruskal-Wallis test with differences p<0.05 considered to be significant. 
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Figure 3-15 Graphic representation of area coverage by 10e4 staining 
 
2-3 random fields per biopsy were chosen (dependent on size of the biopsy) and the 
stained area was measured with Comos software. Results represent data from 12 
patients in total (5 normal, 3 acute rejection 1a, 2 acute rejection 2a and 2 chronic 
rejection). Statistical analysis was determinded by non-parametric Kruskal-Wallis test 
with differences p<0.05 considered to be significant. 
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This is in contrast to HS3A8 staining, which came up late during chronic stages 
of allograft rejection. 
3.3.1.4 Optimisation of CCL2 antibody staining 
CCL2 staining was first carried out as previously described by Roberson et al, 
(Robertson et al., 1998), but antigen retrieval by citrate buffer boiling did not 
result in appropriate staining (Figure 3-16A) and when a scan of fluorescence 
emission was performed, the residual staining was identified as 
autofluorescence, as no emission was collected at 530 nm, the emission 
wavelength of FITC (Figure 3-16B).  
 
 
Figure 3-16 CCL2 expression in human renal biopsies 
 
CCL2 antibody was used at 1/20 dilution and visualized by a FITC-labelled secondary 
antibody (A). Antigen retrieval was performed by citrate buffer boiling. Fluorescence 
spectra were collected and analysed using Leica software (B). Scale bar represents 75 
µm. 
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Figure 3-17 Immunofluorescent detection of CCL2 expression in renal biopsies 
 
Secondary antibody control (A) and CCL2 staining (B).CCL2 antibody was used at 1/20 
dilution and visualized by a FITC-labelled secondary antibody. Antigen retrieval was 
performed by trypsin digestion. Scale bar represents 75 µm. 
 
CCL2 staining with trypsin mediated antigen retrieval showed better results; 
however, the staining pattern was different compared to the literature  (Al-
Hamidi et al., 2008, Lai et al., 2007, Robertson et al., 1998), where basolateral 
expression of CCL2 and other CC chemokines was reported (Figure 3-17). 
Instead of the basolateral surface of tubules, the luminal side revealed CCL2 
staining. Repeated experiments resulted in similar staining pattern and a 
western blot was performed to verify the specificity of the antibody. The 
immunoblot revealed a clear band around 10kDa, which validated the specificity 
of the antibody (Figure 3-18). 
 
 
 
Figure 3-18 CCL2 expression by PBMCs 
 
60 µg of total protein lysate from PBMCs were used for immunoblotting. Blots were 
probed with mouse monoclonal α-CCL2 antibody (1/20) and HRP-conjugated anti-mouse 
IgG (1/5000) 
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3.3.1.4.1 CCL2 expression during rejection 
 
 
Figure 3-19 Changes in CCL2 expression during renal rejection 
 
CCL2 antibody was used at 1/20 dilution and visualized by a FITC-labelled secondary 
antibody. Antigen retrieval was performed by trypsin digestion. Biopsies are 
representative for the indicated stages of disease (n=2). Scale bar represents 75 µm. 
 
Figure 3-19 demonstrates that CCL2 was expressed in all groups of renal 
biopsies investigated. During renal acute rejection 1a an increase in CCL2 
expression was observed, no differences between the other groups was found.   
 
In addition to antibody staining, an antibody binding assay was developed to 
investigate the ability of differentially modified HS to present CCL5. This binding 
experiment was thought to give more insight into the physiology of HS during 
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rejection compared to staining (Segerer et al., 2007). Unfortunately the assay 
failed to work in these settings (data not shown). 
3.3.2 Hepatic rejection 
Expression of HS epitopes was also examined during liver rejection.  
3.3.2.1 HS3A8 staining in liver 
3.3.2.1.1 Optimisation HS3A8 staining in liver 
 
 
 
Figure 3-20 Optimisation of HS3A8 staining in liver biopsies 
 
HS3A8 antibody was used at 1/6 dilution and visualized by a Cy3-labelled secondary 
antibody. Fluorescent staining A, brightfield-fluorescent overlay B and control staining 
omitting primary antibody C. Antigen retrieval was performed by trypsin digestion. Scale 
bar represents 75 µm. 
 
 
Trypsin retrieval proved to work for HS3A8 in liver tissue and staining was found 
more or less uniformly in all sinusoids. HS3A8 antibody also labelled bile duct 
basement membranes (Figures 3-20 and 3-21). 
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3.3.2.1.2 Distribution of the HS3A8 in normal human liver 
 
 
Figure 3-21 Distribution of HS3A8 epitope in human liver biopsies 
 
Human liver biopsies were stained with HS3A8 antibody and the staining pattern 
analysed by confocal microscopy. Scale bar represents 75 µm. 
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3.3.2.1.3 Changes in HS3A8 HS epitope expression during liver rejection 
A range of liver biopsies were investigated for their expression of HS epitopes 
during rejection. Changes in HS3A8 expression were examined and an 
increase in overall staining during late rejection could be observed. A more 
detailed quantitative analysis of bile duct staining confirmed the first impression 
and revealed rejection related changes. Ductular HS3A8 staining decreased 
slightly during moderate rejection (p<0.01), before it increased during late 
rejection and chronic hepatitis (p<0.01) (Figures 3-22 and 3-23). 
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Figure 3-22 Changes in HS3A8 expression during liver rejection 
 
HS3A8 antibody was used at 1/6 dilution and visualized by a Cy3-labelled secondary 
antibody. Liver sections are representative for the indicated stages of disease. Scale bar 
represents 75 µm. Arrows indicate bile duct-like structures. 
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Figure 3-23 Quantitative analysis of ductular HS3A8 expression during liver disease 
 
Ductular structures were examined manually and fluorescence readings taken by Leica 
software. Results represent data from 12 patients in total with varying numbers of bile 
duct readings in each group (time 0: n=8, mild acute rejection: n=6, moderate to severe 
acute rejection: n=13, late acute rejection: n=11 and chronic hepatitis: n=11). Statistical 
analysis was determinded by non-parametric Kruskal-Wallis test with differences p<0.05 
considered to be significant. 
3.3.2.2 HS4C3 staining in liver 
3.3.2.2.1 Optimisation of HS4C3 staining in liver 
 
HS4C3 antibody worked similar to HS3A8 antibody with trypsin mediated 
retrieval and staining patterns were comparable too. Sinusoids and bile ducts 
basement membranes were the main compartments stained in the biopsies 
(Figures 3-24 and 3-26). As it was shown for HS4C3 staining in kidney, the 
antibody labelled nuclei in livers as well (Figure 3-25). Again, nuclear staining 
was not uniform and therefore could not be used for quantitative analysis. 
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Figure 3-24 Optimisation of HS4C3 staining in human liver biopsies 
 
HS4C3 antibody was used at 1/6 dilution and visualized by a Cy3-labelled secondary 
antibody. Fluorescent staining A, brightfield-fluorescent overlay B and control staining 
C. Antigen retrieval was performed by trypsin digestion. Scale bar represents 75 µm. 
 
 
 
Figure 3-25 Nuclear staining of HS4C3 in human liver biopsies 
 
HS4C3 antibody was used at 1/6 dilution and visualized by a Cy3-labelled secondary 
antibody. Antigen retrieval was performed by trypsin digestion. Scale bar represents 75 
µm. 
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3.3.2.2.2 Distribution of the HS4C3 HS epitope in normal human liver tissue 
 
 
 
Figure 3-26 Distribution of HS4C3 epitope in human liver biopsies 
 
Human liver biopsies were stained with HS4C3 antibody and the staining pattern 
analysed by confocal microsocopy. Scale bar represents 75 µm. 
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3.3.2.2.3 HS4C3 expression during liver disease 
Even though no quantification of HS4C3 staining was feasible, qualitatively an 
increase in overall staining of time 0 transplants compared to chronic hepatitis 
biopsies was detectable (Figure 3-27). 
 
 
 
Figure 3-27 HS4C3 expression during liver disease 
 
HS4C3 antibody was used at 1/6 dilution and visualized by a Cy3-labelled secondary 
antibody. Liver sections are representative for the indicated stages of disease. n = 3 
each. Scale bar represents 75 µm. 
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3.3.2.3 10e4 HS staining in liver  
 
 
Figure 3-28 Distribution of 10e4 staining in human liver biopsies 
 
10e4 antibody was used at 1/100 dilution and visualized by a FITC-labelled secondary 
antibody. Antigen retrieval was performed by citrate buffer boiling. The staining pattern 
was analysed by confocal microscopy. Scale bar represents 75 µm. 
 
A range of liver biopsies were investigated for 10e4 HS epitope expression. 
10e4 antibody staining was performed after the unmasking of antigens by 
citrate buffer boiling and appeared to be localised on sinusoids and bile ducts. 
When biopsies from rejecting livers were analysed for the expression of 10e4, 
no expression in time 0 transplants and hardly any expression in biopsies with 
mild rejection was observed. Expression of the 10e4 epitope seemed to be 
induced in time with the onset of moderate rejection. The staining was 
distributed throughout the tissue, with most pronounced increases in bile ducts. 
In sections from late stages of acute rejection and chronic hepatitis, a decline in 
overall staining, and a vanishing staining in bile ducts could be observed 
(Figures 3-28 and 3-29). 
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3.3.2.3.1 Changes in 10e4 HS epitope expression during liver disease 
 
 
Figure 3-29 Changes in 10e4 expression during liver disease 
 
10e4 antibody was used at 1/100 dilution and visualized by a FITC-labelled secondary 
antibody. Liver sections are representative for the indicated stages of disease. Scale bar 
represents 75 µm. 
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3.4 Discussion 
HS structure is highly dynamic and variable in chain length and modification 
status. It is believed that the amount and arrangement of sulphated groups 
regulates the biological function of various proteins, including growth factors, 
cytokines and chemokines. These highly sulphated groups are created by a set 
of enzymes which are regulated at different levels. Transcriptional control 
(Carter et al., 2003, Krenn et al., 2008, Rops et al., 2008), translational control 
(Grobe and Esko, 2002) and control via the interaction and affinities of 
individual enzymes have been suggested (Esko and Selleck, 2002, Ledin et al., 
2006). 
HS has received increasing interest with regards to its role in inflammatory 
events. More or less accepted is the fact that HS is involved in all steps of 
leukocyte extravasation, primarily stabilising a chemokine gradient on the 
endothelium (Parish, 2006, Wang et al., 2005). Less attention is paid to other 
structures within the tissue, but as chemokines not only guide inflammatory 
cells into the graft, but also direct them once they have entered the graft, 
identification of HS species in different tissues involved in chemokine 
presentation seemed plausible.  Different organs have been investigated for 
their HS content and differences between healthy and diseased organs were 
found. However, this data was based on overall HS content or modification 
status revealed by disaccharide analysis, none of which identifies physiological 
HS epitopes (Vongchan et al., 2005). A few research groups have started to 
investigate topological changes in HS (Dennissen et al., 2002, Rops et al., 
2007) and the kidney is one of the organs investigated. In 2005 it was shown by 
Ali and coworkers that renal HS increased during acute rejection and described 
the distribution of HS within the tissue (Ali et al., 2005a). In general one can 
assume that changes between healthy and diseased organ mirror those of 
ligands which bind to HS in that particular situation.  Altered or new binding 
sites for new interaction partners can be created by adopting chain length and 
modification status.  
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Observations in renal rejection 
Based on these findings it was decided to examine HS expression during 
transplantation. First, antibody staining of human renal tissue had to be 
optimised. The process of antigen retrieval is of paramount importance, as 
antigens in formalin-fixed paraffin embedded tissues often have to be 
unmasked to be recognised by specific antibodies. HS3A8 and HS4C3 phage 
display antibodies required enzymatic retrieval with trypsin whereas 10e4 
antibody worked best with heat-mediated retrieval by citrate buffer boiling. 
Renal tissues stained with the above mentioned phage display antibodies 
revealed similar staining patterns of tubules and the interstitium. The similarity 
in staining could be explained due to similar essential target modifications, 
being N-sulphation, C5-epimerization, 2O-sulphation and 6O-sulphation for 
HS3A8 and   N-sulphation, 2O-sulphation, 6-O-sulphation and 3-O-sulphation 
for HS3C4. As 2-OST knock out mice lack kidneys (Bullock et al., 1998), the 
existence of 2-O-sulphation as indicated by HS3A8 staining was not surprising. 
Differential HS4C3 staining was observed in the glomerulus and the nucleus, 
with increased labelling of glomeruli and exclusive staining of nuclei. Changes 
in GBM and glomerular endothelial cell HS has been reported in other disease 
settings such as lupus nephritis or diabetes (Rops et al., 2007, van den Born et 
al., 2006) but were not further evaluated in this study. The existence of nuclear 
HS is quite disputable, but some research groups have reported nuclear 
localisation of HS (Richardson et al., 2001, Schubert et al., 2004). As the 
staining is quite variable results have to be interpreted carefully, non-specific 
interaction of the antibody cannot be excluded at this point.  
10e4 staining revealed similar results to phage display antibody staining, 
differences only became apparent when changes of HS were analysed during 
rejection. Here, the 10e4 epitope increased significantly during acute rejection 
1a, whereas the HS3A8 epitope increased significantly during chronic rejection. 
This observation supports the idea of regulated change in HS epitope 
expression during inflammatory responses. The 10e4 epitope could be induced 
during acute rejection to offer specific binding site to inflammatory molecules. 
After this process has taken place different HS species could be induced to 
offer binding sites to molecules involved in chronic settings, as HS3A8 during 
chronic rejection. 10e4 upregulation is consistent with observations of Ali et al, 
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who described increased 10e4 staining during acute kidney rejection (Ali et al., 
2005a). As HSPGs are excreted with the urine, a link between HS expression 
and stage of disease could potentially give invaluable information about the 
progress of the disease and antibodies could be used as diagnostic tools. 
To validate this idea a chemokine binding assay was developed. The theory 
was that chemokine binding could be observed in conjunction with 
appearance/disappearance of specific HS motifs. CCL5 was chosen because of 
its well defined GAG binding motif which has been described by various 
research groups (Ali et al., 2002, Kuschert et al., 1999, Proudfoot, 2006). A few 
binding assays employing CCL5 have been published (Ali et al., 2005a, Celie et 
al., 2007, Segerer et al., 2007), but the assay failed to work in our experimental 
settings. One reason could be that only paraffin embedded formalin-fixed tissue 
was available and binding studies are preferably performed on frozen tissues.  
Instead of binding, chemokine staining was conducted. CCL2 was chosen as it 
has been reported to be involved in renal disease (Robertson et al., 1998, 
Ruster et al., 2004, Segerer et al., 2000). Staining was strongly increased 
during acute rejection 1a with moderate staining at later stages. The staining 
pattern of CCL2 in renal biopsies however was somehow unexpected as it was 
focused on the luminal side of the tubules rather than the basolateral surface, 
where it was reported previously (Al-Hamidi et al., 2008, Lai et al., 2007, 
Robertson et al., 1998). A western blot confirmed that the antibody was specific 
and one possible explanation could be that the CCL2 found in the tubules has 
been fixed during the fixation process while it was excreted with the urine. 
Indeed, increased urinary excretion of CCL2 during acute renal allograft 
rejection has been reported (Prodjosudjadi et al., 1995). As CCL2 is mainly 
produced by tubular epithelial cells, increased CCL2 expression possibly 
contributes to the damage of renal tubules (Morii et al., 2003a, Morii et al., 
2003b).  
Recently the significance of chemokine-HS interaction was highlighted in a 
model of mouse aortic allograft transplant. Either NDST1 or chemokine receptor 
2 (CCR2) deficiency reduced inflammation and vasculopathy after aortic 
transplantation in a mouse model, proving GAG-chemokine interaction being 
the central regulatory step in inflammatory responses after transplantation. In 
addition, administration of the viral chemokine modulating protein M-T7, which 
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interferes with GAG binding for C, CC and CXC chemokines, resulted in 
prolonged survival and reduced inflammation in renal allograft transplants in 
mice (Dai et al., 2010). 
Furthermore, the importance of HS during renal rejection was also 
demonstrated in a model of experimental renal transplantation in rats. Rather 
than the HS GAG-chains the HS core proteins were examined in this study and 
induction of perlecan in glomerular basement membranes and collagen XVIII in 
cortical tubular basement membranes was observed (Rienstra et al., 2010). 
 
Observations in liver rejection 
In order to investigate if the findings of differentially expressed HS during renal 
rejection would also apply to different organs, liver allografts were examined. 
Due to the unique properties of the liver (low immunogenicity, high regeneration 
capacity) chronic rejection is a rare event (Tiegs and Lohse, 2010). It was 
therefore decided to include a group of specimens with chronic hepatitis, 
representing a group of chronic inflammatory disease. HS3A8, HS4C3 and 
10e4 antibodies stained in a similar fashion: sinusoids, bile ducts and basement 
membranes were the main compartments labelled by all the antibodies within 
the biopsies. Again, HS4C3 gave inconsistent results with regards to nuclear 
staining and was not analysed quantitatively. Inconsistency with HS4C3 staining 
pattern has also been reported previously by Toin van Kuppevelt (Harden 
conference, Cambridge UK, March 2009). The existence of the 3-O-sulphated 
domain on liver sinusoids has also been described previously (Ten Dam et al., 
2006). Isoforms 3-OST-A, 3-OST-B and 3-OST-1 have been found in liver 
(Shworak et al., 2002, Tatrai et al., 2010). The distribution and alteration of the 
HS4C3 epitope is in line with data recently published on HS in normal liver 
(Tatrai et al., 2010).   
When HS epitopes were compared during different stages of rejection, the 10e4 
expression was induced during moderate acute rejection particularly of bile 
ducts while there was hardly any expression at time 0, mild rejection or in late 
rejection. HS3A8 staining on the other hand increased during late rejection and 
chronic hepatitis compared to moderate/severe rejection. HS4C3, which shares 
requirement for N- and O-sulphation with HS3A8, also showed increased 
expression during chronic hepatitis. A rise in 3-O sulphation correlating with 
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increased levels of 3-O-ST-1 has also been reported for fibrotic liver. In HCC, 
also a slight 6-O-undersulphation most likely caused by enhanced levels of 6-O-
sulphatase 1 was observed (Tatrai et al., 2010). 
 
Taken together, in both renal and liver allograft rejection, distinct HS epitopes 
are induced at specific time points during rejection. In both organs, the 10e4 N-
sulphated HS epitope appeared at earlier times of the rejection whereas the 
HS3A8 (N-sulphation, 2-O- and 6-O-sulphation, epimerisation) and to some 
extent the HS4C3 (N-sulphation, 3-O- and 6-O-sulphation) motif was found to 
be induced at later time points, possibly providing differential binding sites for 
growth factors, cytokines or chemokines at that specific stage of the disease. 
Concluding from this preliminary case study, early inflammatory factors would 
be dependent on N-sulphation whereas during later events more sophisticated 
modification would be required.  
 
Possible consequences of altered HS motifs on ligand binding 
 
Although no binding experiments were carried out successfully, the 
consequences of the altered HS on ligand binding should be discussed.  
 
L-selectin 
L-selectin is expressed constitutively by leukocytes. Besides its role in 
lymphocytes homing it is involved in inflammation and expression of its ligands 
on the endothelium have been described in various diseases including rejection 
(Rosen, 1999). Endothelial HS has been identified as L-selectin ligand in a 
mouse model, where an endothelial specific NDST1 knockout resulted in 
reduced chemokine transcytosis, presentation and decreased leukocyte 
migration (Wang et al., 2005). Analysis of various tissues made clear that renal 
collagen XVIII, a HSPG found in the ECM, is the HS ligand in the kidney. It was 
also shown that L-selectin binding was dependent on chain length, O-sulphation 
and N-sulphation and inhibited by iduronate (Celie et al., 2005). This could 
suggest that L-selectin binds to NA/NS domains (alternating N-acetylated and 
N-sulphated residues), which are recognized by 10e4 antibody. It also has been 
shown that during acute renal rejection leukocytes enter the tissue and damage 
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the tubular epithelium, attracted by chemokines presented by HS on tubular 
basement membranes (Robertson and Kirby, 2003).  
Indeed, induction of L-selectin and CCL2 ligands on tubular epithelial cells 
under inflammatory conditions have been demonstrated as well as increased 
binding of L-selectin and CCL2 to HSPGs in the interstitial matrix during renal 
disease (Celie et al., 2007). Recently, the expression of proinflammatory 
HSPGs was also demonstrated in an ischemia/reperfusion induced 
inflammatory response after kidney transplantation, where L-selectin and CCL2 
binding domains where expressed under the endothelium on the basement 
membrane. The loss of SULF1, a 6-O-endosulphtase, is believed to be 
responsible for the induction of these inflammatory HS domains which require 
6-O-sulphate groups which would not be expressed under normal conditions 
(Celie et al., 2007).  
Overall, our findings in kidney support these models, as upregulation of the 
10e4 epitope during acute rejection 1a was found in the interstitium and on the 
tubular epithelium, where L-selectin mediated damage to the tubules takes 
place. The early involvement of L-selectin in the rejection process is further 
supported by the expression of the HS3A8 epitope during chronic stages, as the 
iduronic acid represented by this antibody would be inhibitory for L-selectin 
binding during early events, as ischemia/reperfusion injury or acute rejection. 
 
Chemokines 
Chemokines are known to bind HS and the residues of chemokines responsible 
for GAG interaction have been described but very little is known about the 
corresponding region of GAGs (Proudfoot et al., 2001, Severin et al., 2010). It 
was long thought that the exact saccharide composition and modification 
pattern would determine the interaction of chemokines and HS, but so far there 
is no data regarding exact modification and distribution that would be 
mandatory. N- and O-sulphation are said to be required (Kuschert et al., 1999, 
Schenauer et al., 2007) and apart from the sulphation status itself the spacing 
of the NS-domains by less modified NA domains creating distinct charge 
topologies (Lortat-Jacob, 2009). For a few chemokines HS binding domains 
have been investigated and all bind preferentially to saccharides with increased 
sulphation. N-sulphation and 2-O-sulphation have been shown to facilitate 
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CCL2 binding (Sweeney et al., 2006). Among saccharides with constant 
sulphation CCL2 preferentially bound to an HS octasaccharide containing an N-
acetylated residue (Schenauer et al., 2007). This would again be in agreement 
with our data, where CCL2 was found during acute rejection in conjunction with 
increased 10e4 staining, which represents N-sulphated and N-acetylated HS 
domains. Moreover, CCL2 was shown recently to bind to a heparin 
octasaccharide which is devoid of 3-O-sulphation, which is in agreement with 
our data where increased 3-O-sulphation, represented by HS4C3 staining, did 
only occur during chronic stages of rejection  (Meissen et al., 2009). 
 
AntithrombinIII 
The antithrombinIII (ATIII) binding site is the only specific heparin binding site 
known so far. Although certain binding requirements have been reported for 
other molecules, including FGFs, IFNγ or chemokines, no exact sequence has 
been experimentally proven. Structural analysis revealed a unique 
pentasaccharide sequence containing a very rare 3-O-sulphation required for 
high affinity binding (Lindahl et al., 1984, Petitou et al., 2003). The binding 
causes conformational changes in the protein, which enhances the 
neutralization of thrombin leading to anticoagulant effects. This interaction is of 
great medical importance as heparin is widely used as anticoagulant.  
3-OST-1 and to a lesser extent 3-OST-5 are the only isoforms of the 3-O-
sulphotransferase family which are capable of synthesizing anticoagulant HS 
(Girardin et al., 2005, Xia et al., 2002). As HS4C3 antibody recognises 3-O-
sulphation (Ten Dam et al., 2006), independent of the enzyme involved in 
generating the substitution, it is not clear if the identified domain has 
anticoagulant activity. In liver the existence of 3-OST-1, in addition to 3-OST-A 
and B, has been reported (Shworak et al., 1999, Tatrai et al., 2010) and 
therefore the existence of anticoagulant HS seems likable.  The upregulation of 
the HS4C3 epitope during chronic hepatitis in conjunction with heparanse could 
lead to a breakdown of anticoagulant environment in the transplanted organ, 
possibly causing intravascular coagulation and fibrin deposits in the rejecting 
allograft (Shriver et al., 2000). Indeed, upregulation of heparanase has been 
demonstrated recently in fibrotic liver disease (Tatrai et al., 2010). The biopsies 
in this study representing chronic hepatitis have not been further characterized, 
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but as chronic hepatitis is often caused by infection with viruses, such as 
hepatitis B and C, it would be interesting to investigate the involvement of the 
upregulated 3-O-sulphate group with regards to these viruses. So far only 
dependency on N-sulphation has been reported for hepatitis infection (Barth et 
al., 2006) but as 3-O-sulphated epitopes are upregulated during chronic 
hepatitis this would appear an interesting new approach. 
 
FGF2 
Well studied interaction partners of HS are fibroblast growth factors (FGFs) and 
their receptors (FGFRs). Two FGF molecules and two FGFR must bind to HS 
forming a ternary complex in order to signal properly (Kan et al., 1993, Powell et 
al., 2002, Rapraeger et al., 1994) (Harmer, 2006). Although there is an 
oligosaccharide which is bound with preference, no unique or specific binding 
site has been described. The most favourable sequence is composed of N-
sulphation on the non-reducing end glucosamine, 2-O-sulphation on iduronic 
acid and variable 6-O-sulphation on the reducing end glucosamine (Kreuger et 
al., 2001). The spatial arrangement of this binding motif is crucial for signalling 
of FGFs via their receptors. All of the above described modifications of HS 
necessary for FGF2 binding are represented by the antibody HS3A8. HS3A8 
epitopes are significantly upregulated in tubules and the interstitium during 
chronic rejection of kidney and in bile ducts during late acute rejection as well 
as chronic hepatitis in liver. This would imply increased levels of FGF2 during 
chronic inflammatory events.  Indeed, increased levels of FGF2 in interstitial 
and tubular renal cells (Strutz et al., 2000) were reported. Since allografts with 
chronic rejection undergo fibrotic changes, involvement of FGF2 is quite likely.  
 
Although the phage display antibodies are a great tool for investigating changes 
in HS composition, nothing is known about the relative abundance of individual 
modifications (Rops et al., 2008, Smits et al., 2006). 
An increase in staining could be due to high levels of N-sulphation and 
moderate levels of O-sulphation or vice versa. Therefore, disaccharide analysis 
in conjunction with staining would be very helpful in interpreting the data. In a 
recent study regarding phage display antibody specificity, significant differences 
between the existence of epitopes in situ (in tissue sections) and in vitro (in dot 
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blots of tissue extracts) were reported. A number of epitopes were not or only 
weakly recognized in situ but highly recognized in tissue extracts (and vice 
versa) (Thompson et al., 2009). This could be due to the masking of the HS 
epitope in situ by endogenous ligands and should be considered in the future. 
 
In summary, distinct HS epitopes have been identified during different stages of 
rejection. Both organ systems analysed revealed a time dependent 
appearance/disappearance of distinct epitopes: N-sulphated domains came up 
at early time points during rejection in kidney and liver allografts whereas highly 
sulphated domains came up late during chronic rejection in kidney and chronic 
hepatitis in liver.  In addition, increased expression of the chemokine CCL2 was 
observed during acute rejection 1a in kidney. The physiological consequence of 
these differentially modified motifs during rejection should be further explored by 
improved binding assays and matching studies between HS binding protein and 
distinct HS motives. 
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4 Regulation of Heparan Sulphate biosynthesis 
4.1 Introduction 
HS is a very heterogeneous molecule with a variety of functions. How the cell is 
capable of synthesizing such an information rich molecule in a cell/tissue as 
well as developmental stage/age specific manner (David et al., 1992, Ledin et 
al., 2006, Ledin et al., 2004) is still poorly understood. Unlike other molecules 
which carry biological information, such as DNA, there does not seem to be a 
code or any other form of template. So where does the regulation take place? 
At the transcriptional, translational or posttranslational level? Or is it assembly 
of the biosynthetic enzymes that determines their activity? 
4.1.1 The sequential model of HS biosynthesis 
In this established model it is believed that the HS biosynthetic enzymes act in a 
sequential manner. Therefore NDST1 would be regarded as the key player in 
HS biosynthesis (see section 1.6.3.1), as it is the first modifying enzyme to act 
on the HS chain. All other enzymes responsible for further 
modifications/sulphations would depend on prior action of NDST1.  This model 
is based on observations that without N-sulphation no further modifications, 
such as C5-epimerization or O-sulphation, occur (Lindahl et al., 1998, Salmivirta 
et al., 1996). 
4.1.2 The GAGosome model of HS biosynthesis  
Recently, a different model of HS biosynthesis was suggested by Esko and 
Selleck, which was later experimentally investigated by Ledin and co-workers. 
Based on studies in embryonic mouse liver tissue it was suggested that no 
regulation at the transcriptional, translational or posttranslational level takes 
place at all. Regulation is rather due to the assembly of the enzyme complex 
and the selection of enzymes into this complex, called the GAGosome (Esko 
and Selleck, 2002, Ledin et al., 2006). This model would offer a more flexible 
way of modification where enzymes involved in HS chain processing can act 
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simultaneously or before or after each other. The GAGsome is thought to offer a 
limited number of binding sites for NDSTs and that their affinity will predict 
which isoform gets incorporated.  
Even though the GAGosome model is a recent concept, there is some evidence 
to support it.  In 2004 it was demonstrated that HS synthesised from embryonic 
stem cells deficient in NDST1 and NDST2 lack N-sulphation but still contain 6-
O-sulphate groups (Holmborn et al., 2004), indicating modification of HS without 
prior N-sulphation. However, different research groups have shown 
transcriptional, translational and post-translational control of HS biosynthesis 
and it would be almost unbelievable that a molecule as complex as HS would 
be generated „by chance‟, solely depending on the enzymes available and their 
affinities. 
 
Translational control of NDST enzymes has been suggested; sequence 
analysis revealed that all 4 murine isoforms of NDST have extremely long and 
complex 5‟ untranslated regions (5‟UTRs) with a high degree of secondary 
structures and contain several upstream AUG codons which interfere with 
normal cap-dependent ribosome scanning and translation initiation. These 
Internal Ribosome Entry Sites (IRES) offer regulation on the translational level. 
Interestingly, some of the growth factors that bind to HS (FGF2, VEGF) reveal 
very similar 5‟UTRs. This could suggest the possibility of a coordinated 
regulation of growth factors and their co-receptors HS (Grobe and Esko, 2002). 
 
A few research groups have also shown that HS biosynthetic enzymes can be 
regulated by exogenous stimuli, such as proinflammatory cytokines.  Mouse 
glomerular endothelial cells were activated with either TNF-α or IL-ß and an 
upregulation of a range of enzymes involved in HS biosynthesis (NDST1, 
NDST2, 6-OST) was the consequence (Rops et al., 2008). This is consistent 
with data from TNF-α and IFN-γ stimulated human microvascular endothelial 
cells which also showed upregulation of NDST1 transcript (Carter et al., 2003). 
In agreement with that, stimulation of dermal human microvascular endothelial 
cells with LPS also resulted in upregulation of NDST1 (Krenn et al., 2008).  
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4.1.3 Protein-protein interaction of HS biosynthetic enzymes 
The GAGosome model is based on the formation of a complex involving the HS 
biosynthetic enzymes. So far only a few protein-protein interactions of HS 
enzymes have been identified.  
The first interaction between HS synthesizing enzymes has been demonstrated 
by affinity chromatography (Schwartz et al., 1974), where the xylosyltransferase 
and the galactosyltransferase1 have been shown to interact.  
The chain elongation enzymes EXT1 and EXT2 have been shown to form a 
heterooligomeric complex in the Golgi compartment, which is said to be the 
biologically active form of the chain elongation machinery (Munro, 1998, Nilsson 
et al., 1994, Salmivirta et al., 1996).  
Relocation studies where the C5 epimerase was relocated from the Golgi to the 
ER in CHO cells caused parallel redistribution of the 2-O-sulphotransferase, 
providing evidence for physiological interaction and complex formation (Pinhal 
et al., 2001). 
Recently, immunoprecipitation experiments revealed that EXT2 and NDST1 
interact with each other. This model suggests that EXT2 is acting as a 
chaperone, responsible for the transport of NDST1 to the Golgi apparatus. In 
this model, supporting the GAGosome concept, EXT1 and NDST1 compete for 
binding sites of EXT2 and the relative amount of the proteins decides which one 
gets incorporated, thus greatly influencing the sulphation pattern of HS (Presto 
et al., 2008).  
4.1.3.1 Protein-protein interaction: Tandem Affinity Purification (TAP) 
Different experimental approaches have been used to study protein-protein 
interactions, including co-immunoprecipitation, mammalian 2-hybrid systems 
and various fusion tags. The TAP-tag is the latest technology to analyse 
protein-protein interactions. Originally developed for purification of yeast protein 
complexes (Puig et al., 2001), this method has now been refined for use in 
mammalian systems. The tandem affinity purification method uses two different 
affinity purification tags that are fused to the protein of interest. After two 
consecutive purification steps, the targeted complex can be gently eluted and 
the interacting protein partners can then be identified by mass spectrometry. 
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The advantages of this system are that it allows purification under native 
conditions and the proteins recovered are very pure. It is now the method of 
choice for purification of recombinant protein complexes.  
As NDST1 plays a crucial role in HS biosynthesis it was decided to investigate 
its regulation on the level of protein-protein interaction. 
4.1.4 Specific aims 
This part of the work aimed to investigate the regulation of HS biosynthesis by 
studying the regulation of NDST1 at the protein level. Specific goals: 
 
 Design and cloning of the NDST1-TAP-tag construct 
 
 Optimisation of protein purification conditions 
 
 Purification of protein complexes and identification of interacting partners 
 
 Validation of the interaction 
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4.2 Specific Materials and Methods 
4.2.1 PCR 
PCR (polymerase chain reaction) is a simple method used to amplify DNA. The 
target DNA is bordered by a pair of oligonucleotide primers. PCR primers are 
usually 18-35 nucleotides in length and both primers should have approximately 
the same GC content and share a similar melting temperature. Primers should 
not be self-complemetary or complemetary to other primers used in the reaction 
to avoid homo- or heterodimerization. 
 
There are three basic steps in PCR cycles.  
Initially, the DNA is denatured at 95ºC. After that primers can anneal to the 
single stranded DNA template at a temperature 5ºC below their melting 
temperature. Finally, elongation of the DNA takes place at 72ºC. 
For PCRs using taq polymerase and Platinum taq the temperature settings 
shown in Table 4-1 were used. 
 
Table 4-1 Temperature settings of typical PCR reactions 
 
Taq polymerase Platinum Taq 
15 min 95 °C 2 min 94 °C 
1 min 94 °C 30 sec 94°C 
1 min 56°C 30 sec 55°C 
3 min 72°C 2.6 min 68°C 
10 min 72 --------- 
 
Despite the temperature settings and the amount of template, the concentration 
of primers and nucleotides are of importance.  
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A typical PCR reaction was set up as shown in Table 4-2: 
 
Table 4-2 Composition of a typical PCR reaction 
compound volume (µl) final concentration 
DNA template 1 1-10ng plasmid DNA 
dNTPs 10μM 1 200nM each 
fw primer 10 μM 1 200nM 
rev primer 10 μM 1 200nM 
Buffer 10x 5 1x 
polymerase 0.5 2.5U 
H20 40.5  
final volume 50  
 
For routine PCR, Taq polymerase from Qiagen was used. As this enzyme has 
no proofreading activity, mutations are quite common (error rate 1.1x104/bp 
(Tindall and Kunkel, 1988). For PCR reactions where the amplified fragment 
was needed for expression, an enzyme with proofreading activity was used, 
such as Platinum Taq high fidelity polymerase from Invitrogen. This enzyme 
mixture is composed of a recombinant Taq polymerase and a second 
polymerase with proof reading activity which increases fidelity approximately six 
times over that of Taq polymerase alone (invitrogen.com). Due to the Taq 
polymerase the amplified product ends with an A overhang at the 3‟ end, which 
makes it applicable for TA-overhang cloning and the 3‟ exonuclease activity 
from the second enzyme reduces the error rate. 
A plasmid (pcDNA3) containing the entire reading frame of human NDST1 
including 3‟ untranslated region was kindly provided by Dr. Humphries, Boston 
University, USA). Primers for PCR amplification were designed using Primer3 
open source software (frodo.wi.mit.edu). In order to subclone the DNA fragment 
directionally, restriction sites were added to each primer. In addition to PCR 
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primers also sequencing primers were designed to ensure integrity of the whole 
insert and not just the fusion region. 
 
Table 4-3 Primer design for NDST1 amplification and sequencing 
 primer 5’ addition sequence 5’→ 3’ 
    PCR primers forward EcoRI (gaattc) ggaggccaggatgcctg 
reverse XhoI (ctcgag) cctggtgttctggaggtcct 
Sequencing 
primers 
forward - cgtggatgccgtggccttcc 
reverse - aatcatcaacgggggcgagctc 
4.2.2 TA-cloning 
In order to facilitate subcloning of a PCR fragment, a PCR cloning kit 
(Stratagene) was used.  This technology allows cloning without the use of 
restriction enzymes and ligase. It is based on the fact that topoisomerase is 
able to cleave and rejoin DNA molecules. Taq polymerase amplified products 
contain a 3‟ adenosine overhang which allows ligation into the TA-vector 
through A-T base-pairing followed by topoisomerase mediated strand ligation. 
The resulting vector contains a LacZ‟ α-complementation cassette to allow blue-
white screening on agar plates containing 20µg/ml X-gal (5-bromo-4-chloro-3-
indolyl-ß-D-galactopyranoside). The host strain used here does not require the 
addition of IPTG as inducer for the lac operon. As two EcoRI sites flank the 
MCS, vectors containing an insert can easily be verified by EcoRI digestion 
followed by agarose gel electrophoresis. 
4.2.3 Protein cross-linking 
Protein cross-linking was performed to investigate the formation of multi-protein 
complexes. Two amine-reactive crosslinkers were employed. 
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4.2.3.1 Formaldehyde 
Formaldehyde (methanol-free, Pierce) was used as a cross-linking agent as it is 
highly reactive and cell permeable. The single carbonyl group of formaldehyde 
functions as a homobifunctional crosslinker. It reacts with the nitrogen of the 
lysine residues of the protein forming a methylene bridge. Cells were seeded in 
100mm dishes, grown to ~80% confluency and incubated with Formaldehyde 
(0-1%) for 20 minutes at 37°C. Following extensive washing in PBS, the 
reaction was stopped by the addition of glycine to a final concentration of 
0.125M. After washing the cells twice, lysis buffer was added and cells were 
scraped on ice. After spinning for 20 minutes at 16.000 x g, the supernatant was 
collected and analysed by Western blotting. 
 
4.2.3.2 DST (disuccinimidyl tartrate) 
DST is a membrane permeable homobifunctional crosslinker, suitable for 
intracellular or intramembrane protein conjugation. Cells were seeded in 
100mm dishes, grown to ~80% confluency and incubated with 1mM DST in 
DMSO for 30 and 45 minutes at RT after extensive washing in PBS. The 
reaction was stopped by the addition of glycine. After washing the cells twice, 
lysis buffer was added and cells were scraped on ice. After spinning for 20 
minutes at 16.000 x g, the supernatant was collected and analysed by Western 
blotting. 
4.2.4 Tandem affinity purification 
The tandem affinity purification method uses two different affinity purification 
tags that are fused to the protein of interest. After two purification steps, the 
targeted complex can be gently eluted. The interacting protein partners are then 
identified by mass spectrometry. 
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Figure 4-1 Schematic representation of the pCTAP vector  
 
In this study the InterPlay mammalian TAP system from Stratagene has been 
used. In this system the protein of interest is fused to a streptavidin binding 
peptide (SBP) and a calmodulin binding peptide (CBP). The SBP tag has a high 
affinity for the streptavidin resin and can be eluted with biotin. The CBP tag has 
a high affinity for the calmodulin resin in the presence of calcium. When calcium 
is removed, the tagged protein complex can be eluted. 
 
Figure 4-2 Overview of TAP-technology 
 
The protein of interest is fused to the strepatvidin binding peptide (SBP) and the 
calmodulin binding peptide (CBP). After incubation with cell extracts the bound proteins 
are purified in two consecutive steps and interacting proteins are eluted under native 
conditions. 
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In brief, approximately 6 x 107 cells were harvested. After two washes with ice-
cold PBS, the cells were removed mechanically from the culture flasks and 
maintained at 4ºC during the whole purification process. Cells were 
resuspended in lysis buffer and were then subjected to three successive cycles 
of freeze-thawing by incubating cells at -80ºC for 20 minutes followed by 
incubating cells in a cold water bath at 4ºC for 10 minutes. Cells were harvested 
at 16.000 x g for 10 minutes to pellet cell debris and the supernatant was 
supplemented with 4µl of 0.5M EDTA and 0.7µl of 14.4M β-mercaptoethanol 
per ml of lysate. 50 µl of washed streptavidin resin slurry (25 µl resin) was 
added to 1ml of protein lysate and the mixture was incubated at 4ºC for 2h 
whilst rotating to allow the tagged protein to bind to the resin. After collecting the 
resin by centrifugation at 1500 x g and two further washes, 100 µl streptavidin 
elution buffer was added. Proteins were eluted by rotating the tube for 30 
minutes. After collecting the supernatant via centrifugation at 500 x g for 5 
minutes it was supplemented with 2 µl streptavidin supernatant supplement and 
25 µl washed calmodulin resin slurry (12.5 µl resin) per ml of supernatant. After 
2 additional hours of incubation and rotation, the resin was collected by 
centrifugation for 5 minutes at 1500 x g. The supernatant was discarded and the 
tagged proteins bound to the calmodulin resin were eluted by rotating the tube 
for 30 minutes after adding 50 µl calmodulin elution buffer. Finally, the resin was 
collected by centrifugation for 5 minutes at 1500 x g and the supernatant 
containing the Tandem Affinity Purified complexes was stored at -20 ºC until 
further processing. 
In order to concentrate the sample, the TAP-purified protein complexes were 
TCA precipitated and then loaded onto a 4-12% gradient SDS-PAGE 
(Invitrogen).  
4.2.4.1.1 Staining of the SDS-PAGE 
The SDS-PAGE was stained with colloidal coomassie blue (SimplyBlue 
SafeStain, Invitrogen). In brief, the gel was rinsed 3 times for 5 minutes in 
deionised water before staining for 1h at room temperature. After washing the 
gel in deionised water for 1h at room temperature, bands were excised and sent 
for MS analysis.   
Chapter 4 Regulation of Heparan Sulphate biosynthesis 
 110 
 
4.2.4.1.2 Mass spectrometric analysis 
After enzymatic (trypsin) digestion of the excised bands, proteins were identified 
by peptide-mass fingerprinting (PINNACLE, Newcastle University). 
The individual samples from peptide mass fingerprinting were analysed using 
the Mascot Mowse score, which basically compares the calculated peptide 
masses of all entries in the sequence database with the experimental data of 
the sample and if the calculated value falls within the set mass tolerance it 
counts as a match. The Mascot protein score is -10*Log (P), where P is the 
probability that the match observed is random. The e-value in Mascot 
corresponds to the number of times one would expect this score by chance 
alone (Pappin et al., 1993, Perkins et al., 1999). The settings for the 
identification of unknown proteins by peptide mass fingerprint were as follows: 
 
Taxonomy: the taxonomy was set to „all entries‟ and not restricted to a specific 
species albeit only samples from human origin were analysed as  restricting the 
taxonomy could prevent finding a match if for instance the protein is not present 
in database yet. In that case, a homologous protein match from a different 
species could give invaluable information about the protein identity. Further, not 
all databases do have a rigorous taxonomy system. 
 
Enzyme: the serine protease trypsin was used for all digestions. 
 
Variable modifications: with variable modifications, which may but may not be 
present in the samples, each potential site is tested with or without the 
modification. Variable modifications were: Carbamidomethyl (cystein), which is 
as a result of the alkylating reaction with iodoacetamide during sample 
preparation; Oxidation  M (methionine either normal or methionine+oxygen) and 
Peptide N-terminal Gln to pyro-glu N-terminal either glutamine or pyro-glutamic 
acid) 
Mass values: Monoisotopic was chosen, where mass is determined by the 
masses of the most abundant isotopes 
Protein Mass: Unrestricted 
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Peptide mass tolerance: the mass tolerance was expressed as fraction as 
parts per million (ppm) and individual settings can be seen in the results tables  
 
Peptide charge state: 1+ 
 
Max missed cleavage: a perfect digestion would mean that no partial 
fragments are present, but as often samples are only partially digested, this 
parameter was routinely set to 1. 
 
(www.matrixscience.com) 
4.2.5 Co-IP 
Antibody immobilisation 
The AminoLink Plus coupling resin was equilibrated at room temperature and 
50μl of the resin slurry was added into a spin column, which was centrifuged at 
1000 x g for 1 minute to collect the resin. After the flow-through was discarded, 
the resin was washed twice in 200 μl of coupling buffer and excess liquid was 
removed carefully with a paper towel. 75 μg of affinity purified beta tubulin 
antibody (Abcam) in 200μl of coupling buffer (10 μl of antibody at a 
concentration of 1 μg/μl plus 190 μl of coupling buffer) was added directly to the 
resin. 3μl of Sodium Cyanoborohydride solution was added and the column was 
incubated for 120 minutes on a rotator at room temperature. After centrifuging 
the column once at 1000 x g for 1 minute, the column was washed twice with 
200 μl coupling buffer and once with 200 μl of quenching buffer. The column 
was incubated with 3μl of Sodium Cyanoborohydride in 200 μl of quenching 
buffer for 15 minutes with gentle shaking at room temperature before the 
column was washed with 200 μl of quenching buffer twice. After six additional 
washes with 150 μl of washing solution the resin was ready for the following Co-
IP. 
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Cell Lysis 
Cells were grown to ~80% confluency in 100mm dishes, washed twice in PBS 
and lysed in 500 μl of lysis/wash buffer for 10 minutes on ice with periodic 
mixing. After lysis, the supernatant was collected at 13.000 x g for 10 minutes 
and transferred into a fresh tube for protein concentration determination. Cell 
lysate was adjusted to 400 μl with lysis/wash buffer. 
 
Co-IP 
All steps were performed at 4°C. The column, containing the antibody-coupled 
resin, was washed twice with 500 μl of lysis/wash buffer and excess liquid was 
carefully removed with a paper towel. Lysate and controls were added to the 
resins and incubated with gentle rocking for 2 hours. The column was 
centrifuged (flow-through was saved for later analysis), placed in a new 
collection tube and washed three times with 500 μl of lysis/wash buffer. 
Elution of Co-IP 
The column was placed in a new collection tube and 10 μl of elution buffer were 
added. After centrifuging, 70 μl of elution buffer was added and columns were 
incubated for 5 minutes at room temperature. Finally, the column was 
centrifuged and the flow-through was collected for further analysis. 
 
Protein samples were analysed by Western blotting probed for NDST1. 
 
The control resin, which is composed of the same material as the Co-IP resin 
but is not activated, was carried along as negative control. 
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4.3 Results 
4.3.1 Cloning of NDST1-pCTAP 
4.3.1.1 Cloning of NDST1 into the pCTAP-vector 
In order to create a C-terminal tagged form of NDST1 the stop codon of the 
human NDST1 cDNA was removed by PCR. Prior to PCR amplification of 
NDST1 cDNA the sequence was verified by sequencing using routine 
sequencing primers T7 and Sp6 (see appendix section 8.1). Figure 4-3 shows 
successful amplification of the PCR product. 
 
 
Figure 4-3 Representative agarose gel of PCR products 
 
Lanes 1 and 8 contain DNA hyperladder, lanes 3, 5 and 6 containing amplified ORF of 
NDST1, lane 2 containing no enzyme control and lane 4 and 7 contain no template 
controls. 
 
To facilitate subcloning, Taq polymerase was used for the PCR reaction with  
an additional proof reading enzyme in the reaction mix. Due to the A overhang 
provided by the Taq polymerase the PCR product was subcloned into a TA-
vector. Blue-white screening allowed identification of positive clones (Figure 4-
4). 
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Figure 4-4 Blue white screening of TA clones 
 
PCR- amplified NDST1 cDNA was cloned into the TA-vector and transformed into 
competent E.coli. Blue-white screening was performed using agar plates containing X-
gal. A) representing the positive control transformation and B) clones transformed with 
the PCR-amplified NDST1 cDNA. 
 
Positive (white) clones were selected, expanded and DNA extracted. The DNA 
was EcoRI digested (two EcoRI sites flank the MCS in the TA-vector) to identify 
clones carrying the insert (Figure 4-5).  
 
 
Figure 4-5 Representative agarose gel of restriction digests of TA-clones 
 
Lane 1 and 15 contain DNA hyperladders with fragment sizes as indicated, lane 2-8 and 
12 contain EcoR1 digested plasmid plus insert (approximately 2.6 kbp), lane 9 contains 
uncut plasmid as a control, lane 13 contains EcoR1 digested plasmid without insert and 
lane 10 and 14 were used as spacers. 
 
NDST1 DNA fragments of the correct size (approximately 2.65 kbp) were 
excised from the gel, purified and ligated into the pCTAP vector which 
previously had been linearized with the corresponding enzymes (EcoRI and 
XhoI). After transformation into competent E. coli, colonies were picked from 
agar plates, DNA was isolated and restriction digestion was performed to 
screen for positive clones (Figure 4-6).  
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Figure 4-6 Representative agarose gel of restriction digests of pCTAP-NDST1 clones 
 
Clones were analysed by Not1 and Xho1 restriction mapping. Lane 1 and 13 contain DNA 
hyperladder, lanes 4 and 6 contain clones carrying NDST1 insert, lanes 2, 3, 5 and 7-12 
containing false-positive clones without insert. 
 
DNA of 2 clones, which appeared to have correctly sized fragments, was 
excised and sent for sequencing to ensure the integrity of the amplified product. 
As the insert exceeds 2400bp internal sequencing primers were designed to 
ensure integrity of the whole insert. Figure 4-7 shows a schematic 
representation of the NDST1-TAP-tag construct (the complete sequence of the 
construct can be found in the appendix section 8.2).  
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a 
 
 
b 
 
Figure 4-7 Schematic representation of NDST1-pCTAP construct 
 
NDST1 cDNA has been cloned between EcoRI and XhoI restriction sites in frame with the 
SBP-tag of the pCTAP vector. DNA sequence of fusion region with restriction sites (a) 
and schematic representation of the cloned construct (b). 
 
Prior to transfection of HEK 293 cells the NDST1-pCTAP construct was 
linearized to improve integration frequency into the host genome. As there was 
no singular restriction site available for linearization, the MluI site which 
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overlapped with 1 base at the end with the SV40 polyA signal was chosen 
(Figure 4-8). 
 
 
 
Figure 4-8 Linearisation of pCTAP and pCTAP-NDST1 
 
Lane 1 and 4 containing hyperladder, lane 2 containing NDST1-pCTAP in circular form 
and lane 3 containing pCTAP-NDST1 which was linearized by MluI restriction digestion. 
4.3.1.2 Transfection of HEK 293 cells with NDST1-pCTAP and control plasmid 
Various DNA:Effectene  ratios were used for transfection without any significant 
effect on the efficiency. Transfectants were selected with 800µg/ml of G418 and 
kept under selection pressure (400µg/ml) whilst expanding. 
4.3.1.3 Screening of NDST1 transfectants 
The 20 surviving clones were screened via Western blotting for the expression 
of NDST1 protein with antibodies raised against NDST1 (NDST1 antibody 
Santa Cruz, see section 2.5.6) and against the calmodulin binding peptide 
(Santa Cruz). Figure 4-9 shows that neither the C-terminal tag nor the 
linearization of the DNA prior to transfection interfered with the expression of 
NDST1, as the protein was expressed correctly sized and non-degraded. 
Transfectant 15 revealed upregulation of NDST1 protein and was used for 
further experiments.  
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Figure 4-9 Expression of pCTAP-NDST1 
 
Western blots of pCTAP-NDST1 stably transfected HEK 293 cells (Transfectant 5, 15 and 
19). 70µg of total cell lysates were used, blots were probed with α-CBP- and α-NDST1- 
specific antibodies as indicated. Representative for n=2. 
 
FACS analysis revealed functionality of the tagged enzyme as F15 cells 
showed significantly increased staining for 10e4 (Figure 4-10). 
 
 
 
 
Figure 4-10 10e4 epitope expression of NDST1 overexpressing F15 cells 
 
F15 cells were incubated with 10e4 antibody (1/50) and anti-mouse-FITC conjugated 
secondary antibody. Unstained cells were incubated in FACS buffer (5% FCS/PBS) and 
cells incubated with the secondary antibody, omitting the primary antibody incubation 
step, served as a control. Representative flow cytometry plots (a). Differential expression 
of 10e4 HS epitope of wild type and NDST1 overexpressing F15 cells (b). Data 
representative for 2 individual experiments performed in duplicates. Statistical analysis 
was determinded by student’s t-test with differences p<0.05 considered to be significant. 
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4.3.2 Protein complex formation 
4.3.2.1 Formaldehyde crosslinking  
Proteins crosslinking was used to study protein complex formation. As 
formaldehyde is membrane permeable it can be added to living cells and 
proteins in close proximity (within 2 Å distance) are able to form bonds. Prior to 
the Tandem affinity purification, NDST1 overexpressing cells were used for 
these chemical cross-linking experiments, as it seemed plausible that due to 
overexpression of NDST1, complex formation with interacting protein partners 
could be observed.  
Subconfluent flasks of HEK 293 NDST1 transfectant cells were incubated with 
0.5% or 1% of methanol-free formaldehyde and incubated for 20 minutes at 
37°C before glycine was added to stop the reaction. Reaction time and 
temperature were chosen as they have been shown to work in similar settings 
(Vasilescu et al., 2004).  
 
 
Figure 4-11 Western Blot of formaldehyde crosslinked protein lysates 
 
NDST1 overexpressing clone F15 was incubated with varying concentrations of 
Formaldehyde for 20 minutes at 37°C.  Blots were probed with NDST1 specific 
antibodies. SDS-PAGE was run under denaturing (A) or non-denaturing (B) conditions. 
F15C1 served as a control without formaldehyde treatment, whereas F15C2 served as a 
control without formaldehyde treatment but addition of glycine. Representative for n=2. 
 
As seen in Figure 4-11, no protein complex formation was observed under 
either denaturing or non-denaturing conditions. If NDST1 had interacted with 
other proteins, one would expect a shift towards higher molecular weight on the 
Western blot. Similar experiments were also carried out with DST as 
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crosslinking agent but also failed to reveal protein complex formation (data not 
shown). 
4.3.2.2 Screen for protein-interacting partners: Tandem Affinity Purification  
As no protein complex formation was observed using chemical cross-linking, 
NDST1 overexpressing HEK 293 cells were used for affinity purification. In this 
study a purification kit optimized for cytoplasmatic proteins was used. As 
NDST1 is a non-soluble membrane protein with one transmembrane domain 
lysis conditions had to be optimized. In the first approach, the lysis buffer 
provided with the kit was supplemented with nonidet NP40 to a final 
concentration of 1%, as suggested by Seraphin and co-workers, who initially 
developed this method (Puig et al., 2001). 
 
4.3.2.2.1 Purification using original lysis buffer 
The purification was carried out according to the standard protocol, starting with 
6 x 107cells. After the purification, total protein lysates were separated by a 
gradient SDS-PAGE. 
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Figure 4-12 Affinity purification using original lysis buffer 
 
4-12% colloidal coomassie-stained SDS-PAGE loaded with TAP-purified proteins.  
Approximately 6 x10
7
cells were used.  Lane 1: protein ladder, lane 2: whole lysate (2µl 
loaded), lane 3: SBP-wash (2µl loaded), lane 4: SBP-eluate (20µl loaded), lane 5: CBP-
wash (20µl loaded),, lane 6: final eluate (all loaded after TCA precipitation). 
 
Figure 4-12 shows no evidence of  NDST1 purification. In the final eluate (lane 
6), no band around 100kDa, where NDST1 would be expected, is visible. This 
suggests that the addition of NP40 to the original lysis buffer is incompatible 
with the purification process. As the composition of the lysis buffer provided with 
the kit is proprietary, it was decided to develop completely new lysis conditions. 
4.3.2.2.2 Purification using ‘home-made’ lysis buffer 
As the original lysis conditions failed to purify NDST1, a new lysis buffer was 
used for the next purification (50mM Tris, 150mM NaCl, 10mM Na3VO4 and 
1%NP40) based on the method originally developed by Puig (Puig et al., 2001). 
Again, 6 x 107cells were used as starting material.  
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Figure 4-13 Affinity purification using modified lysis buffer 
  
4-12% colloidal coomassie-stained SDS-PAGE loaded with TAP-purified proteins. 
Approximately 6 x10
7
cells were used. Lane 1: protein ladder, lane 2 whole lysate (2µl 
loaded), lane 3: SBP-wash (2µl loaded), lane 4: SBP-eluate (20µl loaded), lane 5: CBP-
wash (20µl loaded), lane 6: final eluate (all loaded after TCA precipitation). 
 
Figure 4-13 proves that the new lysis conditions worked well in conjunction with 
the purification kit and a distinct band around 100kDa plus one smaller band 
were visible in the finale eluate. Both bands were excised with a clean scalpel 
and sent for MS-identification. 
 
Table 4-4 MS-analysis of TAP-purified, co-eluted proteins using modified lysis conditions 
band identified as e-score protein score 
(significance) 
queries 
matched/total 
nr of queries 
mass 
tolerance 
(+/- ppm)  
a NDST1 1e -26 325 (>78) 44/83 55 
b HSP 70 
precursor 
3e -13 177 (>64) 16/25 50 
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The band around 100kDa was identified as NDST1 (Table 4-4), which proved 
that the new lysis buffer worked in conjunction with the purification kit 
(representation of NDST1 MS peptide mass fingerprinting analysis can be found 
in the appendix 8.3). The second band was identified as a precursor of HSP70. 
Heat shock proteins have been found as common contaminants in almost every 
purification reported and therefore have to be accepted with reservation (Gavin 
et al., 2002, Shevchenko et al., 2002).  
The protein score is -10*Log (P), where P is the probability that the match 
observed is random  and the e-value corresponds to the number of times one 
would expect this score by chance alone therefore making high p-scores and 
low e-scores desirable.  
4.3.2.2.3 Purification using optimised lysis conditions and increased cell number 
Having shown that the system works in principle and NDST1 can be purified by 
this technique, the next step was to increase the cell number, as apart from 
HSP70 no other proteins were co-eluted together with NDST1 from the resin.  
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Figure 4-14 Affinity purification using optimised lysis buffer and increased cell number 
 
4-12% colloidal coomassie-stained SDS-PAGE loaded with TAP-purified proteins. 
Approximately 1.2 x10
8
cells were used. Lane 1: protein ladder, lane 2: whole lysate (2µl 
loaded), lane 3: SBP-wash (2µl loaded), lane 4: SBP-eluate (20µl loaded), lane 5: CBP-
wash (20µl loaded), lane 6: final eluate (all loaded after TCA precipitation).  
 
Approximately 1.2 x 108cells were used for purification and the resins for 
purification were pooled. With increased cell number, more proteins were co-
eluted with NDST1 from the resin. Figure 4-14 shows five distinct lanes which 
were excised as indicated (a-e) and identified by MS analysis (Table 4-5). 
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Table 4-5 MS-analysis of TAP-purified, co-eluted proteins using increased cell number 
band identified as e-score protein score 
(significance) 
queries 
matched/total 
nr of queries 
mass 
tolerance 
(+/- ppm)  
a NDST1 6.52 -16 217 (>78) 29/52 100 
b Hsp 70 
precursor 
8.1e -06 116 (>78) 17/48 100 
c Hsp 70 
precursor 
0.0002 102 (>78) 16/50 100 
d Beta-tubulin 1.2e -15 201 (>64) 28/48 50 
e ADP-ATP 
translocase 
0.0017 93 (>78) 12/46 100 
 
Using increased number of cells a band was detected above the 100kDa band 
of NDST1. This was later identified as NDST1 by MS analysis. This could mean 
that proteins were not fully denatured when loaded onto the PAGE and NDST1 
is still in complex with a protein binding partner, therefore appearing at a higher 
molecular weight.  Similar to the first purification, heat shock proteins were 
identified. 
Beta tubulin was also co-eluted. This is interesting, as NDST2 has been 
reported to interact with beta tubulin in mice (Ledin et al., 2006). The last protein 
to be identified in this mixture was ADP-ATP translocase.  
4.3.2.2.4 Purification using optimised lysis conditions and optimised cell number 
After optimising lysis conditions and cell number, a control transfectant (C7) 
was used along with transfectant F15 for purification. The control transfectant 
was created by transfecting HEK 293 cells with an empty pCTAP vector (not 
carrying the NDST1 insert). This is important, as this control helps to 
discriminate between specific binding partners of NDST1 and proteins, which 
eventually stick to the streptavidin binding peptide or the calmodulin binding 
peptide on its own. This seemed to be an appropriate control and of more 
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informative value than a mock transfectant for instance. Figure 4-15 shows the 
pattern of eluted proteins of F15 and control cells. 
 
 
Figure 4-15 Affinity purification using optimised conditions of NDST1-pCTAP and control 
 
4-12% colloidal coomassie-stained SDS-PAGE loaded with TAP-purified proteins. 
Approximately 1.2 x10
8
 cells were used. Lanes 2-6 were loaded with proteins from 
NDST1-pCTAP clone 15, whereas lanes 7-12 were loaded with proteins from vector 
control clone 7. 
Lane 1: protein ladder, lane 2: whole lysate (0.5µl loaded), lane 3: SBP-wash(1µl loaded), 
lane 4: SBP-eluate (20µl loaded), lane 5: CBP-wash (20µl loaded), lane 6: final eluate (all 
loaded after TCA precipitation), lane 7: protein ladder, lane 8 whole lysate (0.5µl loaded), 
lane 9: SBP-wash (0.5µl loaded), lane 10: SBP-eluate (20µl loaded), lane 11: CBP-
wash(20µl loaded), lane 12: final eluate (all loaded after TCA precipitation). 
 
Both clones, transfectant F15 and control transfectant C7, were grown in 
parallel under the same conditions and the same number of cells was used for 
cell lysis and subsequent purification. When the patterns of the two SDS-
PAGEs (Figure 4-15) are compared, a lack of the 100kDa band corresponding 
to NDST1 in the control can be observed. Hardly any bands, apart from one 
around 70kDa, probably representing a heat shock protein, can be detected in 
the control purification.  
Eight bands from transfectant F15 were excised and sent for MS identification 
(Table 4-6). 
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Table 4-6 MS-analysis of TAP-purified, co-eluted proteins using optimised conditions 
band identified as e-score protein score 
(significance) 
queries 
matched/total 
nr of queries 
mass 
tolerance 
(+/- ppm)  
a NDST1 4.1e-18 239 (>78) 22/27 100 
b NDST1 2e-18 242 (>78) 22/28 50 
c NDST1 6.5e-12 177 (>78) 17/23 50 
d NDST1 1e-18 239 (>78) 21/25 50 
e HSP70 
precursor 
0.0089 62 (>64) 8/18 80 
f HSP70 
precursor 
1.3e-8 144 (>78) 12/23 20 
g ATP synthase 
subunit + 
NDST1 
8.1e-11 166 (>78) 17/20 50 
h Beta tubulin 9.3e-22 262 (>64) 25/30 50 
 
Surprisingly, NDST1 peptides were detected in five out of the eight samples. 
Three were of a higher molecular weight than NDST1 whereas two migrated 
below NDST1. For the higher molecular weight samples, this could again mean 
that NDST1 is still in complex with other proteins which were not fully denatured 
before loading onto the PAGE. However, this cannot fully explain the existence 
of the smaller bands. Maybe they are remains of proteins complexes which 
have been partially degraded. In one case NDST1 was found as a mixture with 
a subunit of the ATP synthase. Beta tubulin was again identified by MS. 
4.3.2.2.5 Purification using optimised lysis conditions and cell number under 
stringent denaturation conditions 
Further alterations were introduced to the standard protocol for the last 
purification. The cell number was increased to 1.5 x 108 cells and resins for 
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purification were pooled. Additionally, the washing steps were doubled (4 
instead of 2 five minute washes) at each individual step of the purification.  
In an attempt to dissolve the higher molecular weight bands more stringent 
denaturation conditions were chosen. After the purification, protein lysates were 
boiled for 30 minutes in 4 x loading buffer supplemented with 2% LDS (lithium 
dodecyl sulphate) and ß-mercaptoethanol as a reducing agent. Figure 4-16 
reveals a similar protein elution profile compared to the previous one.  
 
 
Figure 4-16 Affinity purification under stringent denaturation conditions 
 
4-12% colloidal coomassie-stained SDS-PAGE loaded with TAP-purified proteins. 
Approximately 1.5 x10
8
 cells were used. Lanes 2-6 were loaded with proteins from 
NDST1-pCTAP clone 15, whereas lanes 9-12 were loaded with proteins from vector 
control clone 7. Prior to loading protein samples they were denatured in 4xNU-PAGE 
sample buffer containing 2% LDS and β-mercaptoethanol by boiling for 30 minutes. 
Lane 1: protein ladder, lane 2: whole lysate (0.5µl loaded), lane 3: SBP-wash (1µl loaded), 
lane 4: SBP-eluate (20µl loaded), lane 5: CBP-wash (20µl loaded), lane 6: final eluate (all 
loaded after TCA precipitation), lane 7: protein ladder, lane 8 whole lysate (0.5µl loaded), 
lane 9: SBP-wash (0.5µl loaded), lane 10: SBP-eluate (20µl loaded), lane 11: CBP-wash 
(20µl loaded), lane 12: final eluate(all loaded after TCA precipitation). 
 
The control lacked the 100kDa band indicative for NDST1 and did not show too 
many distinct protein bands apart from the ~70kDa band (most likely to be a 
member of the HSP superfamily). Six unknown bands plus the 100kDa NDST1 
band were sent for MS analysis. Despite the harsh denaturation conditions 
higher as well as lower molecular weight bands were identified as NDST1 
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(Table 4-7). Members of the HSP70 superfamily were found on their own 
(HSP70 and BiP) and in conjunction with NDST1. Additionally, beta tubulin was 
detected again in the protein preparation. 
 
Table 4-7 MS-analysis of TAP-purified, co-eluted proteins under stringent conditions 
band identified as e-score protein score 
(significance) 
queries 
matched/total 
nr of queries 
mass 
tolerance 
(+/- ppm)  
A NDST1 7e-21 255 (>66) 30/45 100 
B NDST1 1.8e-13 181 (>66) 27/66 100 
C BiP 64.4e-20 247 (>66) 29/44 100 
D HSP70 3.5e-18 230 (>66) 27/36 100 
E HSP70 and 
NDST1 
1.4e-27 322 (>66) 42/64 100 
F Beta tubulin 5.6e-25 269 (>78) 27/43 100 
G Non-specific  - - - - 
 
Beta tubulin and NDST1 were the only two proteins which were found 
consistently in all the protein preparations with reliable p- and e-scores. Figures 
4-17 and 4-18 illustrate typical protein sequence alignments used to identify 
proteins in this study using Mascot software, a sample of Mascot data analysis 
can be found in the appendix. 
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    1 MPALACLRRL CRHVSPQAVL FLLFIFCLFS VFISAYYLYG WKRGLEPSAD  
    51 APEPDCGDPP PVAPSRLLPL KPVQAATPSR TDPLVLVFVE SLYSQLGQEV  
   101 VAILESSRFK YRTEIAPGKG DMPTLTDKGR GRFALIIYEN ILKYVNLDAW  
   151 NRELLDKYCV AYGVGIIGFF KANENSLLSA QLKGFPLFLH SNLGLKDCSI  
   201 NPKSPLLYVT RPSEVEKGVL PGEDWTVFQS NHSTYEPVLL AKTRSSESIP  
   251 HLGADAGLHA ALHATVVQDL GLHDGIQRVL FGNNLNFWLH KLVFVDAVAF  
   301 LTGKRLSLPL DRYILVDIDD IFVGKEGTRM KVEDVKALFD TQNELRAHIP  
   351 NFTFNLGYSG KFFHTGTNAE DAGDDLLLSY VKEFWWFPHM WSHMQPHLFH  
   401 NQSVLAEQMA LNKKFAVEHG IPTDMGYAVA PHHSGVYPVH VQLYEAWKQV  
   451 WSIRVTSTEE YPHLKPARYR RGFIHNGIMV LPRQTCGLFT HTIFYNEYPG  
   501 GSSELDKIIN GGELFLTVLL NPISIFMTHL SNYGNDRLGL YTFKHLVRFL  
   551 HSWTNLRLQT LPPVQLAQKY FQIFSEEKDP LWQDPCEDKR HKDIWSKEKT  
   601 CDRFPKLLII GPQKTGTTAL YLFLGMHPDL SSNYPSSETF EEIQFFNGHN  
   651 YHKGIDWYME FFPIPSNTTS DFYFEKSANY FDSEVAPRRA AALLPKAKVL  
   701 TILINPADRA YSWYQHQRAH DDPVALKYTF HEVITAGSDA SSKLRALQNR  
   751 CLVPGWYATH IERWLSAYHA NQILVLDGKL LRTEPAKVMD MVQKFLGVTN  
   801 TIDYHKTLAF DPKKGFWCQL LEGGKTKCLG KSKGRKYPEM DLDSRAFLKD  
   851 YYRDHNIELS KLLYKMGQTL PTWLREDLQN TR 
Figure 4-17 Sequence alignment of NDST1 peptide mass fingerprinting 
 
Matching peptides highlighted in red. 
 
 
    1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY  
    51 YNEATGGKYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN  
   101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL  
   151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY  
   201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL  
   251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDAKNMM  
   301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK  
   351 TAVCDIPPRG LKMSATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG  
   401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEFEEEA EEEVA 
Figure 4-18 Sequence alignment of beta tubulin peptie mass fingerprinting 
 
Matching peptides highlighted in red. 
 
Thus, beta tubulin was regarded as the only possible specific interacting protein 
found in this study as it appeared consistently in all purifications with extremely 
low e-values. 
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4.4 Discussion 
HSPGs regulate a huge variety of functions, both during embryonic 
development and adult (patho-) physiology. As a multitude of proteins and 
biomolecules rely on HSPGs to exert their function, HSPGs have become a 
major therapeutic target.  
Different approaches have been made to modulate HS biology. Targets could 
be directly activated or inactivated with glycomimetics, as shown for PI-88, an 
inhibitor of heparanase (Khachigian and Parish, 2004), which currently is in use 
in clinical trials for various cancers based on its anti-angiogenic properties by 
inhibiting VEGF and FGF stimulated tumour angiogenesis (Khachigian and 
Parish, 2004, Liu et al., 2009). Furthermore these glycomimetics could be used 
as competitive ligands, thus preventing „specific‟ protein-HS interaction.  
In theory, HS could be prevented from activating specific inflammatory 
molecules, such as cytokines and chemokines, by blocking with monoclonal 
antibodies. However, efforts in that direction have failed so far, which could be 
due to the fact that HS is hardly immunogenic and antibodies are very difficult to 
raise. An exception are the phage display derived anti-HS antibodies 
(Jenniskens et al., 2000, van Kuppevelt et al., 1998, van Kuppevelt et al., 2001), 
but these are not at a therapeutic stage yet. 
A more generic approach would be the inhibition/modulation of HS biosynthesis 
by targeting the sulphotransferases, hence affecting HS sulphation. Targeting 
HS biosynthesis for therapeutic intervention relies on understanding the 
biosynthesis. So far, not much is known about the regulatory network. A few 
research groups have demonstrated that HS biosynthetic enzymes are under 
transcriptional control. In various experiments it was shown that under 
inflammatory conditions NDST1 expression increases significantly (Carter et al., 
2003, Krenn et al., 2008, Rops et al., 2008). 
Translational control of NDST enzymes was proposed by Esko and co-workers. 
They identified unusually long 5‟-Untranslated Regions (5‟UTR) with embedded 
Internal Ribosome Entry Sites (IRES), allowing regulation at the level of 
translation (Grobe and Esko, 2002).  
The GAGosome model, which was introduced recently, describes the formation 
of an enzyme complex where concentrations of individual enzymes and their 
Chapter 4 Regulation of Heparan Sulphate biosynthesis 
 132 
 
affinity for each other decides which isoform gets incorporated into the complex. 
This formation would rely on protein-protein interactions, of which a few have 
been discovered so far (for example xylosyltransferase and 
galactosyltransferase (Schwartz et al., 1974); EXT1 and EXT2 (Munro, 1998); 
C5 epimerase and 2-O-sulphotransferase (Pinhal et al., 2001); EXT2 and 
NDST1 (Presto et al., 2008). 
 
In order to further our understanding of the regulation of HS biosynthesis, it was 
decided to investigate biosynthetic enzyme regulation at the protein level. 
NDST1 was chosen as it is thought to be the key enzyme in HS biosynthesis. 
A number of experimental procedures to study protein-protein interaction are 
available, all with their individual advantages and disadvantages. The yeast 
two-hybrid system is based on gene activation by a transcription factor. A 
transcription factor can be separated into an activating (AD) and a DNA binding 
domain (DBD). If proteins are tested for their interaction, one is fused to the 
activating domain (AD) and the other one to the DBD. Only if the two proteins 
interact the reporter gene can be transcribed. The advantages of this system 
are that many proteins can be tested for interaction and yeast is an easy model 
to use. However, as this system is based on the transcription of a gene, the 
proteins studied have to be soluble and targeted to the nucleus, which makes it 
unsuitable for membrane proteins Another disadvantage is that it only produces 
binary interactions. In addition, the protein interaction may depend on post-
translational modifications which might not occur in the heterologous yeast 
environment (Bruckner et al., 2009).  
Another method of studying protein-protein interaction is Co-
Immunoprecipitation (Co-IP). This is a purification procedure where an antibody 
is directed against a specific protein and any proteins that interact with the first 
protein can be precipitated out of the solution and identified by Western Blotting. 
The advantage of this system is that it is independent of cloning (which can be 
time consuming) and physiological, as it is not dependent on overexpression of 
a protein but works on the endogenous level. The disadvantage is the 
availability and quality of specific antibodies. Other problems are antibody 
bleeding, where the heavy and the light chains of the protein A/G, which is used 
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as a substrate, are obscuring the bands of interacting proteins during 
electrophoresis. 
The TAP-system was chosen for this study as it allows the purification of protein 
complexes under native conditions. Also, the proteins eluted are very pure as 
two consecutive affinity tags are employed which strongly reduce the 
background. An advantage is also the possibility to gain complex composition 
data and that the existence of specific antibodies is not vital. The technique has 
been successfully adopted for the use in mammalian systems and a variety of 
tag-combinations has been employed (Burckstummer et al., 2006, Knuesel et 
al., 2003), with the combination of CBP and SBP being the only commercially 
available at this time. 
On the downside, the tag itself can hinder or even prevent protein-protein 
interactions and the tagged protein competes with the endogenous, untagged 
form.  
 
NDST1 is a bifunctional enzyme, with its N-deacetylase activity located at the 
N-terminus and its N-sulphotransferase activity at the C-terminus. As N-
deacetylation is a prerequisite for N-sulphation it was decided to place the TAP-
tag at the C-terminal end of NDST1. At this point it could not be excluded that 
the tag itself could impair the viability/stability or function of the protein. A 
different problem arose from the fact that the pCTAP vector did not offer any 
singular site for linearization. Linearization is important, as it hugely increases 
the integration efficiency into the host genome which is desirable for the 
creation of stable transfectants. Generation of stable transfectants was 
essential as cell numbers necessary for TAP (starting with 6 x 107 cells) would 
not be reached with serial transient transfections. The only linearization site 
available overlapped with the SV40-polyA signal by a single base, which is 
important for protein stability, but was used anyway due to the absence of an 
alternative. Western blotting experiments revealed that NDST1 was expressed 
by HEK 293 transfectants despite the C-terminal tag and linearization. Before 
the cells with the tagged NDST1 were used for TAP, an additional experiment 
was carried out to investigate the formation of a protein complex by chemical 
crosslinking. The intention was to incubate the cells overexpressing NDST1 in 
the presence of a chemical crosslinker, which would then crosslink the proteins 
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interacting with each other at the time. Formaldehyde and DST were chosen as 
they are membrane permeable and have been reported to work in similar 
settings (Vasilescu et al., 2004). Complex formation would have been detected 
by a shift towards higher molecular weight on the Western blot when probed 
with NDST1 antibody. However, no such shift was observed. This could be due 
to the number and availability of lysine residues, which are responsible for bond 
formation and maybe due to the existence of the tag itself, which could obstruct 
binding site(s).  
 
In the first TAP experiment cell number and lysis conditions were examined. As 
the system has been developed for cytoplasmic proteins, a few changes had to 
be introduced to optimise it for NDST1, a non-soluble protein in the Golgi 
compartment with one transmembrane domain. In order to not alter the 
conditions specified by the kit too much, the original lysis buffer was adjusted 
from 0.1 to 1% detergent, namely nonidet NP40. As a result no NDST1 was 
purified at all. No distinct protein lanes were visible in the final eluate on the 
stained SDS-PAGE after purification. As the company did not reveal the 
composition of the lysis buffer new lysis conditions had to be developed. 
A basic lysis buffer consisting of 50mM Tris, 150mM NaCl, 10mM Na3VO4 and 
1%NP40 based on the method originally developed by Puig (Puig et al., 2001) 
was applied for the next purification. With these conditions the system seemed 
to work in principle as two distinct bands with high p- and low e-scores were 
detected. The band around 100kDa was identified as NDST1 and the second 
one around 70 kDa as heat shock protein 70 precursor by mass spectrometry. 
With cell lysis conditions resolved the cell number was adjusted from 6 x 107 to 
1.2 x 108 cells for the next purification. With increased cell number, more bands 
were visible on the SDS-PAGE. In addition to the previously found HSP a 
second HSP appeared. A band was detected above the 100kDa band of 
NDST1, which was later identified as NDST1 by MS analysis. Beta tubulin and 
ADP-ATP translocase were also identified within the co-eluted proteins. Up to 
this point any results had to be accepted with reservations, as no appropriate 
controls were included. Based on the conditions optimized in the initial two 
purifications the next TAP was conducted with a control run in parallel. The 
control cells were transfected with the pCTAP vector alone without NDST1 
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insert. This control provides information about non-specific protein binding due 
to affinity for the tags rather than the protein expressed. An additional control 
could be a mock transfectant or cells previously transfected with an unrelated 
protein. 
The control was run alongside the actual purification and revealed that the 
protein band pattern was distinct and hardly any proteins were purified in the 
control settings. Again, bands above the 100kDa size of NDST1 were 
detectable and identified as NDST1. This could be due to complex formation 
which survived the brief denaturation step before loading onto the gel. 
Complexes could be NDST1 plus interacting partners or maybe NDST1 in a 
dimeric/oligomeric form. The existence of NDST1 homo-oligomers has not been 
reported, but at the same time could not be excluded.   
The last purification was performed under stringent denaturation conditions with 
extensive boiling in 4 x loading buffer supplemented with LDS and beta-
mercaptoethanol. The cell number was again increased to 1.5 x 108 and 
purifications were pooled. Unfortunately, bands above 100kDa were still 
detected as NDST1. It appears that conditions were not harsh enough to break 
up the protein complexes. 
As beta tubulin was the only protein found throughout all purifications with 
consistent high p- and low e-values, it is considered the most likely genuine 
interaction partner of NDST1. Beta tubulin together with alpha tubulin 
represents the functional unit of microtubules responsible for the structure and 
function of the Golgi complex (Thyberg and Moskalewski, 1999). These 
microtubules play a crucial role in transportation of newly synthesized proteins 
from the ER to the Golgi. Validation of this interaction was attempted using Co-
IP. Unfortunately the Co-IP failed to work, which is most likely due to the 
unavailability of good quality antibodies against NDST1.  If specific antibodies of 
good quality were available, Co-IP experiments could be carried out with 
NDST1 as „fishing‟ antibody. If beta tubulin was found as the interacting partner 
again, a reciprocal Co-IP with the antibody against the interacting protein as 
fishing antibody could confirm the results.  
FRET (Förster resonance energy transfer) would be another method of 
investigating protein-protein interaction. Confocal microscopy would be able to 
determine if the fluorescence signals overlap, thus proving protein interaction. 
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To avoid the dependence on antibodies of poor quality the two proteins of 
interest could be labelled with fluorescent dyes. This, however, would again 
involve lengthy cloning procedures.  
Interestingly, two more glycosylation enzymes have been reported to interact 
with beta tubulin, namely NDST2 (Ledin et al., 2006) and β-1,4-
galactosyltransferase (Yamaguchi and Fukuda, 1995). This could possibly 
indicate a role in Golgi transport, with tubulin acting as some kind of receptor for 
the type-II-transmembrane glycosylation enzymes which do not possess a Golgi 
retention signal, thereby regulating their rate of transport. 
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5 Modulation of NDST1 and cell surface Heparan Sulphate 
5.1 Introduction 
5.1.1 Diversity of HSPGs 
HSPGs are expressed abundantly and ubiquitously in a tissue- and 
development-specific manner at the cell surface and in the ECM of all 
mammalian cells. They are involved in the regulation of a range of biological 
processes, including inflammation (Bernfield et al., 1999, Parish, 2006). Distinct 
HS epitopes are created during biosynthesis which in turn determine the 
interaction profile of HS with its protein ligands. Modification includes N-
deaceylation and N-sulphation of the N-acetylglucosamine, C5-epimerzation of 
the glucuronic acid and various O-sulphations at positions C2, C3 and C6 of the 
chain. In addition, the chain can be even further modified by the action of the 
endoglucuronidase heparanase, which cleaves the chain at specific sites and 6-
O-endosulphtases, which remove 6-O-sulphate groups (Bishop et al., 2007). 
Overall, the interplay of different enzymes involved gives rise to an 
extraordinary structural diversity of the molecule. How this complex biosynthetic 
machinery is regulated is still poorly understood.  
5.1.2 Differential regulation of HS biosynthesis  
Different levels of control have been suggested for HS biosynthesis, including 
control at the transcriptional and translational level as well as regulation of HS 
biosynthesis controlled by the interaction of individual enzymes based on their 
affinities for each other (see section 4.1.1 and 4.1.2) 
Changes of HS composition in response to exogenous stimuli have been 
reported by various research groups. In most models, the inflammatory 
response was mimicked by stimulation of endothelial cells with proinflammatory 
cytokines. Activation of mouse glomerular endothelial cells with TNFα or IL-1ß 
resulted in upregulation of several core proteins and sulphation specific 
antibodies revealed increased N- and O-sulphation in conjunction with 
upregulation of corresponding HS biosynthetic enzymes (namely NDST1 and 2 
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and 6-OST-1 and 2). The addition of antibodies that recognise the N- and O-
sulphated regions in an in vitro dynamic flow leukocyte adhesion assay caused 
increased rolling velocity and decreased numbers of adhering cells (Rops et al., 
2008). These observations are in agreement with previous studies where 
increased levels of NDST1 and N-sulphation after stimulation of HMEC-1 cells 
with proinflammatory cytokines were reported (Carter et al., 2003).  
5.1.3 Interaction of HS with protein ligands  
Although the importance of overall sulphation is unquestionable, the existence 
of specific binding sites has not been demonstrated yet with the exception of the 
antithrombin III binding domain. There is dispute if selective domain spacing 
and distribution rather than individually tailored sequences are responsible for 
complex formation (Kreuger et al., 2006). It seems likely that individual 
interactions can be either granted by specific and rare modifications (such as 3-
O-sulphation for ATIII) or by the spatial arrangement of common modifications 
(such as N- and O-sulphation for FGF2).  
5.1.3.1 L-Selectin 
L-selectin is a cell adhesion molecule which is involved in lymphocytes homing 
in high endothelial venules (HEVs) and leukocyte migration under inflammatory 
conditions. It is a type I transmembrane glycoprotein and consists of a N-
terminal lectin-like domain, an epidermal growth factor (EGF)-like domain, a 
variable number of consensus repeats and a single membrane domain with a 
short cytoplasmatic tail (Barthel et al., 2007). It binds to a range of sialomucins, 
with sulphation being an important factor for ligand binding (Imai et al., 1993). 
An endothelial specific NDST1 knockout in mice led to the discovery of 
endothelial HS as L-selectin ligand (Wang et al., 2005) and collagen XVIII was 
identified as a ligand in the kidney (Celie et al., 2005). Binding of L-selectin to 
HS was shown to be dependent on chain length, 2-O-, 6-O- and N-sulphation 
and iduronic acid proved to be inhibitory (Celie et al., 2005, Kawashima et al., 
2003).  
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5.1.3.2 CCL5 
CCL5 is a proinflammatory chemokine which binds to its receptors CCR1, 3, 4, 
and 5 and facilitates the migration of monocytes and activated T-cells (Murphy 
et al., 2000). Two clusters of basic amino acid residues, representing GAG-
binding sites, have been identified, a BBXB motif in the 40s loop and a BBXXB 
motif in the 50s loop of the amino acid sequence, both of which contribute to the 
biological function of CCL5 in vivo (Proudfoot et al., 2001, Segerer et al., 2009). 
While the residues involved in the interaction on the chemokine site have been 
described extensively, little is known about the corresponding region of GAGs. 
However, N- and O-sulphation have been reported to be involved (Kuschert et 
al., 1999, Schenauer et al., 2007). Crystallization studies of CCL5 in the 
presence of differently modified heparin disaccharides demonstrated that N-
sulphation is more important than 6-O-sulphation (Shaw et al., 2004). Apart 
from the sulphation status itself the spacing and the distribution of the groups 
involved will influence the binding. 
CCL5 is presented by GAGs on the surface of the endothelium and GAG 
binding facilitates cooperative oligomerisation of the chemokine which is crucial 
for biological activity in vivo (Proudfoot et al., 2003). HS dp (degree of 
polymerization) 14 was recently identified as minimal oligosaccharide binding 
sequence (Rek et al., 2009). On the endothelium CCL5 directs inflammatory 
cells through the endothelial barrier into the tissue. It has been reported to be 
involved in a variety of inflammatory diseases, including renal allograft rejection 
(Ali et al., 2005a, Ruster et al., 2004) and chronic inflammatory liver disease 
(Goddard et al., 2001, Karlmark et al., 2008). 
5.1.3.3 FGF2 
Fibroblast growth factor 2 (FGF2) is a member of the FGF family and is 
produced by many cell types with a variety of biological functions.  It acts as a 
mitogenic and angiogenic factor and is involved in tissue remodelling and 
regeneration. It can be secreted into the ECM where it can act in an autocrine 
or paracrine way via binding to its high affinity receptors FGFR1-4 (Okada-Ban 
et al., 2000). The formation of a ternary complex composed of FGF2, FGFR and 
HS is crucial for FGF2 signalling (Kan et al., 1993, Rapraeger et al., 1994).  
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The FGF2 binding motif of HS typically contains N-sulphation at the non-
reducing end glucosamine, 2-O-sulphated iduronic acid and variable 6-O-
sulphation on the reducing end glucosamine (Kreuger et al., 2001). The minimal 
FGF2 binding domain has been described as a tetrasaccharide which is not 
sulphated at the C6 position (Guglieri et al., 2008). 2-O-sulphation appears to 
be sufficient for binding but 6-O-sulphation is vital for receptor activation (Ornitz, 
2000). These N- and O-sulphated groups are clustered in domains where the 
interaction with the ligand takes place and their abundance, length and overall 
sulphation seem to be more important than selective saccharide sequence. 
Together with FGF1, FGF2 appears to be more promiscuous in the HS binding 
requirements than other members of the FGF family (Allen and Rapraeger, 
2003, Jastrebova et al., 2006).  
5.1.4 Specific Aims 
This part of the work aimed to investigate changes in cell surface HS 
expression after modulation of NDST1 expression, the key enzyme in HS 
biosynthesis. Further, changes in HS expression have been reported for 
inflammatory conditions. Therefore cell surface HS expression following 
experimental ischemia and inflammation and potential outcome of altered HS 
expression on ligand binding should be investigated. Specific goals: 
 
Examination of transfectants following overexpression and silencing of NDST1: 
 
 design and cloning of NDST1 silencing construct 
 
 analysis of HS expression of NDST1 modulated cells 
 
 physiological consequences of altered HS expression 
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Characterization of cell surface HS of cell lines following experimental 
inflammation: 
 
 analysis of changes in HS expression of various cell lines upon hypoxia 
and proinflammatory stimulation with IFNγ and TNFα 
 
 physiological consequences of altered HS expression 
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5.2 Specific Materials and Methods  
5.2.1 Gene silencing technology 
Silencing is a method to mediate specific suppression of gene expression. RNA 
interference is based on the introduction of double stranded RNA, which leads 
to a functional inactivation of the target gene. Its origin is believed to be a 
defence mechanism of plants against viral pathogens or uncontrolled 
transposon mobilization (Cerutti and Casas-Mollano, 2006).  
The basic mechanism relies on a pair of custom made oligonucleotides that 
contains a unique 19bp long sequence that corresponds to a 19bp target 
sequence within the mRNA of interest.  The dsRNA is subsequently processed 
into 21-25bp small interfering RNAs by an RNaseIII-like enzyme called Dicer. 
This siRNA is then incorporated into the RNA-induced-silencing-complex 
(RISC). Binding of the antisense strand of the processed siRNA duplex to the 
mRNA mediates cleveage of the molecule and inhibits target gene expression.  
 
Figure 5-1 Principle mechanism of RNAi 
 
(adapted from Santa Cruz www.scbt.com) 
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In this study the pSUPER.neo vector system (Oligoengine) was used (Figure 5-
2).  
 
Figure 5-2 shRNA vector map of pSUPER.gfp-neo 
 
In contrast to siRNA, which is administered to the cells directly and gets 
degraded quickly, the Oligoengine pSUPER systems directs intracellular 
synthesis of short hairpin RNAs (shRNA) driven by a vector, which allows stable 
suppression of gene expression. 
Briefly, 3 μg of forward and reverse oligonucleotide containing the 19bp target 
sequence (5‟GCCGCTTCAAATACCGCAC3', designed by a former member of 
the group) were annealed in annealing buffer (100mM NaCl and 50nM HEPES) 
(Sigma). The mixture was incubated at 90ºC for 4 minutes and then at 70ºC for 
10 minutes. The annealed oligos were cooled slowly to 10ºC before using them 
in the ligation reaction. The vector was linearized before the ligation using BglII 
and HindIII restriction enzymes. After ligation of the oligonucleotides into the 
vector the construct was transformed into competent E. coli.  
5.2.2 RNA isolation and cDNA generation 
For mRNA isolation and cDNA generation the μMACS technology was used 
(Miltenyi). This kit was developed for the direct isolation of mRNA without prior 
preparation of total RNA.  The isolation is achieved by adding Oligo(dT) 
MicroBeads to the cell lysates which  bind to the polyA-tail of the mRNA. This 
Chapter 5 Modulation of NDST1 and cell surface Heparan Sulphate 
 144 
 
magnetically labelled mRNA can be easily separated from the rest of RNAs in 
the μMACS column and cDNA synthesis can follow subsequently.  
In short, cells were harvested and a maximum number of 107 cells were lysed in 
1ml of Lysis/Binding buffer. To avoid any clumps, lysate was sheared 
mechanically by passing the lysate several times through a 21G needle. The 
sheared lysate was applied on a LysateClear column and centrifuged for 3 
minutes at 13.000 x g. 50µl of Oligo(dT) MicroBeads were added to the lysate. 
After rinsing the column with Lysis/Binding buffer the lysate was applied on the 
column. Magnetically labelled mRNA was retained in the column. For the 
removal of proteins and DNA, the column was rinsed twice with Lysis/Binding 
buffer. During the last four washing steps residual DNA and rRNA were 
removed. 
For cDNA synthesis the column was rinsed with Equilabration/Wash buffer. 
After that the resuspended enzyme mixture was applied onto the column and 
the column was sealed with Sealing Solution to avoid evaporation. Following 1 
hour of incubation at 42ºC the column was rinsed twice with Equilabration/Wash 
buffer. After an additional incubation step with cDNA Release Solution for 10 
minutes at 42ºC, the synthesised cDNA was eluted with cDNA Elution buffer. 
cDNA was quantified using a nanodrop system. All cDNAs showed a ratio of 
A260/280 equal or greater than 1.8. 
5.2.3 Quantitative Real-Time PCR 
Real-time PCR is an advanced form of conventional PCR which allows very 
sensitive and accurate measurement of gene expression. It quantifies the initial 
amount of the template specifically rather than measuring the endpoint. 
Real-time PCR is based on the detection and quantification of a fluorescent 
signal, produced proportionally during the target amplification.  By measuring 
the fluorescence at each cycle it is possible to examine the first significant 
increase in target amplification proportional to the initial amount of template.  
In this study hydrolysis probes, such as TaqMan probes, were used. A TaqMan 
assay comprises of a set of specific primers and a probe. Wherever possible 
primers are designed exon spanning to minimise amplification of possible 
contaminating DNA. The probe anneals to the DNA in a region in between the 
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primer binding sites. The probe contains a fluorescent dye on its 5‟ end and a 
quencher on the 3‟ end.  When the probe gets excited by irradiation the 
fluorescent dye transfers energy to the adjacent quencher dye. When the Taq 
polymerase amplifies the template DNA its 5‟ exonuclease activity cleaves the 
probe, resulting in a separation of the reporter and the quencher. The quencher 
is no longer active and the reporter dye can emit fluorescence. This 
fluorescence signal increases with every cycle proportional to the accumulation 
of template. In the first cycles of the reaction no significant increase in 
fluorescence can be observed. The threshold cycle (Ct) is defined as the 
fractional number of cycles where fluorescence increases beyond the fixed 
threshold (exceeds background fluorescence). This increase in fluorescence is 
based on the exponential growth of the amplicon within the log-linear phase. 
The higher the initial amount of template, the lower the Ct.  
 
Figure 5-3 Principles of Real-Time PCR 
 
(adapted from Applied Biosystems) 
 
In this study primers and probe as well as the PCR mastermix were obtained 
from Applied Biosystems. Primers were exon spanning and the probe contained 
the 5‟ fluorescence probe FAM and the 3‟ quencher TAMRA. The 
concentrations of the primers and probes were 900nM and 250nM, respectively. 
The comparative Ct method (ΔΔCt) for relative quantitation of gene expression 
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was used. The level of gene expression of the gene of interest is normalised by 
including an endogenous control, which is usually a housekeeping gene such 
as β-actin (used in this study), GAPDH or tubulin.  
A typical qRT-PCR reaction was set up as shown in Table 5-1: 
 
Table 5-1 Composition of a typical qRT-PCR reaction 
compound volume (µl) 
primers and probe 1 
2x Mastermix 10 
cDNA 2 
H20 7 
final volume 20 
 
Every time a qRT-PCR reaction was run a NTC (no template control) was 
performed in parallel.  
 
The parameters of the qRT-PCR were as shown in Table 5-2: 
 
Table 5-2 Temperature settings of a typial qRT-PCR reaction 
temperature (degree ºC) time cycles 
50 2 min 1 
95 10 min 1 
95 15 sec 40 
60 1 sec 40 
4 hold - 
 
The reaction was performed in an ABI Prism 7000 Sequence Detection System 
(Applied Biosystems). Data analysis was carried out using the ABI prism 
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software. As the comparative Ct method (ΔΔCt) was used the housekeeping 
gene β-actin served as a normalizer for expression of the gene of interest. 
Target gene expression can be calculated according to the following formula:  
relative expression = 2 –ΔΔCt, where ΔΔCt = ΔCt target - ΔCt normaliser. In order 
to use the ΔΔCt method the efficiencies of the target gene and the reference 
control should be equal. This can be assessed by plotting ΔCt values against 
cDNA dilutions. A slope of -3.32 indicates 100% efficiency of the PCR reaction. 
In general efficiencies should be between 90 and 100% which equals to a slope 
between -3.6 and -3.1. (calculation: Eff = 10
(-1/slope) 
– 1) (Livak and Schmittgen, 
2001). 
A different option for relative quantification without the need for calibration 
curves would be the mathematical model by Pfaffl, where the relative 
expression ratio is calculated from Real-time PCR efficiencies and the crossing 
point deviation of an unknown sample versus control (Pfaffl, 2001). 
5.2.4 Immunocytochemistry 
Immunocytochemistry is a technique used for antigen visualisation within the 
cell compound. To analyze differences in HS of wild type and NDST1 silenced 
cells immunofluorescent staining was utilized. 
Cells were seeded on 4-chamber slides (Nunc) at 60.000 cells/chamber and 
grown under normal conditions for 48h. Cells were rinsed with cold PBS and 
fixed in 4% PFA for 25 minutes at RT. After two washes with PBS the chamber 
structure was removed from the slides and the chambers were circled with a 
hydrophobic marker. The cells were incubated in 5% BSA in PBS for 1h to 
minimize non-specific binding. Incubation with the primary antibody took place 
over night at 4ºC. After decanting the primary antibody (anti-HS antibody 10e4, 
1/100, Seikagaku) slides were washed in 0.2% Tween 20 in PBS three times for 
5 minutes. An additional wash step in PBS was carried out before incubation 
with the secondary (anti-mouse TRITC, 1/20, Dako) for one hour at room 
temperature. Three washing steps for 5 minutes in 0.2% Tween 20 in PBS were 
followed by washes in PBS for 5 minutes. The slides were then mounted wet in 
fluorescence mounting medium (DakoCytomation, DAKO) and stored in the 
dark at 4ºC. 
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To ascertain the levels of background fluorescence appropriate negative 
controls were carried out. These consisted of an unstained population of cells 
and cells stained with the secondary antibody only.  
5.2.5 Flow cytometry  
Flow cytometry is a technique to analyse suspensions of cell populations 
qualitatively and quantitatively. A range of different parameters such as cell 
size, cell-cycle status and expression of extra- as well as intracellular markers 
can be assessed.  All flow cytometry experiments in this study were performed 
using a BD (Becton Dickinson) LSRII flow cytometer. Data were collected and 
analysed using FloJo Software. 
 
5.2.5.1 Staining of cell surface antigens by FACS 
Adherent cells were split using non-enzymatic cell dissociation media (Sigma). 
Cells in suspension were transferred into a FACS tube and following a washing 
step incubated with primary antibodies in 5%FCS/PBS for 45 minutes. All 
incubation steps were performed at 4ºC. After another two washing steps 
fluorescently labelled secondary antibodies were added and incubated for 
further 30 minutes. For the phage display antibodies, a tertiary fluorescently 
labelled antibody incubation step was necessary (anti-mouse-FITC, 1/100, 
Sigma, for further 30 minutes). Cells were resuspended in 200µl of 5%FCS/PBS 
and analysed using appropriate laser and filter settings (488nm emission, 
530nm extinction for FITC). All flow cytometry data is expressed as mean 
fluorescent intensity (MFI). 
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Antibodies used in this study are listed in Table 5-3. 
 
Table 5-3 Antibodies used in this study and their specific binding requirements 
Antibody Subtype Target 
sequence 
Dilution Supplier Secondary ab 
10e4 Monoclonal 
Mouse IgM 
GlcA-GlcNS-
GlcA-GlcNAc 
1/100 Seikagaku Anti-mouse-
FITC 
(1/100), Dako 
HS3A8 Single chain 
phage display-
derived 
GlcNS6S-
IdoA2S 
1/6 Gift from Prof. 
Kuppevelt, 
Nijmengen, 
Netherlands 
Anti-VSV-Cy3 
(1/300), Sigma 
HS4C3 Single chain 
phage display-
derived 
GlcNS3S6S-
GlcA/Ido2S 
1/6 Gift from Prof. 
Kuppevelt 
Nijmengen, 
Netherlands 
Anti-VSV-Cy3 
(1/300), Sigma 
Abbreviations GlcA: glucuronate; GlcNac: N-acteylated-glucosamine; GlcNS: N-
sulphated-glucosamine; IdoA: iduronate; 2,3,6S: 2,3,6 sulphate (Smits et al, 2006; Rops 
et al, 2008) 
5.2.6 Chemotaxis assay 
To compare the chemotactic potential of the biotinylated CCL5 to the wild type 
CCL5 a chemotaxis assay was employed. 3µm filter in corresponding 24 well 
plates (Falcon) were used for migration experiments. 800µl of RPMI 1640 
medium supplemented with 0.1% BSA containing the desired concentrations of 
chemokine was added to the lower chamber. 500.000 THP-1 cells were 
resuspended in 200 µl of complete RPMI 1640 and added to the upper 
chamber. The filters were incubated at 37ºC and 5%CO2 for 90 minutes.  Before 
fixing and staining, the filters were wiped with a cotton bud to remove cells 
which have not migrated. Then the filters were fixed in methanol at -20ºC over 
night. After few washes with water the filters were stained with haematoxylin 
(Sigma) for 5 minutes. The stained filters were immersed for 10 minutes in 
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Scotts‟ Tap Water (166mM MgSO4, 24mM NaHCO3).They were then 
dehydrated through increasing concentrations of ethanol (50%, 75%, 90% and 
100%). The filters were air dried and mounted onto glass-slides with DPX 
mountant (Fluka).  
5.2.7 Adhesion assay 
To compare the influence of HS expression on adhesion to L-selectin, a well 
known HS-binding molecule, a solid phase adhesion assay was developed. Flat 
bottomed 96-well ELISA plates were coated with 10µg/ml goat anti-human IgG 
Fc-antibody (Sigma) over night at 4°C. After two washes in PBS, L-selectin-Fc 
fusion protein (10µg/ml, R and D) was added in HBSS buffer (Sigma) for a 
further 18h at 4°C. Excess protein was washed twice with HBSS buffer and 
non-specific binding was blocked with 1% BSA in HBSS for 2 h. 1x106 cells 
were labelled with 1.5 µM BCECF-AM (Sigma) for 20 min at 37°C in the dark. 
After washing twice in HBSS, 4x104 cells were resuspended in HBSS and 
added to each well and plates were centrifuged at 80 x g for 2 minutes to allow 
cells to adhere. After 45 min of incubation at 37°C in the dark, fluorescence was 
measured with wavelengths set at 488 and 535nm using a plate fluorimeter 
(Fluostra Optima, BMG Labtech) . Following removal of non-adherent cells by 
mechanical oscillation, plates were carefully washed with HBSS and 
fluorescence readings were taken again.  
5.2.8 ELISA 
An enzyme linked immunosorbent assay was employed to quantify the amounts 
of chemokine eluted from the heparin column. Samples were incubated over 
night at 4ºC in coating buffer (15mM Na2CO3, 35mM NaHCO3, ph 9.6; Sigma), 
allowing the proteins to adhere to the plate. After two washes with 0.05% 
Tween/PBS plates were blocked with 5%BSA/PBS for 1 hour. 100µl of primary 
antibody (anti-CCL5, R and D) made up in 0.5%BSA/PBS was added and 
incubated for 3 hours at RT. Plates were then washed again twice with 0.05% 
Tween/PBS before secondary antibody (anti-goat-HRP, 1/5000, Abcam) was 
added and incubated for 1h at RT. Plates were washed twice before being 
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incubated with substrate solution (Fast OPD, Sigma) for 30 minutes. Plates 
were read at 450nm using an Opsys MR plate reader (Dynex). 
5.2.9 FPLC 
To investigate if the addition of the biotin group to CCL5 would affect its ability 
to bind to heparin a heparin-sepharose column was used. 1µg of chemokine in 
500µl of 10mM phosphate buffer was loaded onto a 1mlHiTrap heparin HP 
column (Amersham) which was linked to a FPLC system (Amersham). The 
chemokine was eluted from the column by the application of salt gradient (0-1M 
NaCl in phosphate buffer) at a flow rate of 1ml/minute in 30 fractions. 50µl of the 
eluent were used for ELISA. 
5.2.10 Calcium Flux 
In this study, CCL5 and CCL5-biotin were assessed for their ability to induce a 
calcium flux. Changes in calcium mobilization are considered a direct 
consequence of chemokine activity. This can be monitored by using calcium 
binding dyes, such as Indo-1-AM (Molecular probes). The acetyloxymethylester 
form is taken up by the cells passively, as it can permeate the cell membranes. 
Cell endogenous esterases hydrolyze the dye rendering the indo-1 form which 
is non-permeant. Indo-1 is excited by UV and changes in fluorescence refer to 
calcium bound (440nm) or calcium unbound (530nm) state. The ratio of these 
wavelengths indicates changes in intracellular calcium concentrations. 
In this study, THP-1 cells were serum starved over night and 500.000 cells were 
resuspended in HBSS containing 1mM CaCl2, 1mM MgCl2 and 1% FCS. Cells 
were labelled with 3µg/ml Indo-1-AM for 45 minutes at RT in the dark. Following 
a washing step cells were resuspended in HBSS and warmed to 37ºC before 
taking the basal reading. Following stimulation with chemokine changes in flux 
were recorded before ionomycin (1mg/ml, Sigma) was added as a positive 
control. Calcium flux was analysed with LSRII flow cytometer. 
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5.2.11 Stimulation of cell lines 
HEK 293, HK-2, HepG2 and HMEC-1 cells were grown to 80% confluency  and 
stimulated with TNFα and IFNγ (100ng/ml each, Sigma) for 18h in full media 
before cell surface Heparan sulphate was analysed by flow cytometry. Due to 
the lack of an incubator with hypoxic conditions, hypoxia was mimicked by 
replacing vented caps of tissue flasks with unvented caps for the duration of 
18h. 
5.2.12 Binding assays  
5.2.12.1 FGF2 binding assay 
The binding of FGF2 has been investigated intensively and relies on the 
formation of a trimeric complex of FGF2, FGF2-receptor and HS. It has been 
shown recently that binding of FGF2 relies on the number of chains and their 
degree of sulphation. A Fluorokine FGF2 flow cytometry kit was used in this 
study (R and D). 
In brief, cells were detached using cell dissociation media and after 2 washes in 
PBS 100.000 cells were mixed with FGF2 at a final concentration of 570ng/ml 
and incubated for 60 min at 4ºC. Avidin-FITC was added without prior wash to 
the cells and further incubated for 30 min at 4ºC. After two more washes cells 
were resuspended in 200µl of wash buffer and analysed by flow cytometry. As a 
negative control, cells were incubated with an unrelated biotinylated soybean 
protein. FGF2 binding was analysed with LSRII flow cytometer. 
 
5.2.12.2 CCL5 binding assay 
A chemokine binding assay similar to the FGF binding assay was developed to 
investigate the ability of differentially modified HS to retain chemokines on the 
surface of cells. 
Biotinylated CCL5 (Almac) was added to a final concentration of 100ng/ml in 
PBS and cells were incubated for 60 min at 4ºC. Streptavidin-FITC (1/100, BD) 
was added without prior wash to the cells and further incubated for 30 min at 
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4ºC. After two more washes cells were resuspended in 200µl of wash buffer 
und analysed by flow cytometry. As a negative control cells were incubated with 
FACS buffer instead of chemokine solution. CCL5 binding was analysed with 
LSRII flow cytometer. 
5.2.13 Statistical analysis 
Student‟s t-test was used to compare data that followed the Gaussian 
distribution. A one-way Anova (analysis of variance) with Tukey‟s post test was 
used to compare the means of 3 or more independent groups and differences 
with p<0.05 were considered to be significant. Error bars represent the standard 
error of the mean (SEM). 
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5.3 Results 
5.3.1 Silencing of NDST1 
5.3.1.1 Cloning of the NDST1 silencing construct 
In an attempt to suppress NDST1 expression and investigate its effect on HS 
expression, a NDST1 silencing construct was employed, which was designed 
by a former member of the group. The 19bp target sequence 
(5‟GCCGCTTCAAATACCGCAC3') corresponding to exon 1 of the NDST1 
mRNA was previously chosen according to the guidelines of the Oligoengine 
website.  
The pSUPER silencing vector was linearized using BglII and HindIII restriction 
enzymes and after DNA purification the annealed oligonucleotides, flanked by 
corresponding restriction sites, were incorporated into the vector in a ligation 
reaction. The resulting construct was transformed into chemically competent E. 
coli and 3 colonies were isolated from ampicillin containing agar plates. 
Resistant clones were picked, propagated and isolated DNA was subjected to 
restriction digestion with EcoRI and XhoI in order to identify clones carrying the 
correct insert. DNA digests were run on a 2% agarose gel and fragment sizes 
were analysed. Positive clones comprised a fragment of 281bp, whereas false 
positive clones were expected to reveal a 248bp fragment (Figure 5-4). 
 
 
Figure 5-4 Cloning of NDST1silencing construct 
 
Representative agarose gel of restriction digests of NDST1 silencing constructs. Lane 1 
containing DNA hyperladder with fragment sizes as indicated. Lane 2 and 3 containing 
DNA fragments excised by EcoRI and XhoI restriction enzymes revealing positive clones 
carrying the insert. Lane 4 representing EcoRI and XhoI digested DNA fragment without 
the insert revealing a negative clone.  
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Plasmids revealing correctly sized fragments were sent for sequencing and 
after sequence verification used for further transfection experiments.  
5.3.1.2 Transfection of HEK 293 cells with NDST1 silencing construct 
Various DNA:Effectene  ratios were used for transfection of HEK 293 cells 
without any significant effect on the efficiency. 50 transfectants were selected 
with 800µg/ml of G418 and kept under selection pressure (400µg/ml) whilst 
expanding. In total 7 clones survived the selection process.  
5.3.1.3 Screening of NDST1 silenced clones by q-RT-PCR 
The 7 remaining clones were assayed for NDST1 downregulation on the mRNA 
level using quantitative RT-PCR. cDNA was generated and ß-actin served as 
an internal control. To avoid amplification of eventually contaminating genomic 
DNA, exon spanning primers were selected. The expression of NDST1 mRNA 
derived from transfectants was calculated relative to the control (untransfected 
cells). Ideally, it would have been calculated relative to a mock transfectant, but 
unfortunately none of the mock transfectants survived the selection process. 
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Figure 5-5 Relative expression of NDST1 mRNA of NDST1 silenced clones 
 
NDST1 expression of HEK 293 wild type cells and stably silenced NDST1 transfectants 
was assessed by q-RT-PCR. NDST1 mRNA expression was normalized to the 
endogenous control ß-actin. Experiment was performed in triplicates. 
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The attempt to suppress NDST1 expression resulted in both up- and 
downregulation of NDST1 transcript (Figure 5-5) with transfectant 10 revealing 
the highest reduction by 64%. 
5.3.1.4 Verification of NDST1 silencing by Western blotting 
To ensure that the reduction of NDST1 mRNA is accompanied by a reduction 
on the protein level, Western blot analysis was carried out. This was of 
importance as mRNA levels do not always correlate with protein levels, 
especially when translational regulation, as suggested for NDST1, could be 
involved. 
 
 
Figure 5-6 Western Blot analysis of wild type and NDST1 silenced clones 
 
Western blot of wild type HEK 293 and NDST1 stably silenced cells (upper panel). 60µg of 
total cell lysates were used, blots were probed with α-NDST1 antibody (1/200) and HRP- 
conjugated anti-goat IgG (1/5000). Copper-phtalocyanine stained membrane verifying 
equal loading (bottom panel). Representative for n=2. 
 
Wild type protein lysates revealed two bands, corresponding to the two human 
NDST1 isoforms. No NDST1 protein was detectable in cell lysates of NDST1 
silenced clone, confirming the results obtained from RT-PCR and transfectant 
10 was chosen for further analysis (Figure 5-6). 
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5.3.1.5 Cell surface HS expression of NDST1 silenced clones 
To investigate the effect of NDST1 suppression on HS expression transfectant 
10 was immunostained for HS epitope 10e4.  
 
 
Figure 5-7 Immunofluorescent 10e4 staining of HEK wild type and NDST1 silenced 
transfectant 10  
 
Cells were stained with mouse anti-Heparan sulphate antibody 10e4 (1/100) and 
visualized by anti-mouse TRITC conjugated secondary antibody (1/20). Representative 
for n=2. Scale bar represents 75 µm. 
 
 
10e4 staining revealed a prominent reduction of cell surface HS of the NDST1 
silenced clone compared to wild type cells (Figure 5-7).  
5.3.2 Overexpression of NDST1 
5.3.2.1 Cell surface HS expression of NDST1 overexpressing clone F15 
In addition to the NDST1 silenced TF10 the NDST1 overexpressing clone F15, 
characterized for protein purification studies (see section 4.3.1.), was assessed 
for HS expression as well. 
Overexpression of NDST1 in F15 cells resulted in increased expression of N-
sulphated HS domains (p<0.0001) demonstrated by 10e4 staining (Figure 5-8). 
However, the same cells revealed a significant decrease in HS3A8 and HS4C3 
staining  (Figure 5-9), indicating that increased levels of N-sulphation do not 
necessarily correspond with increased levels of further modifications, such as 2-
O- and 6-O-sulphation. 
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Figure 5-8 10e4 epitope expression of NDST1 overexpressing F15 cells 
 
F15 cells were incubated with 10e4 antibody (1/50) and anti-mouse-FITC conjugated 
secondary antibody. Unstained cells were incubated in FACS buffer (5% FCS/PBS) and 
cells incubated with the secondary antibody, omitting the primary antibody incubation 
step, served as a control. Representative flow cytometry plots (a). Differential expression 
of 10e4 HS epitope of wild type and NDST1 overexpressing F15 cells (b). Data 
representative for 2 individual experiments performed in duplicates. Statistical analysis 
was determinded by student’s t-test with differences p<0.05 considered to be significant. 
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Figure 5-9 HS3A8 and HS4C3 epitope expression of NDST1 overexpressing F15 cells 
 
F15 cells were incubated with HS3A8 and HS4C3 primary antibody (1/5), anti-VSV-tag 
secondary antibody (1/300) and anti-mouse-FITC tertiary antibody. Unstained cells were 
incubated in FACS buffer (5% FCS/PBS) and cells incubated with the secondary and 
tertiary antibody, omitting the primary antibody incubation step, served as a control. 
Representative flow cytometry plot of HS3A8 and HS4C3 HS epitope expression of 
NDST1 transfected F15 cells (a). Histograms of differential expression of HS3A8 and 
HS4C3 HS epitopes of wild type and NDST1 transfected F15 cells (b). Data representative 
for 2 individual experiments performed in duplicates. Statistical analysis was 
determinded by student’s t-test with differences p<0.05 considered to be significant. 
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A set of experiments was designed to investigate the physiological 
consequences of altered HS expression of NDST1 transfectants. In the first 
instance, a chemotaxis assay was employed to test if altered cell surface HS 
would favour or hinder trans-cellular migration of monocytes.   
5.3.3 Examination of chemokine presentation during chemotaxis 
The transfectant cells were seeded on 3µm chemotaxis filters and grown to 
confluency. Chemokine (10nM) was added to the lower well and monocytes 
were added to the upper well in order to migrate through the monolayer of 
transfectant cells towards the chemotactic stimulus. However, no cells migrated 
through the monolayer of HEK 293 cells. Incubation times varied from 90 
minutes to over night, but even after 24 h of incubation, no migrant cells could 
be found in the bottom well or the bottom side of the filter. To ensure that 
chemokine was still present and not degraded after longer incubation time, an 
ELISA was employed which proved that chemokine was present and functional 
in the system (Figure 5-10). 
 
 
Figure 5-10 Examination of chemokine presentation during chemotaxis 
 
CXCL12 standard curve (a) and chemokine presence in upper und bottom well during 
48h of incubation (b). 
 
Despite the presence of chemokine, no chemotaxis of monocytes occurred 
independent of incubation time. It appeared that HEK 293 cells forming a 
monolayer were blocking the pores of the filter, not allowing monocytes to 
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migrate through. Therefore, the model proved to be unsuitable to investigate the 
effect of altered HS expression on chemokine presentation and migration.   
5.3.4 Adhesion of wild type and NDST1 transfected cells 
In a different approach to test the physiology of differentially expressed HS a 
static adhesion assay was developed. L-selectin, a well known HS binding 
protein was coated onto ELISA plates and fluorescently labelled HEK293 cells 
were tested for their ability to adhere to the molecule. After the optimal BCECF 
dye concentration of 1.5µM was established a series of adhesion assays were 
performed with varying incubation times from 45 up to 120 minutes. 
Independent of the incubation time, hardly any cells adhered to the L-selectin 
coated surface after a washing step (Figure 5-11). It seemed that HEK 293 
cells, which are classed as semi-adherent, were not sufficiently adherent for this 
type of experiment. The influence of HS expression on the adhesion potential 
could not be tested in this setting, as labelled cells only gave background 
readings almost identical to unstained cells or even buffer alone.   
 
Figure 5-11 Adhesion of wild type and F15 HEK 293 cells 
 
Optimisation of BCECF labelling of cells (a) and static adhesion assay (b). 40.000 cells 
were incubated on L-selectin coated 96-well plate for 45 minutes at 37° degree and 
fluorescence readings were taken before and after washing. Unstained cells (cells which 
were not incubated with BCECF but buffer alone) and wells containing PBS without cells 
served as controls. 
 
To test the biological differences of HS expression of NDST1 transfected cells 
chemokine presentation should be investigated. In this assay a biotinylated form 
of the chemokine CCL5 was used to test the potential of HS to sequester 
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chemokines on the cell surface. Even though the biotin group was placed apart 
from the GAG binding motif in CCL5 it first had to be tested for biological 
activity. 
5.3.5 Analysis of CCL5-biotin  
As later experiments would rely on the detection of CCL5-biotin it had to be 
ensured that the altered chemokine would be detectable in a similar fashion to 
the wild type. Primary and secondary antibodies were titrated using wild type 
CCL5 and optimal concentrations were established. ELISA analysis of CCL5-
biotin revealed a reduction in detection but a similar curve shape (Figure 5-12). 
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Figure 5-12 Titration of CCL5 antibodies for ELISA 
 
Goat anti-CCL5 and anti-goat antibodies have been used in different concentrations (as 
indicated) for the development of a CCL5 ELISA (top panel). CCL5 and CCL5-biotin were 
used under optimised conditions (bottom panel). CCL5 wild type and CCL5-biotin were 
incubated with anti-CCL5 antibody (1/150) and anti-goat antibody (1/5000). 
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5.3.5.1 Determination of heparin affinity 
Having established a methodology capable of quantifying chemokines an ELISA 
was set up again and employed to test the heparin affinity of CCL5 biotin by 
FPLC.  
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Figure 5-13 Determination of CCL5-biotin heparin affinity 
 
FPLC was performed to compare the heparin affinities of wild type CCL5 and CCL5-
biotin. 1µg of chemokine in phosphate buffer was loaded onto a heparin column. The 
chemokine was eluted from the column by a salt gradient (0-1M NaCl) in 30 fractions. 
50µl of the eluent were used for an ELISA. 
 
Even though no 280nm readings could be recorded during the elution of the 
proteins from the column the ELISA analysis confirmed the elution of the protein 
fractions. Wild type CCL5 was eluted in fractions 19-21, corresponding to ~0.7M 
NaCl. The biotinylated from was eluted in the same fraction numbers, although 
with a smaller peak (Figure 5-13).  This can be explained by the lower detection 
rate of CCL5-biotin as previously demonstrated in analogous ELISA 
experiments  
5.3.5.2 Determination of biological activity of CCL5-biotin  
Establishing that CCL5-biotin was binding to heparin its ability to further induce 
mobilisation of intracellular calcium was investigated. THP1 monocytes were 
stimulated with 1nM and 10nM CCL5 and CCL5-biotin and changes in 
florescence were recorded. Both forms of CCL5 were capable of causing 
transient calcium fluxes, proving the biotinylated form to be functional (Figure 5-
14). 
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Figure 5-14 Examples of CCL5 induced Calcium flux. 
 
THP1 monocytes were loaded with 3µg/ml of the Calcium sensitive dye Indo-1-AM prior 
to stimulation with 10nM CCL5 wild type (a) or CCL5-biotin (b). The second peak after 
chemokine addition is due to ionomycin addition (1µg/ml) serving as positive control. 
5.3.5.3 Chemotactic ability of CCL5 wild type and CCL5-biotin 
Having demonstrated that CCL5-biotin was binding to heparin in a similar 
fashion to the wild type and proving its functionality by calcium flux studies 
chemotaxis assays were carried out to assay the ability of CCL5-biotin to induce 
cell migration. Chemotaxis assays (Figure 5-15) demonstrated that 1nM of wild 
type or biotinylated chemokine did not drive significant chemotaxis above 
background levels, however, 10 and 50nM of either chemokine was sufficient to 
elicit migration (p< 0.05). Wild type and biotinylated chemokine did induce 
migration to the same extent at 1 and 10nM, however, at 50nM the biotinylated 
form did induce migration to a lesser extent compared to the wild type (p<0.01).  
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Figure 5-15 Chemotaxis mediated by CCL5 and CCL5-biotin 
 
500.000 THP1 cells were migrated across a 3µm transwell filter towards the indicated 
amounts of chemokine for 90 minutes. Wells containing RPMI medium and no chemokine 
served as control. Results representative for 3 independent experiments performed in 
triplicates. 
5.3.5.4 Chemokine presentation by HEK 293 cells 
After the validation of CCL5-biotin, NDST1 transfected cells with altered HS 
expression on the cell surface were investigated for their ability to sequester 
and present the biotinylated chemokine. The dependency on HS for chemokine 
presentation was shown by other members of the group previously by the use 
of CHO cells, which demonstrated that wild type CHO cells were capable of 
sequestering chemokines whereas a GAG deficient mutant was not 
(unpublished data from PhD thesis of Dr. Graeme O‟Boyle). 
Wild type HEK and NDST1 overexpressing cells were grown to 70-80% 
confluency on chamber slides and incubated with CCL5-biotin. Visualization 
with strepatvidin–FITC revealed a stronger capability of F15 cells with increased 
HS expression to present chemokine on the cell surface (Figure 5-16) 
compared to the wild type cells. 
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Figure 5-16 CCL5 presenation by wild type HEK and NDST1 overexpressing cells 
 
Cells were incubated for 60 minutes at RT with exogenous, biotinylated CCL5 (100ng/ml) 
which was visualised with strepatvidin –FITC. Scale bar represents 75 µm. 
5.3.6 Optimisation FGF binding  
In addition to the CCL5 binding assay which was established previously an 
FGF2 binding assay was employed. To verify the dependency of FGF2 binding 
on HS, CHO wild type and GAG-deficient CHO cells were used for initial 
experiments. The GAG deficiency of the CHO-745 cells was confirmed by the 
lack of signal when stained for HS epitope 10e4 and the cells were incapable of 
sequestering FGF2 on the cell surface. CHO wild type cells however showed 
positive staining for 10e4 and FGF2 was retained on the cell surface. FACS 
plots clearly demonstrate the correlation between HS expression and FGF2 
binding capacity (Figures 5-17 and 5-18).  
 
 
Figure 5-17 10e4 staining and FGF2 binding of HS deficient CHO-745 cells 
 
Representative flow cytometry plots of GAG deficient cells stained for 10e4 HS epitope 
(a) and analysed for FGF2 binding capacity (b). 
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Figure 5-18 10e4 staining and FGF2 binding of CHO wild type cells 
 
Representative flow cytometry plots of CHO wild type cells stained for 10e4 HS epitope 
(a) and analysed for FGF2 binding capacity (b). 
 
As the buffer provided with the FGF2 kit was of unknown composition an 
experiment with buffer provided and PBS was carried out which highlighted that 
the provided buffer was not highly stringent, as no differences in FGF2 binding 
between the two washing conditions could be observed (Figure 5-19). 
 
 
 
Figure 5-19 Influence of washing conditions on FGF2binding 
 
Representative flow cytometry plots of HK2 cells binding FGF2. The difference of 
washing conditions (buffer provided with FGF binding kit versus PBS) was investigated. 
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5.3.6.1 FGF2 binding of HEK 293 cells 
After the validation of FGF2 binding NDST1 transfected cells with altered HS 
expression were investigated for their ability to sequester and present FGF2 on 
the cell surface. Wild type HEK 293 cells were capable of binding slightly more 
FGF2 compared to F15 cells, although significance was not reached (Figure 5-
20).  
 
 
Figure 5-20 FGF2 binding of wild type HEK versus NDST1 overexpression F15 cells 
 
Flow cytometry plots of HEK wild type cells binding FGF2 (a) and histograms of 
differential binding of FGF2 to HEK wild type versus NDST1 overexpressing F15 cells (b). 
Statistical analysis was determinded by student’s t-test with differences p<0.05 
considered to be significant. 
5.3.7 Profiling of HS epitope expression and ligand binding upon 
experimental inflammation and hypoxia 
After the analysis of NDST1 HEK transfectants various cell lines were assayed 
for potential changes in HS expression upon induction of hypoxia and 
inflammatory stimulation, mimicking ischemia and an inflammatory response. 
Furthermore the physiological consequences of altered HS expression were 
investigated by chemokine and growth factor binding studies, which have been 
validated previously.  
5.3.7.1 Screening of the embryonic kidney cell line (HEK 293)  
HEK 293 cells were analysed by FACS to measure the levels of cell surface HS 
of resting cells and after hypoxia/stimulation for 18 hours. Basal expression of 
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10e4 epitope was moderate and a significant increase could be observed in 
both groups of stimulated cells and cells undergoing hypoxic stress (p<0.05) 
(Figure 5-21). No significant changes in HS3A8 staining could be observed 
between the groups and HS4C3 staining revealed increased expression after 
hypoxia (p<0.01), but not after stimulation with IFNγ and TNFα (Figure 5-22). To 
see if overall changes in HS expression would have an effect on the binding 
capacity a FGF2 binding assay was performed. Resting cells were capable of 
sequestering slightly more FGF2 than stimulated cells (Figure 5-23). CCL5 
binding experiments were carried out but experimental conditions appeared to 
be too harsh for CCL5 as no readings above the background were taken (data 
not shown). 
 
 
 
Figure 5-21 10e4 staining of HEK 293 cells at basal level and following stimulation 
 
Representative flow cytometry plot of 10e4 HS epitope expression of HEK cells (a) and 
histograms of differential 10e4 expression after stimulation with proinflammatory 
cytokines (18h IFNγ and TNFα) or induction of hypoxia. Data representative for 2 
individual experiments performed in duplicates. Statistical analysis was determinded by 
1-way Anova with differences p<0.05 considered to be significant. 
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Figure 5-22 HS3A8 and HS4C3 staining of HEK 293 cells at basal level and following 
stimulation 
 
Representative flow cytometry plot of HS3A8 and HS4C3 HS epitope expression of HEK 
cells (a) and histograms of differential HS3A8 expression (b) and HS4C3 expression (c) 
after stimulation with proinflammatory cytokines (18h IFNγ and TNFα) or induction of 
hypoxia. Data representative for 2 individual experiments performed in duplicates. 
Statistical analysis was determinded by 1-way Anova with differences p<0.05 considered 
to be significant. 
 
 
 
Figure 5-23 FGF2 binding of stimulated HEK 293 cells 
 
Representative flow cytometry plot of HEK 293 cells binding FGF2 (a) and differential 
binding of FGF2 after stimulation (18h IFNγ and TNFα). 
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5.3.7.2 Screening of renal proximal tubular epithelial cells (HK-2) 
HK-2 cells were analysed analogous to HEK 293 cells by FACS. HK-2 cells 
were chosen as changes in tubular epithelial HS have been shown to occur 
during rejection (Ali et al., 2005a, Celie et al., 2008) and it should be 
investigated if the changes observed in the tissue are reflective of changes in 
tubular epithelial cells. 
Basal expression of all three HS epitopes were higher than in HEKs and a 
decrease in 10e4 (p<0.01), HS3A8 (p<0.01) and HS4C3 (p<0.05 between basal 
and hypoxic group) staining could be observed in both groups of stimulated 
cells and cells undergoing hypoxic stress (Figures 5-24 and 5-25).The decrease 
in HS domains was accompanied by a decrease in FGF2 and CCL5 binding 
(Figures 5-26 and 5-27).  
 
 
Figure 5-24 10e4 staining of HK-2cells at basal level and following stimulation 
 
Representative flow cytometry plot of 10e4 HS epitope expression of HK-2 cells (a) and 
differential expression of 10e4 HS epitope after stimulation with proinflammatory 
cytokines (18h IFNγ and TNFα) or induction of hypoxia. Data representative for 2 
individual experiments performed in duplicates. Statistical analysis was determinded by 
1-wayAnova with differences p<0.05 considered to be significant. 
 
 
Chapter 5 Modulation of NDST1 and cell surface Heparan Sulphate 
 172 
 
 
Figure 5-25 HS3A8 and HS4C3 staining of HK-2 cells at basal level and following 
stimulation 
 
Representative flow cytometry plot of HS3A8 and HS4C3 HS epitope expression of HK-2 
cells (a) and differential expression of HS3A8 (b) and HS4C3 (c) HS epitope after 
stimulation with proinflammatory cytokines (18h IFNγ and TNFα) or induction of hypoxia. 
Data representative for 2 individual experiments performed in duplicates. Statistical 
analysis was determinded by 1-way Anova with differences p<0.05 considered to be 
significant. 
 
 
 
 
Figure 5-26 FGF2 binding of stimulated HK-2 cells 
 
Representative flow cytometry plot of HK-2 cells binding FGF2 (a) and differential binding 
of FGF2 after stimulation (18h IFNγ and TNFα). 
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Figure 5-27 CCL5 binding of stimulated HK-2 cells 
 
Representative flow cytometry plot of HK-2 cells binding CCL5 (a) and differential 
binding of CCL5 after stimulation (18h IFNγ and TNFα). 
5.3.7.3 Screening of the hepatocellular carcinoma cell line (HepG2) 
HepG2 cells were employed as changes in liver HS have been reported in 
chronic inflammatory liver diseases (Murata et al., 1985, Tatrai et al., 2010). 
Stimulation and hypoxic stress of HepG2 cells resulted in a pronounced 
reduction of all HS domains (p-values <0.001) with stimulated cells revealing 
the lowest amount of HS (Figures 5-28 and 5-29). Despite the decrease of all 
HS species analysed the stimulated cells showed a slight increase in binding of 
FGF2 and CCL5 (Figures 5-30 and 5-31). 
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Figure 5-28 10e4 staining of HepG2 cells at basal level and following stimulation 
 
Representative flow cytometry plot of 10e4 HS epitope expression of HepG2 cells (a) and 
differential expression of 10e4 HS epitope after stimulation with proinflammatory 
cytokines (18h IFNγ and TNFα) or induction of hypoxia. Data representative for 2 
individual experiments performed in duplicates. Statistical analysis was determinded by 
1-way Anova with differences p<0.05 considered to be significant. 
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Figure 5-29 HS3A8 and HS4C3 staining of HepG2 cells at basal level and following 
stimulation 
 
Representative flow cytometry plot of HS3A8 and HS4C3 HS epitope expression of 
HepG2 cells (a) and differential expression of HS3A8 (b) and HS4C3 (c) HS epitope after 
stimulation with proinflammatory cytokines (18h IFNγ and TNFα) or induction of hypoxia. 
Data representative for 2 individual experiments performed in duplicates. Statistical 
analysis was determinded by 1-way Anova with differences p<0.05 considered to be 
significant. 
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Figure 5-30 FGF2 binding of stimulated HepG2 cells 
 
Representative flow cytometry plot of HepG2 cells binding FGF2 (a) and differential 
binding of FGF2 after stimulation (18h IFNγ and TNFα). 
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Figure 5-31 CCL5 binding of stimulated HepG2 cells 
 
Representative flow cytometry plot of HepG2 cells binding CCL5 (a) and differential 
binding of CCL5 after stimulation (18h IFNγ and TNFα). 
5.3.7.4 Screening of the microvascular endothelial cell line (HMEC-1) 
Stimulation of HMEC-1 cells led to a small decrease (p<0.01) in 10e4 staining 
whereas no changes were found for cells grown under hypoxic conditions. 
Neither did HS3A8 or HS4C3 staining differ significantly between any of the 
groups (Figures 5-32 and 5-33). FGF2 binding was unaltered as well, only a 
small increase in CCL5 binding of stimulated HMEC-1 cells could be observed 
(Figures 5-34 and 5-35). 
 
 
Figure 5-32 10e4 staining of HMEC-1 cells at basal level and following stimulation 
 
Representative flow cytometry plot of 10e4 HS epitope expression of HMEC-1 cells (a) 
and differential expression of 10e4 HS epitope after stimulation with proinflammatory 
cytokines (18h IFNγ and TNFα) or induction of hypoxia. Data representative for 2 
individual experiments performed in duplicates. Statistical analysis was determinded by 
1-way Anova with differences p<0.05 considered to be significant. 
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Figure 5-33 HS3A8 and HS4C3 staining of HMEC-1 cells at basal level and following 
stimulation 
 
Representative flow cytometry plot of HS3A8 and HS4C3 HS epitope expression of HMEC 
cells (a) and differential expression of HS3A8 (b) and HS4C3 (c) HS epitope after 
stimulation with proinflammatory cytokines (18h IFNγ and TNFα) or induction of hypoxia. 
Data representative for 2 individual experiments performed in duplicates. Statistical 
analysis was determinded by 1-way Anova with differences p<0.05 considered to be 
significant. 
 
 
 
Figure 5-34 FGF2 binding of stimulated HMEC-1 cells 
 
Representative flow cytometry plot of HMEC-1 cells binding FGF2 (a) and differential 
binding of FGF2 after stimulation (18h IFNγ and TNFα). 
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Figure 5-35 CCL5 binding of stimulated HMEC-1 cells 
 
Representative flow cytometry plot of HMEC cells binding CCL5 (a) and differential 
binding of CCL5 after stimulation (18h IFNγ and TNFα). 
 
Tables 5-4 and 5-5 give an overview of the observed changes upon hypoxia 
and stimulation of the employed cell lines. 
 
Table 5-4 Summaryof HS expression of cell lines after stimulation 
 
 stimulation hypoxia 
 10e4 HS3A8 HS4C3 10e4 HS3A8 HS4C3 
HEK 293 ↑ ↔ ↔ ↑ ↔ ↑ 
HK-2 ↓ ↓ ↓ ↓ ↓ ↓ 
HepG2 ↓ ↓ ↓ ↓ ↓ ↓ 
HMEC-1 ↓ ↔ ↔ ↔ ↔ ↔ 
(arrows indicating up- or downregulation or unchanged) 
 
 
 
Table 5-5 Summary of ligand binding of cell lines upon stimulation 
                 stimulation 
 FGF2 CCL5 
HEK 293 ↓ - 
HK-2 ↓ ↓ 
HepG2 ↑ ↑ 
HMEC-1 ↔ ↑ 
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5.4 Discussion 
HS is a multifunctional molecule which can adapt to a changing environment 
quickly. The changes in HS structure reflect changes in HS biosynthetic 
enzymes, which can be influenced by external factors (Carter et al., 2003, Rops 
et al., 2008). In the sequential model of HS biosynthesis, NDST1 is regarded as 
the key enzyme and its activity is a prerequisite for all other enzymes (Lindahl et 
al., 1998). It was therefore decided to investigate how modulation of NDST1 
would affect HS expression in general and further the ability of altered HS to 
interact with HS binding molecules, such as chemokines, growth factors or 
adhesion molecules.  
5.4.1 Modulation of NDST1 
In the attempt to suppress NDST1 expression a silencing construct was 
transformed into E. coli. Once the sequence of the positive transformant was 
verified the construct was used for the transfection of HEK 293 cells. Ideally a 
different cell line, preferably an endothelial one, would have been the cell line of 
choice but due to difficulties in transfecting and establishing stable clones of 
endothelial origin (Lindemann and Schnittler, 2009), HEK 293 cells were used 
as an easy to handle alternative. Initially 50 clones were picked and 
propagated. Only 7 survived the selection process and screening for NDST1 
mRNA expression revealed that both up- and downregulation of NDST1 
occurred in transfected cells. The transfectant with the most prominent effect 
revealed a reduction of 64% on the mRNA level. Higher levels of NDST1 
reduction might not be reached due to the essential role of NDST1 in 
mammalian cells and due to the fact that cells are stably transfected, which 
means they have been cultured for a certain time  whereas up to 80% of 
NDST1 reduction have been reported for transient transfection (Deligny et al., 
2010). The transfectant with the highest reduction was chosen for further 
experiments and the reduction in mRNA level was confirmed at the protein level 
by Western blotting. Even though stable clones with NDST1 gene knockdown 
were generated, only clones from early passage numbers were used for further 
experiments as it is unknown how long shRNA induced gene silencing lasts.  
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The influence of NDST1 reduction was investigated immunocytochemically by 
the application of the 10e4 antibody which revealed a marked reduction in N-
sulphation. The concurrent reduction of NDST1 and 10e4 levels was in line with 
the literature where reduced levels of N-sulphation were reported after silencing 
of NDST1 in cell lines such as L6 muscle cells or Jurkat T cells (Deligny et al., 
2010, Pankonin et al., 2005). In general, the NDST1 silenced transfectants were 
very difficult to handle as they were hardly adherent. Therefore, 
immunofluorescent staining proved very challenging as cells lifted off the 
chamber slides during the staining procedure, often even during the initial 
washes in PBS. Because of this fact 10e4 immunofluorescent staining was only 
successful twice (despite numerous attempts) and as there was quite a time 
span between the two successfull stainings no quantification of the fluorescence 
intensity was performed. 
 
As a stable cell line with decreased HS expression was established, 
comparative studies using NDST1 overexpressing F15 cells, which were 
originally generated for the protein-protein interaction studies, were carried out. 
Analysed for N-sulphated HS those cells demonstrated a marked increase in 
10e4 staining. This has been reported previously for HEK 293 cells 
overexpressing NDST1 (Bengtsson et al., 2003, Pikas et al., 2000). The NDST1 
overexpressing clone F15 also revealed a drastic reduction in both other HS 
domains, namely HS3A8 (indicative for N-sulphation, 2-O- and 6-O-sulphation, 
C5-epimerisation) and HS4C3 (N-sulphation, 3-O- and 6-O-sulphation). This is 
interesting, as according to the sequential model one would expect increased 
amounts of other modifications, such as O-sulphation or epimerization after an 
increase of N-sulphation. However, this was clearly not the case. A possible 
explanation could be that the other endogenous HS modifying enzymes were 
present only at low endogenous levels in the cell and therefore could not make 
use of the increased N-sulphated template. Similarly, due to the overexpression 
of NDST1, NDST1 molecules were present at high levels possibly masking the 
nascent HS chain thus hindering other enzymes gaining access. Increased N-
sulphation does not always go in line with increases in other modifications; 
disaccharide analysis of NDST1 overexpressing HEK 293 cells revealed no 
change in iduronic acid content or O-sulphation despite high levels of N-
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sulphation (Pikas et al., 2000). Similar observations were also made by Rops et 
al., in a model of glomerular endothelial inflammation they found that increase in 
10e4 staining was not correlated with HS3A8 and HS4C3 staining (Rops et al., 
2008). A direct comparision of the HS expression profile of NDST1 over- and 
underexpressing cells was unfortunately not feasible as the tranfectants were 
created at different time points and NDST1 silenced clones were already 
growing for some time before NDST1 overexpressing clones and phage-display 
derived antibodies became available. Due to this fact and the general handling 
problems with the silenced clones (bad adherence to culture flasks and 
chamber slides as well as the GFP signal derived from the GFP-tag of the 
silencing vector) only NDST1 overexpressing cells were employed in further 
experiments. 
5.4.2 Physiological consequence of altered HS of NDST1 transfectants 
5.4.2.1 Chemotaxis 
Having established stable cell lines with altered HS expression the functional 
consequences of the differentially modified HS should be investigated. One 
option was to test the potential of chemokines to induce vectorial migration of 
monocytes across the monolayer of transfected cells with altered HS. This 
model proved unfortunately to be unsuitable as no migration of cells occurred at 
all independent of incubation time. This could be due to HEK 293 cells 
penetrating the pores; a scenario which has been reported for epithelial cells 
when seeded at high densities (Mul et al., 2000). Seeding at high densities is 
however inevitable to avoid the possibility that monocytes would migrate directly 
through the pores on the filter which would not be covered by cells seeded at 
low densities. 
5.4.2.2 Adhesion 
In a different approach the transfected cell lines expressing different amounts of 
HS were tested for their potential to interact with the adhesion molecule L-
selectin, a well known HS binding protein (Wang et al., 2005), and mediate 
adhesion.  Again, this assay failed to work as cells did not adhere to the L-
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selectin coated plate. One possible explanation could be that L-selectin only 
binds to a subset of HSPGs with a collagen XVIII backbone (Celie et al., 2005), 
which might not be expressed by HEK 293 cells. Also, besides N-sulphation, 
binding of L-selectin also depends on 2-O- and 6-O-sulphation (Celie et al., 
2005, Kawashima, 2006), which have been shown to be greatly reduced in F15 
cells. Overall, the lack of adherent potential of semi-adherent HEK 293 cells in 
general does not favour such an assay which involves washing steps and 
mechanic oscillation. 
5.4.2.3 Chemokine presenation 
As chemotaxis failed to work a different way of demonstrating chemokine 
presentation on the cell surface HS was developed. In a chemokine 
presentation assay a biotinylated form of CCL5, a well studied HS binding 
chemokine (Ali et al., 2002, Rek et al., 2009), was used. The biotinylated form 
allows endogenous and exogenous chemokine to be distinguished in the assay 
and facilitated direct visualization via a fluorescently labelled streptavidin; 
avoiding a signal merged with endogenous CCL5, which would have been 
recognised by the application of a specific anti-CCL5 antibody. Although the 
CCL5 was not labelled in house with the biotin but was supplied HPLC purified 
by a company, its biological activity had to be validated.  
 
The most common method to assay chemokine-HS interaction is determining 
the amount of salt required to elute the bound chemokine from a heparin-
Sepharose column. Heparin can be seen as uniformly highly sulphated form of 
HS and this assay demonstrates some degree of specificity for the interaction. 
When wild type and CCL5-biotin were eluted from the heparin column by the 
application of a salt gradient they both eluted at the same fraction numbers 
corresponding to 0.7M NaCl which is slightly lower than the reported value of 
0.8M in the literature (Proudfoot, 2006). The smaller peak of CCL5-biotin can be 
explained by the reduced recognition of the modified molecule by the antibodies 
employed in the ELISA quantification. Although the biotin group is placed 
distant from the GAG-binding motifs it can not be excluded that it interferes with 
the anti-CCL5 antibody recognition site.  
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It was further necessary to demonstrate that CCL-5 biotin was functional and 
calcium flux analysis proved receptor activation, as binding of the chemokine 
ligand to its receptor lead to mobilisation of intracellular calcium. In a final 
validation experiment CCL5-biotin was assessed for its ability to induce trans-
filter migration of THP1 monocytes. CCL5-biotin did support migration of 
monocytes at 1nM and 10nM to the same level as wild type chemokine, 
although with a significant decrease at 50nM. This could mean that the modified 
chemokine is not capable of activating all signalling pathways necessary for 
directing vectorial migration but was employed in the chemokine presentation 
assay as this assay relies on the heparin affinity and does not examine 
migration.  
 
When analysed for chemokine presentation F15 cells showed an enhanced 
capacity to retain CCL5-biotin on its surface due to increased expression of N-
sulphated HS. At the same time, F15 cells showed slightly decreased potential 
to sequester FGF2 on the cell surface in line with decreased levels of HS3A8 
and HS4C3. N-sulphation as represented by 10e4 staining therefore appears to 
be more important for CCL5 binding (Schenauer et al., 2007, Sweeney et al., 
2006) whereas 2-O- and 6-O-sulphation (Guglieri et al., 2008, Kreuger et al., 
2001)  as represented by antibodies HS3A8 and HS4C3 appear to be involved 
in FGF2 binding. Therefore one has to be cautious in attempting indirect 
measurements of HS content by FGF2 binding, as suggested by Garner 
(Garner et al., 2008). 
 
Unfortunately the transfected cells with decreased HS N-sulphation (TF10) 
could not be tested for their potential to sequester chemokine or FGF as they 
required a TRITC-conjugated streptavidin for visualization due to the GFP 
encoded by the plasmid in the cells, which resulted in very high background 
fluorescence.  
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5.4.3 Alteration of HS expression upon experimental inflammation 
Having investigated changes in cell surface HS of HEK 293 transfectants it was 
decided to examine relevant cell lines in physiological settings for changes in 
HS in response to external stimuli. Hypoxia was chosen to mimic ischemia, a 
condition donor organs undergo e.g. in transplantation settings, and stimulation 
of cell lines with the proinflammatory cytokines IFNγ and TNFα to simulate an 
inflammatory response. HEK 293 cells were included in the study as they were 
used extensively in previous experiments as they are easy to transfect.  
HMEC-1 cells were chosen as a representative for an endothelial cell line, as 
endothelial HS is involved in almost every step of an inflammatory response, 
such as chemokine transcytosis and chemokine binding and presentation at the 
luminal surface (Wang et al., 2005). HK-2 cells are renal proximal tubular 
epithelial cells and are involved in the presentation of chemokines and other 
signal molecules on the basement membrane causing an influx of infiltrating 
cells into tubules (see section 3.1.1). The HepG2 cell line was selected to 
represent a liver epithelial cell line, as changes in liver HS have been shown to 
occur during rejection (see section 3.1.2). 
 
In addition to changes in HS the biological significance of these changes should 
be tested by the application of binding experiments. To reassure that binding of 
CCL5 and FGF2 is indeed due to HS, CHO cells were employed. CHO wild type 
cells expressing HS were capable of sequestering chemokine and growth factor 
on its surface whereas CHO 745 cells, a mutant cell line lacking GAGs due to 
deleting the xylosyltransferase, was unable. This system is especially useful as 
CHOs lack FGFRs and CCRs (Di Marzio et al., 2005, Yayon et al., 1991), thus 
making the reaction solely dependent on HS and not any receptors.  
 
Stimulation with proinflammatory cytokines TNFα and IFNγ and hypoxia of HEK 
293 cells lead to an increase in 10e4 (p<0.05) and HS4C3 (p<0.01) staining 
whereas HS3A8 levels stayed unaltered. FGF2 binding decreased only slightly 
after stimulation and CCL5 did not bind to the cells at all. As HS3A8 expression 
did not change it seems plausible that FGF2 binding did not change 
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dramatically, as HS3A8 represents all modifications required for FGF2-binding 
(N-sulphation, C5-epimerization, 2O-sulphation and 6-sulphation).  
HK-2 renal cells showed a decrease of all different HS epitopes after 
hypoxia/stimulation (10e4 and HS3A8 staining p<0.01; HS4C3 staining p<0.05 
basal versus hypoxic). Again, a reduction in HS3A8 level is in line with 
decreased FGF2 binding. CCL5 binding, which is dependent on N-sulphation 
and O-sulphation, was reduced as well. 
Lack of oxygen and stimulation resulted in a reduction of all HS domains of 
HepG2 cells (p<0.01); however, binding of FGF2 and CCL5 was increased 
marginally. This was surprising, as changes of HS3A8 seemed to correlate with 
changes in binding studies previously.   
The observed decrease in cell surface HS could be due to shedding of 
syndecans and glypicans from the cell surface (Fux et al., 2009, Rehm et al., 
2007), which also can be induced by growth factors such as FGF2 (Ding et al., 
2005). 
HMEC-1 cells did not alter HS3A8 or HS4C3 expression, but demonstrated a 
significant reduction in 10e4 staining (p<0.01). This is not consistent with earlier 
results which demonstrated an increase in 10e4 expression after stimulation 
with IFNγ and TNFα over time (Carter et al., 2003); however, it has to be 
pointed out that different time points have been analysed and therefore the 
results cannot be directly compared. In a very similar model the stimulation of 
dermal derived human microvascular endothelial cells with TNFα also resulted 
in a slight overall decrease in sulphation with unaltered levels of NDST1 (Krenn 
et al., 2008) which again would be in line with results obtained in this study. One 
possible explanation could be that cells were exposed to cytokines after serum 
starvation in one case (Carter et al., 2003) whereas cells were stimulated 
without prior starvation in the other case. FGF2 binding stayed unaltered but a 
small subset of cells showed increased capacity of CCL5 retention.  
 
In summary, exogenously administered proinflammatoy cytokines and induction 
of hypoxia did result in distinct changes of the HS expression profile in 
conjunction with changes in ligand binding. As HS is regulated in a tissue/cell 
specific manner it could mean that cell lines exhibiting similar antibody staining 
profiles still differ in their fine structure, thus influencing the reactivity with its 
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ligands. The modifications essential for antibody recognition do give evidence 
about the existence of those modifications, not about their spatial arrangement 
which is crucial for protein binding. Furthermore, nothing is known about the 
hierarchy of the individual modifications. An increase in HS3A8 staining could 
be due to high levels of N-sulphation and moderate levels of O-sulphation, as 
well as little N-sulphation in combination with high levels of C5-epimerization.  
 
In the future chain length and disaccharide composition analysis could, in 
conjunction with antibody staining and protein binding data, shed light into the 
complex biology of HS-protein interaction.    
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6 Final Discussion 
6.1 Summary of Findings 
 Role of Heparan Sulphate in Transplantation 
 
Besides its involvement in embryonic development and adult physiology, HS 
regulates a range of pathophysiological processes as it binds a variety of 
biomolecules, including proinflammatory cytokines and chemokines, thereby 
shaping the inflammatory response (Parish, 2006). HS was shown to be 
involved in all steps of leukocyte extravastion, primarily by stabilising a 
chemokine gradient on the surface of the vascular endothelium (Wang et al., 
2005). But HS is not only crucial for guiding inflammatory cells from the blood 
into the tissue, it is thought that different HS species also further direct immune 
cells to specific subcompartments within the tissue. Differential expression of 
HSPGs has been reported for renal allografts, where an increase in HS 
expression was observed during acute rejection (Ali et al., 2005a). It can be 
proposed that changes in HS expression resemble those of ligands at the 
specific stage of rejection. Therefore, the spatio-temporal expression of distinct 
HS epitopes in human renal and hepatic allografts were investigated in this part 
of the study. 
 
HS expression in the kidney 
An initial series of experiments were performed to optimise staining procedures 
and different retrieval methods were found to be effective for individual 
antibodies. Following optimisation, normal tissue was employed to determine 
the staining pattern of the HS antibodies.  
The phage-display derived antibodies HS3A8 and HS4C3 revealed a similar 
staining pattern, which can be explained by similar essential target 
modifications, being N-sulphation, C5-epimerisation, 2-O-sulphation and 6-O-
sulphation for HS3A8 and N-sulphation, 2-O-sulphation 6-O-sulphation and 3-
O-sulphation for HS4C3. In addition, 10e4 staining, which is mostly dependent 
on N-sulphation, revealed similar results to phage display antibody staining. All 
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antibodies employed exhibited staining of tubules, the interstitium and glomeruli 
in renal biopsies. In addition, HS4C3 staining was also observed in the nucleus. 
Even though nuclear HS has been reported previously (Schubert et al., 2004), 
its role is not fully understood. One possible role for nuclear HS could be to 
function as a shuttle for nuclear transport for heparin binding factors, which 
once in the nucleus can directly influence cellular activities (Hsia et al., 2003). 
As nuclear staining of HS4C3 was not consistent during the studies, results had 
to be interpreted with reservation to this point and quantification of HS4C3 
staining was therefore not feasible.  
 
A total of 12 patients samples (5 cases of normal control biopsies, 3 cases of 
acute rejection 1a, 2 cases of acute rejection 2a and 2 cases of chronic 
rejection) were assayed for differential expression of HS epitopes in this study. 
While all HS species were expressed in normal control tissue, differential 
expression of distinct HS epitopes during different stages of rejection could be 
observed. 10e4 staining was significantly increased during acute rejection 1a, 
which is consistent with observations by Ali et al, 2005 who reported increased 
expression of N-sulphated HS during acute rejecting kidney allografts (Ali et al., 
2005a). In contrast to 10e4 staining, HS3A8 staining (which represents N-
sulphation, C5-epimerisation, 2-O-sulphation and 6-O-sulphation) did not alter 
during acute rejection, it did however increase significantly during chronic 
rejection. In order to investigate if changes in HS expression reflect changes in 
ligand binding, renal biopsies were assessed for the expression of the 
chemokine CCL2, whose involvement in renal disease has been reported 
previously (Robertson et al., 1998). CCL2 was found to be strongly upregulated 
during acute rejection 1a with moderate expression during later stages.  
 
HS expression in the liver 
After optimising the staining procedure, normal liver tissue was assessed for the 
expression and distribution of HS epitopes. HS3A8, HS4C3 and 10e4 
antibodies all stained in a similar fashion in normal tissue and labelled 
sinusoids, bile ducts and basement membranes.  
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A total of 12 patients were examined for HS expression during liver rejection 
and chronic hepatitis in this study. The N-sulphated 10e4 epitope was hardly 
expressed at time 0 in transplants, but was induced at the time of moderate 
rejection with the most pronounced increase in bile ducts.  
Ductular HS3A8 expression decreased slightly but significantly during moderate 
rejection before it increased during late rejection and chronic hepatitis. As 
previously experienced for renal tissue, antibody HS4C3 revealed inconsistent 
nuclear staining and could not be analysed quantitatively, qualitatively an 
increase in HS3A8 staining during chronic hepatitis could however be observed.  
 
Physiological consequences of altered HS expression 
Distinct HS epitopes, offering new or altered binding sites, have been identified 
during different stages of the rejection process in both organ systems 
investigated. N-sulphated HS domains appeared to be important during early 
time points of rejection whereas highly sulphated and heavily modified HS was 
expressed at later stages during chronic rejection in kidney and chronic 
hepatitis in liver. Changes of HS expression are believed to mirror those of its 
ligands and therefore it makes sense to discuss the consequences of altered 
HS epitope expression.  
 
N-sulphation, represented by 10e4 staining, was increased during acute 
rejection 1a in kidney allografts and moderate acute rejection in liver allografts. 
As N-sulphation is the main requirement for L-selectin binding (Wang et al., 
2005), it appears only logical that the expression of the specific HS species 
occurs at early time points. L-selectin expressed on leukocytes could encounter 
its HS ligand expressed on the endothelium, initiating the extravasation of 
leukocytes into the graft. Once the leukocytes have entered the graft, N-
sulphated HS displayed by tubules (kidney) or bile ducts (liver) could guide 
subsets of immune cells further into the tissue (Celie et al., 2007). In line with 
this idea increased expression of CCL2 in conjunction with increased N-
sulphation was found during acute renal rejection 1a, as CCL2, similar to L-
selectin, binds to primarily N-sulphated HS (Schenauer et al., 2007). 
In agreement with this model are also the findings that heavily modified HS, 
represented by HS3A8 and HS4C3 staining, was upregulated during chronic 
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stages of the rejection process. Modifications essential for HS3A8 staining 
resemble accurately the binding requirements for FGF2, with 2-O-sulphation 
being essential (Guglieri et al., 2008, Ornitz, 2000). The increased expression of 
HS3A8 epitope in interstitial and renal tubular cells during chronic rejection and 
bile ducts undergoing late rejection or chronic hepatitis could lead to a fibrotic 
environment involving FGF2. These fibrotic changes could be further facilitated 
by a breakdown of the anticoagulant environment as HS4C3 staining was 
upregulated during chronic rejections processes and represents ATIII binding 
sites due to existence of the rare 3-O-sulphation. 
 
 Modulation of NDST1 and Cell Surface Heparan Sulphate 
 
Many enzymes are involved in the biosynthesis of HS and the interplay of these 
enzymes determines the interaction profile of HS and its protein ligands.  
NDST1 is believed to be the key enzyme as it initiatites the modification 
process. Therefore, it was decided to investigate the effect of NDST1 
modulation on HS expression and the consequences on ligand binding. Further, 
the changes observed in human allografts should be investigated in vitro using 
representative cell lines. 
 
To start with, NDST1 over- and underexpressing constructs had to be created. 
Once stable clones were established, they were assayed for NDST1 
expression. NDST1 silenced clones revealed a reduction of 64% on the mRNA 
level, which was confirmed at the protein level by Western blotting. Further, the 
reduction of NDST resulted in a decrease of N-sulphation, as demonstrated by 
10e4 staining. This is in accordance with the literature where decreased N-
sulphation after NDST1 silencing was reported (Deligny et al., 2010, Pankonin 
et al., 2005). Unfortunately NDST1 silenced cells could not be employed for 
further experiments due to the existence of the GFP within in the cells and 
problems with high background fluorescence of TRITC conjugated secondary 
reagents.  
 
Similarly to NDST1 silenced cells, NDST1 overexpressing transfectants 
revealed increased NDST1 expression in conjunction with increased 10e4 
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staining, which is also in line with the literature (Bengtsson et al., 2003, Pikas et 
al., 2000). Interestingly, when assessed for HS3A8 and HS4C3 expression, the 
NDST1 overexpressing clone showed a marked reduction in both HS domains. 
The observation that increased N-sulphation is not necessarily accompanied by 
an increase of other modifications was also made by other research groups 
(Pikas et al., 2000, Rops et al., 2008). 
 
Different approaches were undertaken to investigate the physiological outcome 
of altered HS expression. An FGF2 binding kit was employed and NDST1 
overexpressing cells showed a slight decrease in FGF2 binding on the cell 
surface in agreement with a reduction in HS3A8 and HS4C3 staining, albeit an 
increased expression of N-sulphated domains. This shows that one has to be 
careful in determining HS expression indirectly by FGF2 binding, as suggested 
by some research groups (Garner et al., 2008).  
In addition, the potential of NDST1 overexpressing cells to retain and present 
chemokines on their surface was investigated. An initial series of experiments 
were performed to validate the chemokine CCL5-biotin in vitro. Heparin affinity 
chromatography demonstrated that the biotinylated form of CCL5 had the same 
affinity as the wild type form and Calcium-flux analysis confirmed receptor 
activation. A series of migration assays proved that CCL-biotin was able to 
induce migration. Employed in a chemokine presentation assay, NDST1 
overexpressing cells were capable of retaining more CCL5 on their surface 
when compared to wild type cells.  
Ligand binding data of NDST1 transfectants resembled the ligand binding 
profile in transplant tissue. In both circumstances, increased N-sulphation 
correlated with increased potential to sequester and present chemokines, 
namely CCL2 in renal tissue and CCL5 in NDST1 overexpressing transfectant 
cells, confirming the dependency of chemokines on N-sulphation, whereas 
increased expression of the HS3A8 epitope was concurrent with increased 
FGF2  binding in both transplant tissue and the transfectant cell line. 
 
To mimic the changes seen in transplant settings, appropriate cell lines 
representing the individual organs were chosen (HMEC-1 cells representing the 
endothelium, HK-2 renal tubular epithelial cells and HepG2 hepatocytes) and 
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inflammatory conditions were simulated by stimulation of cell lines with the 
proinflammatory cytokines TNFα and IFNγ. In addition, hypoxia mimicking 
ischemia after transplantation was induced by non-vented tissue culture flasks. 
Besides the changes in HS expression binding experiments with FGF2 and 
CCL5 were employed.  
 
Overall, exogenous administered proinflammatory cytokines and induction of 
hypoxia resulted in almost identical changes in HS epitope expression. HK2 and 
HepG2 cells revealed a decrease in expression of all HS species. The reduction 
of cell surface HS could be due do constitutive shedding of syndecans and 
glypicans from the cell surface of cultured cells (Fux et al., 2009). In addition, 
inducible shedding of syndecans dependent on FGF2 has been reported, which 
could also explain the apparent reduction of HS in conjunction with reduced 
FGF2 binding (Ding et al., 2005). Ischemia, which was simulated by hypoxia in 
this study, is a condition organs undergo upon removal from the donor. 
Shedding of HS chains and syndecans has been reported for patients during 
ischemia (Rehm et al., 2007). Functionally, shed HS is capable of activating 
antigen presenting cells (APC) which further may initiate the T-helper 1 type 
response in transplant rejection (Ali et al., 2003). 
Interestingly, while this decrease in HS resulted in decreased ligand binding for 
HK-2 cells, the same decrease in HS resulted in an increased binding of HS 
ligand for HepG2 cells. As for HMEC-1 cells, levels of HS stayed almost 
unaltered with a small increase of CCL5 binding, which is dependent on N- and 
O-sulphation (Schenauer et al., 2007, Shaw et al., 2004) of a small subset of 
cells.  This implies that albeit similar HS profile, reactivity with protein ligands 
can still differ due to the spatial arrangements of the residues involved in 
binding.  
 
 Regulation of Heparan Sulphate biosynthesis 
 
The GAGosome model of HS biosynthesis is based on the interaction of 
individual enzymes with each other rather then the strict sequential model.  
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In both models, NDST1 is a key enzyme in HS biosynthesis and was therefore 
targeted for studying the regulation of HS biosynthesis on the protein level by 
Tandem affinity purification. 
 
Initially, a tagged form of NDST1 was created for the intended affinity 
purification studies. After transfection of the construct into HEK 293 cells, stable 
clones with increased NDST1 expression were established. In a series of 
experiments, cell number and lysis conditions were optimised carefully.  
In all affinity purifications carried out beta tubulin was the only partner to 
constantly co-elute with NDST1 and reliable p- and e-scores from Mascot 
analysis confirmed the genuine interaction. Previous studies have shown other 
glycosylation enzymes to interact with beta tubulin, namely NDST2 and ß-1,4-
galactosyltransferase (Ledin et al., 2006, Schonherr and Hausser, 2000, 
Yamaguchi and Fukuda, 1995). This could mean that beta tubulin is acting as a 
receptor for these enzymes, as no Golgi retention signals are known, thus 
influencing their rate of transport.  
The finding that no other HS biosynthetic enzyme co-eluted with NDST1 would 
rather oppose the GAGosome model and strengthen the idea of a more generic 
role in cell movement and migration, as indicated by the interaction with beta 
tubulin. This view is further supported by the findings of altered HS epitope 
expression in various cell lines upon induction of hypoxia or experimental 
inflammation, where transcriptional control of individual enzymes appears to be 
involved. Even though no analysis of mRNA expression of individual enzymes 
was performed at the time, the observed changes in HS expression pattern 
most likely reflect changes in enzyme expression and/or activity. As HS 
expression in different cell lines was due to endogenous levels of enzymes 
rather than exogenous, the change in expression profile must be due to 
transcriptional regulation rather than aberrant expression of proteins as often 
seen for transfected cell lines. 
6.2 Implications of this Study 
It is well established today that HSPGs regulate normal physiology as well as 
pathophysiology by binding a large array of molecules, including those involved 
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in inflammatory responses and rejection. It seems that certain species of HS 
can be linked to certain disease states, such as allograft rejection or cancer (Ali 
et al., 2005a, Rienstra et al., 2010, Tatrai et al., 2010), thus making HS a target 
for therapeutic intervention.  
Modulation of chemokine-HS interaction may allow the blockade of an array of 
proinflammatory cytokines in a localised fashion and would therefore be hugely 
desirable as current immunosuppressive calcineurin inhibitors such as 
cyclosporine A predominantly target IL-2 (interleukin-2) and γ-interferons. 
 
Trying to prevent immune cells from invading the graft can be achieved either 
by targeting chemokines, the molecules guiding the cells from the blood into the 
tissue, or HSPGs, which offer binding sites allowing chemokines to build up 
gradients crucial for leukocyte extravasation. Due to the redundancy within the 
chemokine system HS was chosen for investigations with regards to 
inflammation in this study.   
 
A few studies have highlighted the importance of differential expression of HS 
during various diseases and experiments were carried out to determine the 
changes related to allograft rejection. Distinct HS epitopes could be linked to 
different stages of graft rejection and results from renal allografts where similar 
to results obtained with liver allografts. Changes observed in transplant tissue 
were also partially confirmed by in vitro studies employing appropriate cell lines 
and NDST1 transfectants for binding studies.  
Exploring changes in renal HS during rejection could also be hugely beneficial 
in the clinical setting. As HSPGs are secreted via the kidney with the urine, they 
could potentially be used as some kind of biomarker in the future. 
 
In the clinic, antibodies recognizing distinct HS domains could be administered, 
blocking corresponding binding sites for protein ligands thus preventing 
leukocytes from entering the tissue, limiting the inflammatory response.  
Likewise, chemokines with improved HS binding capacity and knocked out 
GPCR activity could be used to displace the wild type chemokines, as already 
shown by one research group (Potzinger et al., 2006).  
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Alternatively, one could target the biosynthetic enzyme responsible for the 
modification essential for ligand binding directly with small inhibitory peptides 
which requires a deeper understanding of the regulation of HS biosynthesis. In 
case of NDST1 and other glycosyltransferases beta tubulin has been proposed 
as interacting partner and interfering with HS biosynthesis might have an overall 
greater consequence on cell movement and migration. 
 
Taken together, this study indicates that the chemokine–GAG interaction proves 
an attractive target for therapeutic intervention. 
6.3 Future directions 
It is evident that future work will be required to further the understanding of 
chemokine-HS interplay.  
 
Besides the insightful results from allograft studies, an increase in sample size 
is required and the descriptive results of HS epitope expression during rejection 
should be matched with physiological ligand binding studies. Therefore, binding 
assays employing molecules relevant to rejection processes (such as CCL5, 
CCL2 and other chemokines, FGF2, L-selectin and antithrombin III) should be 
optimised to allow matching of ligands to selective HS species. Also, H&E 
(haematoxylin and eosin) staining should be incorporated in the future, which 
amongst others would help identifying blood vessels.  
 
Overall, also other tissues and cell lines should be examined for inflammation 
related changes in HS. In addition to optimised binding studies, cell lines with 
modified HS could also be employed in a leukocyte rolling assay under 
controlled shear using a dynamic flow chamber model simulating leukocyte 
rolling and adhesion in blood vessels. This would be more appropriate than a 
static adhesion assay.  
In addition, a HS ELISA could clarify if reduced levels of HS expression 
following ischemia and inflammation are indeed due to HS shedding rather than 
a decrease in cell surface expression. Although HS shedding can be mediated 
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by proteases and phospholipases, evaluation of heparanase could also help to 
understand this process.  
 
Cell lines with altered HS expression as well as NDST transfectants could be 
analysed for HS composition by disaccharide analysis by reverse-phase HPLC 
(high-performance liquid chromtatography) and ESI-MS (electrospray ionisation 
mass spectrometry). This, in conjunction with antibody staining and ligand 
binding, would allow identification of specific binding sites.  
 
Finally, the interaction of NDST1 with beta tubulin should be verified by Co-IP 
studies or FRET. A NDST1 silenced transfectant could also help verifying this 
interaction, preferably with a viral-based system as this would yield better 
results and a broader range of transfectable cell lines compared to a plasmid 
based approach. 
6.4 Conclusions 
In summary, this study aimed to further our understanding of HS biology. A 
number of different approaches have been made to highlight the importance of 
HSPGs in inflammation and rejection. Distinct HS epitopes have been identified 
which could be linked to different stages of allograft rejection in both kidney and 
liver allografts. Observations from transplant tissues were partially confirmed by 
in vitro studies employing relevant cell lines and NDST1 transfectants in HS 
composition and binding assays. An interesting observation was the interaction 
of the HS biosynthetic enzyme NDST1 with beta tubulin. This interaction could 
well be of general importance beside HS biology, as it possibly illuminates a 
model of Golgi localisation and retention of glycosylation enzymes. 
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8 Appendix 
8.1 Sequence NDST1-pcDNA3 
pcDNA3 vector containing human NDST1 cDNA was sent for sequencing. 
Routine sequencing primers T7 and Sp6 were used for the reaction. Beginning 
and end of NDST1 sequence are highlighted in yellow (first two and last two 
triplets of the NDST1 open reading frame). 
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8.2 Sequence NDST1-pCTAP 
 
Sequence of NDST1-pCTAP was verified by sequencing using routine 
sequencing primers T3 and T7. To ensure correct sequence of the whole insert 
additional internal sequencing primers were designed (internal primer binding 
sites underlined). pCTAP DNA shown in blue, NDST1 cDNA shown in black and 
restriction sites shown in red. 
 
                             E coR I                            N D S T 1 c D N A   
5 ‘ … G G G  C T G  C A G  G A A  T T C G  G A G  G C C  A G G  A T G  C C T  G C C  
C T G  G C A  T G C  C T C  C G G  A G G  C T G  T G T  C G G  C A C  G T G  T C C  
C C G  C A G  G C T  G T C  C T T  T T C  C T G  C T G  T T C  A T C  T T C  T G C  
C T G  T T C  A G C  G T T  T T C  A T C  T C G  G C C  T A C  T A C  C T A  T A T  
G G C  T G G  A A G  C G A  G G C  C T G  G A G  C C C  T C G  G C G  G A T  
G C C  C C C  G A G  C C T  G A C  T G C  G G G  G A C  C C G  C C G  C C T  G T G  
G C C  C C C  A G T  C G C  C T G  C T G  C C A  C T C  A A G  C C T  G T G  C A G  
G C A  G C C  A C C  C C T  T C C  C G C  A C A  G A C  C C G  T T G  G T G  C T G  
G T C  T T T  G T G  G A G  A G C  C T C  T A C  T C G  C A A  C T G  G G C  C A G  
G A G  G T G  G T G  G C C  A T C  C T G  G A G  T C C  A G C  C G C  T T C  A A A  
T A C  C G C  A C A  G A G  A T T  G C G  C C G  G G C  A A G  G G T  G A C  
A T G  C C C  A C G  C T C  A C T  G A C  A A G  G G C  C G T  G G C  C G C  T T C  
G C C  C T C  A T C  A T C  T A T  G A G  A A C  A T C  C T C  A A G  T A T  G T C  
A A C  C T G  G A C  G C C  T G G  A A C  C G G  G A G  C T G  C T G  G A C  
A A G  T A C  T G T  G T G  G C C  T A C  G G C  G T G  G G C  A T C  A T T  G G C  
T T C  T T C  A A G  G C C  A A T  G A G  A A C  A G C  C T G  C T G  A G T  G C G  
C A G  C T C  A A G  G G C  T T C  C C C  C T G  T T C  C T G  C A C  T C A  A A C  
C T G  G G C  C T G  A A G  G A C  T G C  A G C  A T C  A A C  C C C  A A G  T C C  
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C C G  C T G  C T C  T A C  G T G  A C G  C G A  C C T  A G C  G A G  G T G  G A G  
A A A  G G T  G T G  C T C  C C C  G G C  G A G  G A C  T G G  A C G  G T T  T T C  
C A G  T C A  A A T  C A C  T C C  A C C  T A T  G A G  C C A  G T G  C T G  C T G  
G C C  A A G  A C G  C G C  T C G  T C T  G A G  T C C  A T C  C C A  C A C  C T G  
G G C  G C A  G A C  G C C  G G C  C T G  C A T  G C T  G C A  C T G  C A C  G C C  
A C T  G T G  G T C  C A G  G A C  C T G  G G C  C T G  C A C  G A C  G G C  A T C  
C A G  C G C  G T G  C T G  T T T  G G C  A A C  A A C  C T G  A A C  T T C  T G G  
C T G  C A C  A A G  C T T  G T C  T T  C  G T G  G A T  G C C  G T G  G C C  
T T C C  T C  A C G  G G G  A A G  C G C  C T C  T C C  C T G  C C A  T T G  G A C  
C G C  T A C  A T C  C T G  G T G  G A C  A T T  G A T  G A C  A T C  T T C  G T G  
G G C  A A G  G A G  G G C  A C A  C G C  A T G  A A G  G T G  G A G  G A C  
G T G  A A G  G C C  C T G  T T T  G A C  A C A  C A G  A A C  G A A  C T A  C G C  
G C A  C A C  A T C  C C A  A A C  T T C  A C C  T T C  A A C  C T G  G G C  T A C  
T C A  G G G  A A A  T T C  T T C  C A C  A C A  G G T  A C C  A A T  G C T  G A G  
G A C  G C T  G G G  G A T  G A T  C T G  C T G  C T G  T C G  T A T  G T G  A A G  
G A G  T T C  T G G  T G G  T T C  C C C  C A C  A T G  T G G  A G C  C A C  A T G  
C A G  C C C  C A C  C T T  T T C  C A C  A A C  C A G  T C C  G T G  T T G  G C C  
G A G  C A G  A T G  G C C  T T G  A A C  A A G  A A G  T T C  G C T  G T C  G A G  
C A T  G G C  A T T  C C C  A C A  G A C  A T G  G G G  T A T  G C A  G T G  G C G  
C C C  C A C  C A C  T C G  G G C  G T G  T A C  C C C  G T G  C A C  G T G  C A G  
C T G  T A C  G A G  G C T  T G G  A A G  C A G  G T G  T G G  A G C  A T C  C G C  
G T G  A C C  A G C  A C G  G A G  G A G  T A C  C C C  C A C  C T G  A A G  
C C A  G C C  C G C  T A C  C G C  C G T  G G C  T T C  A T C  C A C  A A T  G G C  
A T C  A T G  G T T  C T C  C C A  C G G  C A G  A C C  T G C  G G C  C T C  T T C  
A C A  C A C  A C C  A T C  T T C  T A C  A A C  G A G  T A C  C C T  G G C  G G C  
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T C C  A G T  G A G  C T G  G A C  A A  A  A T C  A T C  A A C  G G G  G G C  
G A G  C T C  T T C  C T C  A C C  G T G  C T C  C T C  A A T  C C T  A T C  A G C  
A T C  T T C  A T G  A C G  C A C  C T G  T C C  A A C  T A T  G G G  A A T  G A C  
C G C  C T G  G G C  C T G  T A C  A C C  T T C  A A G  C A C  C T G  G T G  C G C  
T T C  C T G  C A C  T C C  T G G  A C G  A A C  C T C  C G G  C T G  C A G  A C A  
C T G  C C C  C C T  G T G  C A G  T T G  G C G  C A G  A A G  T A C  T T C  C A G  
A T C  T T C  T C C  G A G  G A G  A A G  G A C  C C G  C T C  T G G  C A G  G A C  
C C C  T G C  G A G  G A C  A A A  C G T  C A C  A A A  G A C  A T C  T G G  T C C  
A A G  G A G  A A G  A C G  T G T  G A C  C G C  T T C  C C A  A A G  C T C  C T C  
A T C  A T C  G G C  C C C  C A G  A A A  A C A  G G C  A C C  A C T  G C C  C T C  
T A C  C T G  T T C  C T G  G G C  A T G  C A C  C C T  G A C  C T A  A G C  A G C  
A A C  T A C  C C C  A G C  T C T  G A G  A C C  T T T  G A G  G A G  A T C  C A G  
T T T  T T T  A A T  G G C  C A C  A A C  T A T  C A C  A A A  G G C  A T C  G A C  
T G G  T A C  A T G  G A G  T T C  T T C  C C C  A T C  C C T  T C C  A A C  A C C  
A C C  T C C  G A C  T T C  T A C  T T T  G A G  A A A  A G C  G C C  A A C  T A C  
T T T  G A T  T C A  G A A  G T G  G C G  C C C  C G G  C G G  G C A  G C A  G C C  
C T C  T T G  C C C  A A A  G C C  A A G  G T C  C T G  A C C  A T C  C T C  A T C  
A A C  C C C  G C G  G A C  C G G  G C C  T A T  T C C  T G G  T A C  C A G  C A C  
C A G  C G A  G C C  C A T  G A C  G A C  C C A  G T G  G C C  C T A  A A G  T A C  
A C C  T T C  C A T  G A G  G T G  A T T  A C C  G C C  G G C  T C T  G A C  G C A  
T C C  T C G  A A G  C T G  C G T  G C C  C T C  C A G  A A C  C G C  T G C  C T G  
G T C  C C T  G G C  T G G  T A C  G C C  A C C  C A C  A T C  G A G  C G C  T G G  
C T C  A G T  G C C  T A T  C A C  G C C  A A C  C A G  A T T  C T G  G T C  T T G  
G A T  G G C  A A A  C T G  C T T  C G C  A C A  G A A  C C T  G C C  A A A  G T G  
A T G  G A C  A T G  G T G  C A G  A A G  T T C  C T T  G G G  G T G  A C C  A A C  
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A C C  A T T  G A C  T A C  C A C  A A A  A C C  T T G  G C G  T T T  G A T  C C A  
A A G  A A A  G G A  T T T  T G G  T G C  C A A  C T G  C T T  G A A  G G A  
G G A  A A A  A C C  A A G  T G T  C T G  G G C  A A A  A G C  A A G  G G C  
C G G  A A A  T A T  C C C  G A G  A T G  G A C  T T G  G A T  T C C  C G A  G C C  
T T C  C T G  A A G  G A C  T A T  T A C  C G G  G A C  C A C  A A C  A T C  G A G  
C T C  T C C  A A G  C T G  C T G  T A T  A A G  A T G  G G C  C A G  A C A  C T T  
C C C  A C T  T G G  C T A  C G A  G A G  G A C  C T C  C A G  A A C  A C C  A G G  
C T C  G A G  G G A  A G C  G G T  A G C  G G T  A C C  A T G  G A C  G A G … 3 ‘  
  Xh o I      pCTAP DNA…………………………......... SBP-tag.................... 
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8.3 Example of MS analysis 
a 
 
 
b 
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c 
 
Figure 8-2 Example of MS peptide mass fingerprinting analysis 
Mascot analysis: results list of peptide hits (a), matching peptides shown in red (b) and 
representation of mass spectra aquired (c). 
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8.4 Presentations arising from this study 
 
NDST1 and Heparan Sulphate in Inflammation 
Julia Spielhofer, Graeme O‟Boyle, John A Kirby and Simi Ali  
Poster presentation, 15th European Carbohydrate Symposium,  
Vienna, Austria, July 2009 
 
Novel targets in Transplant Biology 
Julia Spielhofer 
Poster presentation, Marie Curie conference, a satellite meeting of the 
Euroscience Open Forum, Barcelona, Spain, July 2008 
 
NDST1 in Heparan Sulphate Biosynthesis and Biology 
Julia Spielhofer, Kerstin Lehner, Graeme O‟Boyle, John A Kirby and Simi Ali  
Poster presentation, 4th Glycan Forum, Berlin, Germany, May 2008 
 
Alteration of Heparan Sulphate Composition during Inflammation  
Julia Spielhofer, Kerstin Lehner, John A Kirby and Simi Ali  
Poster presentation, Biochemical Society Annual Symposium „Structure and 
Function in Cell Adhesion‟, Manchester, UK, May 2007 
 
 
 
 
 
   
 
 
 
 
 
 
 
